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ABSTRACT 
 
 The research described herein details various studies with solution-state nuclear magnetic 
resonance (NMR) spectroscopy to aid in the elucidation of structures of various medicinally relevant 
peptides.  The first system studied was that of the prochlorosins, an unusual family of lantipeptides all 
modified to their mature form by a single lantibiotic synthetase.  Next was the two peptide lantibiotic 
cytolysin, unique among bacteriocins in that it has hemolytic activity in addition to bactericidal activity.  
Nisin, the prototypical lantibiotic, was studied in the context of the immunity protein, NisI, which is 
believed to confer immunity against lysis to the producing organism.  The final system was phosphite 
dehydrogenase, an enzyme putatively useful in the regeneration of nicotinamide cofactors.  By studying 
these systems, it is believed that advances could be made toward novel antibiotic compounds to alleviate 
the increasing pressure of resistance seen in clinical settings. 
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CHAPTER 1 
 
Introduction 
 
1.1   The Rising Need for Novel Antibiotics 
1.1.1   The innovation gap and variations on a theme 
Since the advent of penicillin in 1928, widespread use of antibiotics has created strong 
evolutionary pressure for bacterial resistance to modern antibacterial drugs.  Resistance has been 
developed to every antibiotic in current clinical use;1 about 70% of the bacteria found in hospitals are 
resistant to at least one of the most commonly used antibiotics.1  Further compounding this problem, only 
four new classes of antibiotics have been introduced since the 1960s (Figure 1.1).1,2  As microbes 
continue to be exposed to these antibiotics and their derivatives, they evolve due to selective pressures, 
allowing future generations to evade the antibiotic mechanism.3  Methicillin-resistant Staphylococcus 
aureus (MRSA) alone causes 19000 deaths annually in the US.1  Clearly, the need to develop novel 
antibiotics cannot be overlooked. 
Ultimately, the hurdle posed by antibiotic resistance is that once evolution has revealed a 
pathway by which bacteria can circumvent death, only bacteria with that bypass pathway will survive, 
thereby selecting for resistant strains.  If researchers continue to target bacteria by the same mechanisms 
of action, the bacteria have already developed methods of resistance, lessening the efficacy of novel 
antibiotic compounds. 
1.1.2   The current state of peptide-based antimicrobials 
More than 60 therapeutic peptides are in commercial use, with over 150 currently undergoing 
clinical trials.4  These peptides serve a number of uses, ranging from antimicrobials to 
immunosuppressants.4 
 Presently considered the drug of last resort, vancomycin – a glycopeptide antibiotic – exerts 
bactericidal activity by binding lipid II, a crucial bacterial cell wall precursor, at the pentapeptide moiety 
(Figure 1.2).5  Ramoplanin, a lipoglycodepsipeptide antibiotic that also binds to lipid II, has had moderate 
	  
Figure 1.1.  Classes of antibiotics with introduction to clinic and when resistance first discovered.  Adapted from Clatworthy et 
al. Nature Chemical Biology, 2007, 3, 541-548. 
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success and has reached phase 2 clinical trials.3  Given the successes of these two antibiotics, it would 
seem targeting of lipid II provides a viable strategy for rational development of novel antibiotic 
compounds.3 
While linear peptides may fall short of expectations in the clinic due to quick degradation and poor 
biodistribution, cyclic peptides tend to be more ideal.4  In addition to warding off proteolysis, such peptides 
adopt conformations that may allow them to more specifically and tightly bind molecular targets.4 
Several classes of peptide natural products have been discovered, many of which are produced 
by mechanisms similar to those that generate the lantibiotics.6  These include the microcins, oxazole- and 
thiazole-containing peptides targeting DNA gyrase and RNA polymerase; the cytolysins, oxazole- and 
thiazole-containing peptides with hemolytic activity; the cyanobactins, thiazole-containing peptides with 
antitumor activity; the thiopeptides, thiazole-containing peptides with inhibitory activity against protein 
biosynthesis; the microviridins, lactone- and lactam-containing peptides with strong protease inhibition; 
and the conopeptides, containing disulfide-linked heterocycles and targeting a number of membrane 
channels.6  Conducting genome searches for homologs of known enzymes in other organisms has 
allowed for the discovery of even more ribosomally synthesized peptide products; such has been the 
case with Prochlorococcus MIT9313.4  Given the direct link between the genetically encoded peptide and 
the final product as well as the short biosyntheses, ribosomally synthesized peptides are readily 
derivatized and a very appealing class for exploration.3,4 
Given the need for novel antibiotics with unique mechanisms of action, lantibiotics have emerged 
as notable candidates due to their broad diversity of structure and function, as well as their 
chemotherapeutic capacity.7  Also of interest is their low nanomolar to micromolar inhibitory 
	  
Figure 1.2.  Chemical structure of lipid II (A) and cartoon representation (B).  The site of binding of vancomycin is indicated. 
O
NH
HO O O
ONH
O
OH
O
OH
O
P
O
O
O
P O
O
O
8
2
R
R = N
H
O H
N
O
OH
O
N
H
O
NH2
H
N
O
N
H
O
OH
O
HO
(A) 
(B) 
 3	  
concentrations against a number of medically relevant strains of resistant bacteria, including methicillin-
resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococci (VRE), and oxacillin-resistant 
Gram-positive species.7 
 
1.2   History of Lantibiotics 
Lantibiotics are a family of ribosomally synthesized class I bacteriocins, recognizable by their 
post-translational modifications.8  Lantibiotics contain characteristic non-proteinogenic amino acids, 
including dehydroalanine (Dha) and dehydrobutyrine (Dhb) residues formed by the dehydration of serine 
and threonine residues, respectively.8,9  Lanthionine and methyllanthionine moieties, from which this class 
of bacteriocins derives its name,10 are produced by Michael-type cyclization of cysteine side-chains to 
Dha and Dhb, respectively.8  These rings impart structural rigidity allowing for greater stability against 
proteolytic and thermal degradation, as well as tighter recognition of their targets.3,10,11  Further stability is 
provided by introducing D-amino acids, a result of cyclization.  Recent studies have demonstrated the 
efficacy of improving peptide antibiotic lifetimes by introducing cyclic and D-amino acid moieties.12  This 
resistance to proteolytic degradation is one of several features that make lantibiotics intriguing as a class 
of novel antibiotics.  Lantibiotics possess considerable promise as human therapeutics due to potency 
and novel modes of action.  However, much remains to be optimized, including solubility and stability of 
the peptides under physiological conditions. 
Lantibiotics are synthesized by a wide variety of bacteria – many of which are considered safe –3 
and display broad spectrum activity against Gram-positive bacteria.8  Other posttranslational 
modifications commonly found in lantibiotic peptides include S-aminovinyl cysteine and lysinoalanine 
linkages, D-alanine, oxobutyryl groups, and 17 other rare amino acids.10 
Following translation of the precursor peptide, consisting of the C-terminal core peptide and the 
N-terminal leader sequence, the peptide is modified by one of several types of enzymes.  Four classes of 
lantibiotics have been discovered to date, each deriving its name from the mechanism through which 
lanthionine rings are installed.4 In class I lantibiotics, serines and threonines are dehydrated by a 
dehydratase – generically termed LanB; the newly unsaturated sites are then acted upon by cysteine 
residues in a Michael-type condensation catalyzed regio- and stereospecifically by the generic cyclase 
LanC.4  Class II lantibiotics employ a single enzyme – LanM – to carry out both the dehydration and the 
cyclization on similar time scales with a high preference for N-to-C processing.13  Class III are cyclized by 
RamC-like synthetases and class IV by LanL synthetases.14  Genomic screening for such enzyme-
encoding genes led to the revelation that sublancin, long thought to be a member of the lantibiotic family, 
was in fact an S-linked glycopeptide.15  Of the class I lantibiotics, nisin is the most well studied.8 
Due to the presence of low levels of activity of modification enzymes in the absence of leader 
peptide, it is believed that the leader peptide may – rather than allosterically activating the enzyme – 
serve to shift the equilibrium of the enzyme to a more constitutively active form.6  It seems likely that the 
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leader sequences may have evolved from original attempts to encode for protein secretion, eventually 
adopting other functions such as preventing aberrant activity within the producing cell.6 
Optimization of lantibiotic peptides was previously limited by issues of cytotoxicity or the ability to 
incorporate non-native amino acids.16  Recently, the van der Donk laboratory has made efforts to allow 
the in vivo expression of fully modified lantipeptides in E. coli.17  So far, this has been applied to the 
prochlorosins, haloduracin, and nisin, but it is anticipated to be a broadly applicable approach.17  By 
removal of the leader peptides with exogenous proteases, issues of toxicity within E. coli cells may be 
avoided by releasing the cytotoxic active compound in vitro rather than within the producing cell.17 
 
1.3   Previous Studies of Lantibiotic Structures by NMR Spectroscopy  
Several structural studies have been carried out on the prototypical lantibiotic nisin using both 
solution-state and solid-state nuclear magnetic resonance (NMR) spectroscopy, producing high resolution 
structures of nisin in various biologically relevant contexts.18  Among the phenomena studied are the 
orientation of nisin on a membrane surface, the mode of interaction between nisin and its molecular target 
lipid II, and the formation of pores by nisin.18  Through these studies, it was determined that nisin 
associates with lipid II through the interaction of the A- and B-rings of the former with the pyrophosphate 
moiety of the latter, allowing a two step formation of pores in which nisin is first recruited to the membrane 
surface by both its positive charge and its affinity for lipid II and then, upon binding to lipid II, adopts a 
transmembrane conformation with the C-terminal portion of nisin inserting into the membrane.18  NMR 
studies have proven that no interactions occur between nisin’s leader sequence and the mature peptide.19  
In aqueous solution, leader peptides have been demonstrated to have no noticeable secondary structure, 
though α-helical character was noted in the presence of trifluoroethanol.6 
A recently revised structure of lantibiotic 9751820 demonstrates some of the inherent pitfalls of 
assigning a structure of lantibiotics solely on the basis of NMR studies and that care must be taken to 
assure reliable assignments.  Despite an N-terminal region of ten amino acids of which six are identical to 
those in nisin, lantibiotic 97518 was originally classified as neither mersacidin- nor nisin-type lantibiotic 
folds.21  Overlapping signals for Ala7 and Ala11 were further resolved by variant temperature 15N,1H-
HSQC-TOCSY spectra.20  Revised assignments were verified by MS-MS analysis and chemical 
derivitization studies to introduce a new proposed structure, placing it in the nisin-type family of 
lantibiotics.20 
A previously published structure of sublancin suggested the peptide was a lantibiotic; data 
supporting this conclusion included NMR spectra.22  However, a recent study in the van der Donk group 
has demonstrated otherwise: sublancin is actually an S-linked glycopeptide.15 
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The published structure of Halβ was verified by 2D NOESY (Nuclear Overhauser Effect 
Spectroscopy) NMR. After conflicting mass spectrometry data was acquired regarding the published 
structure of Halβ (Figure 1.3), one subunit of the two-component lantibiotic haloduracin, solution NMR 
spectra were acquired (Figure 1.4).  2D NOESY spectra (nt=50; mix=0.15; ni=512; phase=1,2; processed 
with 5 Hz linebroadening in each dimension) confirmed the previously published structure on the basis of 
three anti-phase cross peaks between methyl and vinyl protons.  Cross-correlation of vinyl methyl protons 
at 2.05 ppm with vinyl protons at 5.90 ppm, which were predicted by ChemDraw to have a clearance of 
0.4 ppm from the nearest chemical shifts – three peaks were expected for the published structure. 
 
1.4   Goals of Research Projects 
In this thesis, I describe the results of studies aimed to solve several questions by using NMR 
spectroscopy.  In chapter 2, prochlorosin lantipeptides are examined to determine ring topologies of 
several peptides, all installed by a single promiscuous LanM synthetase.  In chapter 3, I investigate the 
two-component lantibiotic cytolysin, the only known bacteriocin to also possess hemolytic capabilities.  In 
chapter 4, the studies turn toward NisI, the immunity protein that protects nisin producing species against 
	  
	  
Figure 1.3.  Published structure of Halβ (A) and proposed change to A ring structure indicated by MS results (B). 
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self-killing.  Finally, in chapter 5, phosphite dehydrogenase is investigated; this enzyme has potential 
usage in cofactor regeneration for pharmaceutical synthesis applications. 
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Figure 1.4.  NOESY NMR spectrum of Halβ (A) with expansion around area of interest (B).  Three distinct peaks are noted as 
shown in the boxes, verifying the original published structure. 
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CHAPTER 2 
Investigation of Prochlorosin Structures by NMR Spectroscopy 
 
2.1   Introduction 
2.1.1 Prochlorococcus marinus and the discovery of the prochlorosin peptides  
While the overwhelming majority of lantibiotics possess antibacterial activity,1 a recent few have 
come to light lacking demonstrable antibiotic activity.  In silico genome screening for homologs of LanM 
synthetases resulted in the identification of several putative lantipeptides produced by Prochlorococcus 
MIT9313; including those found in other strains, over 150 prochlorosin genes have been identified so far.2  
Interestingly, a single lanthionine synthetase can act on multiple substrate peptides that have very 
conserved leader peptides and very diverse core peptides. 
If leader sequences do encode for a recognition site to allow for the modification of the precursor 
peptides by the cellular machinery,3 the prochlorosin system is very promising due to the structural 
diversity of mature peptides produced.  It could be envisioned to use this system to generate compounds 
of enhanced activity or to allow for the incorporation of nonproteinogenic amino acids.3 
Prochlorosins belong to the class II lantibiotics, typically encoded with a leader sequence rich in 
Asp and Glu residues, ending in a double glycine motif (Gly-Gly, Gly-Ala, or Gly-Ser/Thr), and generally 
containing an ELXXBX motif, where B can be Val, Leu, or Ile.3 
In the native producer, prochlorosin peptides are produced at a yield of less than 10 µg per 20 L 
culture;4 however, using the biscistronic pRSFDUET-1 vector system, yields have been improved to 
greater than 10 mg per L in E. coli.5  In addition, co-expression of the ProcA precursor peptide with the 
ProcM synthetase substantially increased the proportion of soluble peptide.5  This method also allowed 
for the inclusion of nonproteinogenic amino acids into the prochlorosin peptides using amber stop codon 
methodology.5 
 
2.1.2   Previous forays into lantibiotic synthetases as rogue modification machinery 
Previous studies on LanM synthetases have suggested that both dehydration and cyclization 
occur in a distributive manner on similar time scales, rather than all dehydrations occurring followed by all 
cyclizations.6  In addition, a general propensity has been noted for N-to-C terminal processing so that 
modifiable residues closest to the bound leader sequence get processed first.6 
By mutating Arg399 to a Met in LctM, the enzyme can no longer eliminate phosphate moieties 
from Ser/Thr residues, effectively creating an LctM kinase.6  The leader peptide is not strictly required for 
LctM dehydration activity, which suggests an equilibrium between active and inactive conformations of 
the enzyme.6  Provision of the leader peptide in trans abolished directionality of dehydration.6 
Promiscuous substrate specificity has been shown for LctM with various LctA mutants, including 
truncants and those containing non-native linker moieties such as triazoles.7  LctM was demonstrated to 
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tolerate addition of protease-resistant amino acids such as D-amino acids, β-amino acids, and peptoids in 
the core region of LctA.8 
 
2.1.3   Use of ProcM as promiscuous enzyme for installation of modified residues to stave off proteolytic 
degradation 
Four prochlorosin peptides have been studied previously by NMR spectroscopy (Pcn1.1, Pcn1.7, 
Pcn2.11, and Pcn3.3).9  Of the remaining 25 prochlorosins, Yanxiang Shi has characterized the structures 
of five using MS/MS spectrometry: Pcn2.1, Pcn2.4, Pcn2.8, Pcn3.2, and Pcn4.3.  In addition, Shi has also 
cloned and overexpressed several other prochlorosins using the biscistronic pRSFDuet-1 vector system; 
the His-tagged leader sequences were removed from the fully modified peptide following purification by 
the addition of exogenous protease.  Studies using aminopeptidase have demonstrated proteolysis will 
halt at the site of a modification,10,11  which may be valuable for removal of the leader sequences from 
prochlorosin peptides that prove refractory to other proteolytic means.  Taking these data into 
consideration, the research project described herein was embarked upon. 
 
2.1.4   Goals of this research project 
 The following four prochlorosin peptides were chosen for NMR spectroscopy: Pcn1.2, Pcn1.5, 
Pcn2.1, and Pcn3.2.  Pcn1.2 has 28 core amino acids, with 2 Cys and 2 Thr, giving a potential two 
dehydrations and two cyclizations; Pcn1.5 has 23 core amino acids, with 3 Cys, 1 Ser, and 3 Thr, for a 
potential four dehydrations and three cyclizations; Pcn2.1 has 28 core amino acids, with 4 Cys, 2 Ser, 
and 3 Thr, with a total potential five dehydrations and four cyclizations; and Pcn3.2 has 28 core amino 
acids, with 3 Cys and 3 Thr, for a potential three dehydrations and three cyclizations.  All of these 
prochlorosin-encoding genes had been cloned into multiple cloning site (MCS) 1 of pRSFDuet-1, between 
restriction sites for EcoRI and NotI. 
Four additional prochlorosin peptides were selected as potential candidates for NMR 
spectroscopy, but which would first require cloning into pRSFDuet-1 prior to NMR studies: Pcn2.7, 
Pcn3.4, Pcn4.2, and Pcns.2.  Pcn2.7 has 15 core amino acids, with 2 Cys, 2 Ser, and 2 Thr, for a 
potential four dehydrations and two cyclizations; Pcn3.4 has 17 core amino acids, with 2 Cys, 2 Ser, and 
3 Thr, giving a potential five dehydrations and two cyclizations; Pcn4.2 has 16 core amino acids, with 1 
Cys, 1 Ser, and 3 Thr, producing a potential four dehydrations and one cyclization; and Pcns.2 has 32 
core amino acids, with 3 Cys, 4 Ser, and 1 Thr, for a potential five dehydrations and three cyclizations.  
Cloning of the gene encoding Pcn2.7 required moving the gene from pET15b, where it was present 
between NdeI and XhoI restriction sites, to pRSFDuet-1, using the restriction sites EcoRI and NotI, as 
previously done by Shi. 
Cloning of the genes for Pcn3.4, Pcn4.2, and Pcns.2 would require moving the genes from the 
genome of the native producing strain into pRSFDuet-1.  The high degeneracy of leader sequences of the 
prochlorosins necessitates use of an exo primer to amplify the gene of interest from genomic DNA prior to 
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generation of megaprimers; this exo primer must be located upstream of the region encoding the leader 
sequence to allow initial amplification of the localized gene region.  The megaprimers should include a 
protease site for exogenous removal of the leader peptide sequence, though it has been noted by 
Yanxiang Shi that Factor Xa had not always worked efficiently in producing modified core prochlorosin 
peptides. 
 
2.2   Results and Discussion 
2.2.1   Selection of prochlorosin constructs for structural characterization by NMR spectroscopy 
After discussing the project with both Yanxiang Shi – who had previously carried out much of the 
cloning, overexpression, and modification of these peptides – and Weixin Tang – who had characterized 
the structure of four prochlorosin peptides (Pcn1.1, Pcn1.7, Pcn2.11, and Pcn3.3) by solution NMR 
spectroscopy – several prochlorosin peptides were chosen to study by NMR spectroscopy.  Peptides 
were chosen on the basis of simplicity, presence or absence of overlapping rings, and the demonstrated 
ability to produce the compound in vitro.  Of the 25 prochlorosins which remained unexplored by NMR 
spectroscopy, five had been characterized structurally by Yanxiang Shi using MS/MS spectrometry: 
Pcn2.1, Pcn2.4, Pcn2.8, Pcn3.2, and Pcn4.3.  It was decided to initially pursue Pcn1.2, Pcn1.5, Pcn2.1, 
and Pcn3.2 –  all of which were available in pRSFDuet-1 – for NMR studies. 
For the previously generated pRSFDuet-1 constructs, the proteases used are as follows: 
ProcA1.2A−1K  LysC 
ProcA1.5A−1K  LysC 
ProcA2.1G−1E  GluC 
ProcA2.1G−1R  Trypsin 
ProcA3.2TEV  TEV Protease 
Two constructs had been generated for Pcn2.1, though neither was cleaved optimally; they were both 
used to increase the final yield of peptide.  In addition to these constructs, which could be immediately 
overexpressed and purified, novel constructs were chosen to be cloned into pRSFDuet-1. 
 
2.2.2   Cloning of prochlorosin constructs into pRSFDuet-1 
 Amplification attempts to clone procAs.2 from genomic DNA were unsuccessful for unknown 
reasons; parallel amplifications of procA3.4 and procA4.2 provided the expected size of gene products.  
The primers were checked, as was the anticipated amplicon size with respect to the elongation step of 
the thermocycler protocol.  Neither of these could account for the lack of amplification seen. 
 The genes for procA2.7, procA3.4, and procA4.2 were amplified successfully from pET15b 
(procA2.7) or genomic DNA.  Megaprimers containing the restriction sites for cloning into pRSFDuet-1 
were also successfully generated, as evidenced by agarose gel.  As anticipated, the forward megaprimer 
was larger than the reverse.  Combining the two and further amplifying provided gene products of the 
anticipated size (~300 bp), as confirmed by agarose gel. 
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 It was noted that the reverse primer for amplification of procAs.2 was 60% GC, which may 
account for initial problems amplifying the gene. 
 
2.2.3   Overexpression of in vivo modified peptides 
 Transformation and overexpression appear to have occurred quite well (Table 2.1).  SDS-PAGE 
analysis (Figure 2.1) demonstrated the clear overexpression of the ProcM synthetase, encoded by the 
gene in multiple cloning site 2, which strongly suggests that the substrate peptides, encoded by the gene 
in multiple cloning 
site 1, would also 
have been 
transcribed. 
Previous 
overexpression 
experiments using 
a fermentor 
(Yanxiang Shi) 
 Cell pellet mass in my work (g) Cell pellet mass of YS (g) 
ProcA1.2A−1K 3.70 1.80 
ProcA1.5A−1K 2.49 n.d. 
ProcA2.1G−1E 3.15 4.30 
ProcA2.1G−1R 3.46 n.d. 
ProcA3.2TEV 2.54 4.80 
 
Table 2.1.  Cell pellet mass per liter of overexpression.  YS = Yanxiang Shi; n.d. = no data 
	  
Figure 2.1.  Overexpression gel of prochlorosin peptides co-expression with ProcM synthetase.  Red 
boxes indicate band demonstrating overexpression of ProcM in each culture following induction. 
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demonstrated an increased yield of cells per L of growth culture, from 2-5 g per L using standard 
overexpression methods to 7.5 g per L using fermentation. 
 
2.2.4   Purification of in vivo modified peptides 
Peptides behaved much as anticipated based on the previous results of Yanxiang Shi and her 
rotation students.  In all instances, eluted peptide was apparent in fraction 2 from the Ni2+ affinity column 
due to an increased yellow tinge in the solution.  Initial theoretical yields have been calculated for 100% 
conversion from His-tagged leader + core (HLC) peptide to core (C) peptide, but a 10-80% efficiency 
conversion was more likely, per Shi.  As such, it was likely that some of the peptides will have to be 
overexpressed multiple times to generate adequate stocks of core peptide for solution NMR studies. 
Purification of the mature prochlorosins (core peptide only) was aided by a shift in retention 
compared to the cleaved His6-tagged leader (HL) peptide due to the modifications; generally, smaller 
peptides show an increase in retention upon cyclization whereas larger peptides show a decreased 
retention, per experiments of other students within the van der Donk laboratory (Patrick Knerr, Trent 
Oman).  This allowed collection of pure modified peptide with no contamination from the HL peptide.  
However, resolution of the various dehydration states of a given core peptide had previously proven 
daunting by HPLC (Weixin Tang).  It should be noted that the HL peptide was seen to be phosphorylated 
by MALDI-MS. 
 U LC (g) U L (g) U C (g) Dehydratable 
Residues 
Dehydrations 
Seen 
Previously 
M C (g) 
ProcA1.2A−1K 11947.09 8831.66 3133.45 5 4 3061.45 
ProcA1.5A−1K 10800.68 8641.38 2177.32 4 3-4 2105.32 
ProcA2.1G−1E 11486.47 8681.35 2823.14 5 4 2751.14 
ProcA2.1G−1R 11513.55 8708.42 2823.14 5 4 2751.14 
ProcA3.2TEV 11718.70 8800.48 2936.28 3 2-3 2882.28 
Table 2.2.  Expected masses of peptides.  U = unmodified, L = leader peptide, C = core peptide, M = modified 
 HLC (mg) Theoretical yield C (mg) Actual yield (mg) % yield 
ProcA1.2A−1K 28.7 8.98 0.663 (3.697) 7.4 (41.2) 
ProcA1.5A−1K 12.5 2.46 (−2.801) −113.9 
ProcA2.1G−1E/R 134.7 32.94 1.098 (7.961) 3.3 (24.2) 
ProcA3.2TEV 50.9 12.58 1.616 (4.713) 12.8 (37.5) 
Table 2.3.  Calculated yields of pure peptide.  Parenthetical values are contaminated with mixed dehydration species and 
were not to be used for NMR spectroscopy, but were reserved for further purification should more compound be needed.  
HLC = His6-Leader-Core peptide, C = core peptide 
	   13	  
 Pcn1.2 eluted between 
38-41% Buffer B1 (0.653% 
TFA, 30.4% ACN to 0.625% 
TFA, 32.8% ACN).  The 
expected m/z was 3061.45, 
corresponding to four 
dehydrations.  However, 
contamination with the triply 
dehydrated species was noted 
(Figure 2.3). 
 Pcn1.5 eluted between 
46-53% Buffer B1 (0.580% 
TFA, 36.8% ACN to 0.516% 
TFA, 42.4% ACN).  The 
expected m/z was 2105.32, 
corresponding to four 
dehydrations.  Contamination 
with less dehydrated species 
was seen (Figure 2.4). 
ProcA1.2A-1K:  
MSGSHHHHHHSQDPNSMSEEQLKAFIAKVQADPSLQEQLKAEGADVVSIAKAAGFSITTEDLNSH
ITTKLNLSEEELEGVAGKMDCVSSTAQQTECRPGGPRASYCWDDLR 
ProcA1.5A-1K: 
MSGSHHHHHHSQDPNSMSEEQLKAFIAKVQADTSLQEQLKVEGADVVAIAKAAGFSITTEDLNTH
RQNLSDDELEGLHGKGPGCTGGWWAFTDCTAGGGSCEG 
ProcA2.1G-1E: 
MSGSHHHHHHSQDPNSMSEEQLKAFIAKVQADSSLQEQLKAEGADVVAIAKAAGFSITTEDWDQ
RPVRTLSDEELEGAAGECCITGESPGSAPTNDYKCTKGRGPGGCY 
ProcA2.1G-1R: 
MSGSHHHHHHSQDPNSMSEEQLKAFIAKVQADSSLQEQLKAEGADVVAIAKAAGFSITTEDWDQ
RPVRTLSDEELEGAAGRCCITGESPGSAPTNDYKCTKGRGPGGCY 
ProcA3.2TEV: 
MSGSHHHHHHSQDPNSMSEEQLKAFIAKVQADASLQEQLRTEGADVVAIAKAAGFSITTEDLNSHRQNLS
DDELENLYFQGGGCDGIRITDKQTVADNTIVPCSCFHQ 
 
Figure 2.2.  Peptide sequences of prochlorosin peptides.  Red corresponds to the His6 tag, blue to the leader peptide, and black to 
the core peptide.	  
	  
Figure 2.3.  MALDI-TOF mass spectrum of purification of Pcn1.2 showing presence of 
expected peak at 3062.43 m/z, as indicated by the star (expected 3061.45 m/z). 
!
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 Pcn2.1 eluted between 
34-38% Buffer B1 (0.689% TFA, 
27.2% ACN to 0.653% TFA to 
30.4% ACN) with the expected 
m/z of 2751.14, corresponding to 
four dehydrations.  Contamination 
with triply dehydrated species was 
noted (Figure 2.5). 
 Pcn3.2 eluted between 
39-40% Buffer B1 (0.644% TFA, 
31.2% ACN to 0.634% TFA, 
32.0% ACN).  The expected m/z 
was 2882.28, corresponding to 
three dehydrations, though there 
was contamination with less 
dehydrated species (Figure 2.6). 
 The conditions used for 
proteolysis worked, but the 
variously dehydrated species 
were insufficiently resolved by the 
C18 reverse-phase HPLC 
column.  A C12 column was 
previously noted to give better 
resolution of different dehydration 
states of peptides (Trent Oman, 
Patrick Knerr).  Repurifying with 
the C12 column produced pure 
peptide of the correctly 
dehydrated species for all but 
Pcn1.5, which could still not be 
adequately resolved.  
 
2.2.5   Elucidation of the structure 
of in vivo modified peptides by 
solution NMR spectroscopy 
 According to Weixin 
Tang, 3.6 mg of Pcn1.1 in 0.4 mL 
	  
Figure 2.4.  MALDI-TOF mass spectrum of purification of Pcn1.5 showing presence 
of expected peak at 2108.68 m/z, as indicated by the star (expected 2105.32 m/z). 	  
!
	  
Figure 2.5.  MALDI-TOF mass spectrum of purification of Pcn2.1 showing presence of 
expected peak at 2741.19 m/z, as indicated by the star (expected 2748.53 m/z). 	  
!
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of solution in a standard NMR tube and 1.6 
mg of Pcn1.7 and 4 mg of Pcn3.3, each in 
0.25 mL of solution, were sufficient quantities 
for NMR studies of both peptides.  Pcn3.3 
proved more difficult for her to assign given 
that it possessed three alanine residues and 
five glycine residues within the 23 amino acid 
peptide. 
 NMR spectra were acquired for both 
Pcn2.1 and Pcn3.2, in H2O and D2O.  The 1D 
1H spectra for Pcn2.1 (Figure 2.7) and for 
Pcn3.2 (Figure 2.8) both show smaller than 
expected signals in the amide proton region, 
from 7 ppm to 10 ppm; this is in contrast to 
the rather large signals corresponding to 
aliphatic protons, in the region from 0 ppm to 
5 ppm.  This is also echoed through the 2D 
spectra that were acquired and reflect that a 
second set of spectra, optimized for the 
amide protons, may be needed.  Despite the 
fact that these spectra were acquired using D2O as a solvent, a noticeable water peak is still present 
around 5 ppm, but this is significantly less severe than in spectra acquired in water.  Therefore it was 
anticipated that the most reliable spectra for topological assignment would be those produced by the D2O 
samples. 
	  
Figure 2.6.  MALDI-TOF mass spectrum of Pcn3.2 showing 
peak at 2884.66 m/z, as indicated by the star (expected 2882.28 
m/z). 
!
	  
Figure 2.7.  1D NMR spectrum of Pcn2.1 in D2O. 
	  
Figure 2.8.  1D NMR spectrum of Pcn3.2. 
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 NOESY spectra were taken to monitor through space correlations, which would greatly assist in 
determining residues involved in linkages, such as lanthionine or methyllanthionine rings.  Unfortunately, 
those spectra acquired in D2O (Figure 2.9A for Pcn2.1, Figure 2.10A for Pcn3.2) showed a strange 
symmetry indicative of a problem during acquisition.  Despite several attempts to convert the raw data, 
nothing was found to alleviate the problem.  Therefore, it was decided to return to a spectrum acquired in 
water. 
 Using the jump-return method of solvent suppression, the best spectra were acquired (Figure 
2.9B for Pcn2.1, Figure 2.10B for Pcn3.2).  While the spectra lack the odd symmetry seen in the D2O 
spectra, there is an absence of cross-peaks, meaning that no correlations can be made with the spectra 
acquired. 
 TOCSY spectra were acquired for each peptide (Figure 2.11 for Pcn2.1, Figure 2.12 for Pcn3.2), 
both at 60 ms mixing time (Figures 2.11A and 2.12A) and at 90 ms mixing time (Figures 2.11B&C and 
2.12B&C).  These spectra would allow for assignments of residues by through bond transfers, potentially 
	  
Figure 2.9.  NOESY NMR spectra of Pcn2.1 (A) in D2O and (B) in water. 
	  
Figure 2.10.  NOESY NMR spectra of Pcn3.2 (A) in D2O and (B) in water. 
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along the entire R chain of each amino acid.  The 60 ms mixing time should show closer protons, while 
the 90 ms mixing time would allow the polarization to travel further prior to detection. 
  
	  
Figure 2.11.  TOCSY NMR spectra of Pcn2.1 (A) with 60 ms 
mixing time, (B) with 90 ms mixing time, and (C) with 90 ms 
mixing time cut at a lower threshold to show more noise. 
	  
Figure 2.12.  TOCSY NMR spectra of Pcn3.2 (A) with 60 ms 
mixing time, (B) with 90 ms mixing time, and (C) with 90 ms 
mixing time cut to a lower threshold to show more noise. 
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Upon preliminary examination, the TOCSY spectra appear to have abundant cross-peaks, all stacked 
along a single chemical shift in the x dimension; this would normally allow for full assignment of the 
correlated residue.  However, upon cutting the spectra further down to allow more of the noise to show, it 
could be noted that the cross-peaks form a series of lines parallel to the diagonal.  This is likely not a 
product of both peptides individually, but rather an artifact from the experimental set-up.  Again, like the 
NOESY spectra, the TOCSY spectra proved unreliable for assignments. 
 DQCOSY spectra were acquired for each peptide (Figure 2.13 for Pcn2.1, Figure 2.14 for 
Pcn3.2).  The double quantum modification to the pulse code allows for minimization of the diagonal 
signal, which in turn makes cross-peak signals appear larger.  While several of the characteristic clover-
leaf cross-peaks are visible in each spectrum, there are not as many as expected and without any data 
from TOCSY and NOESY spectra, no assignments could be made. 
 
2.3   Conclusions 
Five prochlorosin constructs were chosen for structural analysis by solution NMR spectroscopy, 
the goal being the determination of the ring topology of each species.  All were successfully 
overexpressed and purified, though only three in high enough yield for NMR studies.  Of these, one did 
not produce a quality 1D 1H spectrum.  The two remaining peptides were run through a series of NMR 
experiments, including COSY and TOCSY experiments for through bond correlations and NOESY 
experiments for through space correlations.  Unfortunately, the data produced was insufficient for 
assignment of the ring topology.  Given that the 1D spectra for these peptides contained a large number 
of peaks, it is most likely that the problems existed in the acquisition of data rather than with the samples 
or peptides themselves. 
Four other prochlorosin constructs were generated using molecular biology.  These gene 
products will be available for future study and characterization. 
 
	  
Figure 2.13.  DQCOSY NMR spectrum of Pcn2.1 in D2O. 
	  
Figure 2.14.  DQCOSY NMR spectrum of Pcn3.2 in D2O. 
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2.4   Future Research Direction 
 NMR studies must be carried out again on Pcn2.1 and Pcn3.2 to generate spectra suitable for 
assignment.  Potential problems with the NOESY spectra may have stemmed from a mixing time that was 
too long – 200 ms was used, so shorter mixing times should be tried in future experiments.   
 NMR data may be supplemented with other techniques.  Cyanogen bromide digestion will cleave 
C-terminally to Met residues, which would allow for either NMR or MS analysis of smaller fragments.  In 
the instance of prochlorosin peptides putatively containing the N-terminal OBu (2-oxobutyryl) modification, 
1,2-diaminobenzene in aqueous acetic acid will remove the moiety, again allowing for more definitive 
analysis by NMR and/or MS.  Lanthionine and methyllanthionine rings may undergo desulfurization and 
subsequent reduction of Dha and Dhb residues in the presence of nickel boride and sodium 
borodeuteride;12 if a ring is present, a single β-D will be incorporated whereas if a ring has not formed, 
both a β-D and a α-D will be incorporated.  Site-directed mutagenesis in conjunction with MS/MS analysis 
could also be used to further determine ring topology. 
 
2.5   Experimental Procedures 
2.5.1   Cloning of procA genes into pRSFDuet-1 
Cloning of prochlorosin genes (LAGJ.X.011) 
 For cloning procA2.7 from pET15b into multiple cloning site 1 (MCS 1) of pRSFDuet-1 – which 
already contained procM in multiple cloning site 2 (MCS 2) – the following primers were used: 
procA2.7 pET15b to Duet FP (EcoRI): 
5’- GTG CCC CGC GGC GAA TTC G ATG TCA GAA GAA CAA CTC AAG-3’ 
procA2.7 pET15b to Duet RP (NotI): 
5’-CTT TCG GGC TTT GTT AGC AGC CGG AGC GGC CGC TTA GCT CCG-3’ 
To allow for proteolytic removal of the His-tagged leader peptide, the glycine just prior to the 
commencement of the core peptide was mutated to a lysine residue using the following primers: 
procA2.7G−1K FP: 
5’-GAA GGT GTG GCT GGG AAG GCT GGT TGT TAT CCG ATC-3’ 
procA2.7G−1K RP: 
5’-GAT CGG ATA ACA ACC AGC CTT CCC AGC CAC ACC TTC-3’ 
 All other genes to be cloned originated from the genomic DNA and therefore required an extra 
initial primer due to the high degeneracy of the leader sequences of the prochlorosin peptides.  Therefore, 
an exo primer was used to amplify out the region around the gene, beginning slightly upstream of the 
start of the genes.  Primers used were as follows: 
procA3.4 genomic to Duet FP exo: 
5’-TTA CTG TGA TGG CGA TAG CGC TGG CAG AAG CGC TCA TAG-3’ 
procA3.4 genomic to Duet FP (EcoRI): 
5’-TAG ATA AAG AAT AGA CAA CTA GAA TTC G ATG TCA GAA GAA CAA CTG AAG GCA TTC-3’ 
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procA3.4 genomic to Duet RP (NotI): 
5’-CTT TGA GTG TGT AGC CGC GGC CGC TCA ACT GCA GCA AAA TGC AAT-3’ 
procA3.4G−1K FP: 
5’-CTT GAG GGT GTG GCT GGG AAC ACT ACT GCT TTC ACT-3’ 
procA3.4G−1K RP: 
5’-AGT GAA AGC AGT AGT CTT CCC AGC CAC ACC CTC AAG-3’ 
procA4.2 genomic to Duet FP exo: 
5’-GAG CCA GCA AAA AAA TCC CAG AAA ATT AGT GAC CTT TTA AGC GTT CAA TTC CAG TGC-3’ 
procA4.2 genomic to Duet FP (EcoRI): 
5’-GAA GCG ACC GAA TCC G ATG TCA GAA GAA CAA CTC AAG GCA TTC-3’ 
procA genomic to Duet RP (NotI): 
5’-CGC CTA TTC TTT TAC TTT TGC GGC CGC TTA ACA TTC GGC AGC-3’ 
procA4.2G−1K FP: 
5’-GGT GTG GCT GGT AAG ACG AAT GTG ACA GTC ACT GGA GCA-3’ 
procA4.2G−1K RP: 
5’-TGC TCC AGT GAC TGT CAC AAT CGT CTT ACC AGC CAC ACC-3’ 
procAs.2 genomic to Duet FP exo: 
5’-CAG ACT TGA GTT TAA TGT ACA CTC TTA TGG TTG GGA AAG TAG TAC GCC-3’ 
procAs.2 genomic to Duet FP (EcoRI): 
5’-AGG GAA ATG AAC TAA GCC CTT GAA TTC G ATG TCA GAA GAA CAA-3’ 
procAs.2 genomic to Duet RP (NotI): 
5’-TTC GCT TAT CTG TAT GGT AAG TGC GGC CGC CTA TTG CGG TGG TAC-3’ 
procAs.2G−1K FP: 
5’-GAA GAT GCG GCT GGG AAA GGG GCT CAG-3’ 
procAs.2G−1K RP: 
5’-CTG AGC CCC TTT CCC AGC CGC ATC TTC-3’ 
procAs.2TEV FP: 
5’-GAG ATT TCA GAT GCA GAG GGG AAC CTG TAC TTT CAG GGG GCT CAG GGC-3’ 
procAs.2TEV RP: 
5’-GCC CTG AGC CCC CTG AAA GTA CAG GTT CCC CTC TGC ATC TGA AAT CTC-3’ 
 
 All pRSFDuet-1 containing cultures were grown in the 
presence of ampicillin; those containing pET15b were also grown in 
the presence of ampicillin. 
 For amplification of genes from genomic DNA, the initial 
amplification reaction was run with a forward exo primer (upstream 
of the leader sequence encoding region due to the high degeneracy 
 Expected size (bp) 
procA2.7 240 
procA3.4 455 
procA4.2 516 
procAs.2 577 
Table 2.4.  Expected size of amplification 
products 
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of prochlorosin leader sequences) and a reverse primer.  Amplification products were visualized by 
running on 2% agarose gel. 
 Once the region surrounding the gene of interest had been amplified out, megaprimers were 
produced using forward and reverse primers encoding restriction sites for cloning into pRSFDuet-1 
(EcoRI in the forward primer, NotI in the reverse primer).  The protocol used was borrowed from Yanxiang 
Shi.  The megaprimer amplification products were verified by agarose gel. 
 The next amplification was run using the forward and reverse megaprimers to generate the full, 
restriction-site-flanked genes.  Stoichiometric amounts of both megaprimers were added to the reaction 
mixture and allowed to self-anneal for 8 cycles.  At this point, the program was paused and additional 
forward and reverse primers were added to amplify the template gene formed by the self-annealed 
megaprimers.  The products were again monitored by agarose gel. 
 The amplified products were digested simultaneously with EcoRI and NotI in a 20-µL reaction 
containing BSA and NEBuffer EcoRI (New England Biolabs, Ipswich, MA) 
 Genomic amplification of procAs.2 was attempted again, with modified conditions, substituting the 
GC buffer provided with Phusion polymerase (New England Biolabs, Ipswich, MA) for the previously used 
HF buffer (also provided with Phusion polymerase). 
 
2.5.2   Overexpression of in vivo modified peptides 
Overexpression of modified prochlorosin peptides (LAGJ.IX.083).  Chemically competent E. coli cells 
BL21(DE3) (EMD Millipore, Darmstadt, Germany) were transformed with pRSFDuet-1 plasmids 
containing procM in MCS 2 and in MCS 1 either procA1.2A-1K, procA1.5A-1K, procA2.1G-1E, 
procA2.1G-1R, or procA3.2TEV; this was accomplished using the heat shock method provided with the 
cells.  From the single colonies produced, overnight 10-mL cultures were inoculated, which were in turn 
used to inoculate 2-L cultures at 37 °C (in 4-L baffled Erlenmeyer flasks).  Once the cell densities had 
reached an OD600 value of ~0.6 (generally within 4 h), the cultures were induced to 0.1 mM IPTG (final 
concentration) and moved to 18 °C for overnight growth. 
An aliquot of pre- and post-induction culture was then used to assess the quality of 
overexpression in each growth by SDS-PAGE (4-20%; 195 V for 30 min).  Cell densities were normalized 
using the Nanodrop and subsequent volume adjustment.  Overexpression was apparent not by the 
appearance of the substrate bands (anticipated to be approximately 11 kDa) but by the presence of the 
synthetase band, which showed up solely in the post-induction lanes at ~110 kDa.  It is expected that if 
the protein encoded in MCS 2 was produced, so too should be the peptide encoded in MCS 1. 
 
2.5.3   Purification of in vivo modified peptides 
Purification of procA peptides (LAGJ.X.018). The protocol used for purification was provided by Yanxiang 
Shi.  Cell pellets were thawed on ice in 25 mL of LanA Start Buffer (20 mM NaH2PO4, 500 mM NaCl, 0.5 
mM imidazole, 20% [v/v] glycerol; pH 7.5).  The cells were lysed using sonication under microtip 
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conditions (35% amplitude, 4 s on, 9 s off; 5 min total sonication).  Post-lysis, the mixture was clarified by 
centrifugation (23700xg, 30 min, 4 °C) and the supernatant was kept.  The pellet was resuspended into 
25 mL of LanA Start Buffer, then lysed and centrifuged again, once more keeping the supernatant.  The 
pellet was resuspended, this time into 25 of mL LanA Buffer 1 (6 M GnHCl, 20 mM NaH2PO4, 500 mM 
NaCl, 0.5 mM imidazole; pH 7.5), then lysed and centrifuged.  This supernatant was also kept.  The 
supernatants were applied to a pre-equilibrated Ni2+-affinity IMAC column (5 mL; IMAC Sepharose High 
Performance, GE Healthcare, Piscataway, NJ) after washing the column with 2 CV of the corresponding 
buffer.  After loading, the column was washed with 2 CV of LanA Buffer 1 and 4 CV of LanA Buffer 2 (4 M 
GnHCl, 20 mM NaH2PO4, 300 mM NaCl, 30 mM imidazole; pH 7.5), collecting fractions.  The peptide was 
eluted with 2 CV of LanA Elution Buffer (4 M GnHCl, 20 mM Tris, 100 mM NaCl, 1 M imidazole; pH 7.5), 
collecting in 2.5-, 7.5-, 5-, and 5-mL fractions.  Fraction 2 generally contained the peptide; this could be 
seen by a yellow tint to the solution, which was absent in all other elution fractions.  Fraction 2 was then 
injected onto a pre-equilibrated C4 column on the Waters HPLC using a gradient from 2% Buffer A (80% 
acetonitrile containing 0.086% TFA) and 98% Buffer D (0.1% TFA) to 100% Buffer A over 45 min at a flow 
rate of 8 mL/min.  Fractions were collected as they eluted between 56% and 74% Buffer A (from 0.488% 
TFA, 44.8% ACN to 0.324% TFA, 59.2% ACN).  The presence of peptide was verified by MALDI-MS 
analysis.   
All fractions containing the peptide of interest were combined and concentrated by rotary 
evaporation under vacuum to remove acetonitrile.  The samples were then lyophilized to a white, fluffy 
powder.  Using the molecular weights calculated for modified His-Leader-Core (HLC) peptide and 
modified Core (C) peptide, the theoretical yields post-proteolysis were calculated.  The dried peptides 
were stored at -80 °C to await proteolysis and subsequent purification. 
Proteolytic removal of leader sequences (LAGJ.XI.070).  Experimental parameters were determined by 
slight modifications of those previously employed by Yanxiang Shi.5  For cleavage with proteases, a 
corresponding buffer solution was prepared as follows: LysC (ProcA1.2A−1K and ProcA1.5A−1K) and 
trypsin (ProcA2.1G−1R), a stock buffer solution of 500 mM Tris (pH 8.5); GluC (ProcA2.1G−1E), a stock 
buffer solution of 500 mM NH4HCO3 (pH 7.8); and TEV protease (ProcA3.2TEV), a stock buffer solution 
of 20X TEV Buffer (1 M Tris, 10 mM EDTA; pH 8.0).  Each peptide was resuspended to 6 mg/mL in 
deionized water.  Reactions were run in multiple parallel vessels to cleave each sample fully (Table 2.5). 
 For cleavage with LysC, one vial of the protease (Roche, Indianapolis, IN) was resuspended to 
700 µL (100 µL per reaction to 
be run); reactions were allowed 
to proceed at room 
temperature overnight.  For 
cleavage with GluC, one vial of 
the protease (Roche) was 
resuspended to 250 µL (50 µL 
Conditions for cleavage by: LysC GluC Trypsin TEV 
Peptide (µL; 6 mg/mL) 1250 1300 1300 1781 
Protease (µg) 0.71 10 4.2 107 
Buffer (µL) 150 150 150 200 
Total volume (µL) 1500 1500 1500 4000 
Table 2.5.  Reaction components for largescale proteolysis of prochlorosin peptides. 	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per reaction to be run); reactions were allowed to proceed at room temperature overnight.  For cleavage 
with trypsin, two vials of the protease were resuspended to 300 µL each (50 µL per reaction to be run); 
reactions were allowed to proceed at room temperature for 1 h.  For cleavage with TEV, previously 
purified TEV stocks were provided by Yanxiang Shi; reactions were allowed to proceed at room 
temperature overnight.  Following proteolysis, all reactions were quenched with 1 part TFA per 200 parts 
total reaction volume. 
 The quenched proteolysis reactions were purified by reverse phase HPLC using a C18 column.  
Eluting fractions were collected as monitored by absorbance at 220 nm.  All fractions were analyzed by 
MALDI-MS and those identified to contain the species of interest were pooled and lyophilized.  The 
preliminarily purified mature prochlorosin peptides were then subjected to a second round of HPLC 
purification using a C12 column (Jupiter 10 µm Proteo 90, 250 x 15 mm; Phenomenex, Torrance, CA) to 
better resolve the species of interest, using the same solvents, flow rate, and gradient as before.  Again, 
all fractions were collected and analyzed by MALDI-MS.  Those containing the correctly modified 
prochlorosin species were combined and concentrated.  At this point, it was noted that the amount of 
Pcn1.5 was insufficient to proceed with NMR analysis. 
 
2.5.4   Elucidation of the structure of in vivo modified peptides by solution NMR spectroscopy 
All NMR spectra were acquired in the VOICE laboratories at the University of Illinois at Urbana-
Champaign on the Varian Unity Inova 500NB (500 MHz, 5mm Varian 1H{13C/15N} PFG Z probe) and 
Varian Unity Inova 600NB (600 MHz, 5mm Varian 1H{13C/15N} PFG X, Y, Z probe) instruments. 
Preparation of samples for NMR analysis (LAGJ.XI.016).  The pooled samples were concentrated down 
by lyophilization, then resuspended into deionized water and concentrated to dryness by rotary 
evacuation.  An analytical balance was used to weigh out the final yield of purified prochlorosin peptides.  
Each sample was then loaded into various volumes of 10% D2O containing 1 µL of 70 mg/mL DSS as a 
reference to yield a final concentration of approximately 1 mM (Table 2.6). 
 
 The Pcn1.2 sample was loaded into a low-volume NMR tube from Shigemi (BMS-003; ID 2.5 mm 
with insert with OD-A 2.4 mm, OD-B 2.47 mm; Allison Park, PA); this tube was tuned to D2O to provide a 
better spectrum with lower sample quantities. 
 NMR data were acquired for Pcn2.1 and Pcn3.2; no suitable signal could be found for Pcn1.2 and 
so it was not further studied. 
  
 Mass (mg) Amount (nmol) Volume (µL) Final Concentration (mM) 
Pcn1.2 0.663 216.5 250 0.866 
Pcn2.1 1.098 399.1 400 0.998 
Pcn3.2 1.616 560.6 400 1.401 
Table 2.6.  Composition of samples for NMR spectroscopy. 
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The following experiments were performed at 500 MHz: 
 Pcn2.1  1D, gDQCOSY, NOESY, TOCSY (mixing times of 70 and 80 ms) with 
presaturation solvent suppression 
 Pcn3.2  1D, gDQCOSY, NOESY, TOCSY (mixing times of 70 and 80 ms) with 
presaturation solvent suppression 
 The following experiments were performed at 600 MHz: 
 Pcn2.1  1D, DQCOSY, NOESY, TOCSY (mixing times of 50, 70, and 80 ms) with 
presaturation solvent suppression; 1D, DQCOSY, NOESY (mixing time of 200 ms), TOCSY (mixing times 
of 60 and 85 ms) with jump-return solvent suppression 
 Pcn3.2  1D, DQCOSY, NOESY, TOCSY (mixing times of 70 and 80 ms) with 
presaturation solvent suppression; 1D, DQCOSY, NOESY (mixing time of 200 ms), TOCSY (mixing time 
of 60 and 85 ms) with jump-return solvent suppression 
For better solvent suppression, the samples were concentrated down to dryness and 
resuspended into 100% D2O.  With the new samples, the following experiments were run at 600 MHz: 
Pcn2.1  1D, DQCOSY, NOESY (mixing time of 200 ms), TOCSY (mixing times of 60 and 
90 ms) with presaturation solvent suppression 
Pcn3.2  1D, DQCOSY, NOESY (mixing time of 200 ms), TOCSY (mixing times of 60 and 
90 ms) with presaturation solvent suppression 
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CHAPTER 3 
Interrogation of the Structure of Cytolysin to Determine Putatively Harmful Moieties 
 
3.1   Introduction 
3.1.1   Introduction to cytolysin 
Cytolysin makes an interesting system to study as it is the first and only lantibiotic with toxin 
activity in human and animal studies.1,2  Cytolysin is a well-characterized virulence factor produced by 
Enterococcus faecalis, it may provide  an evolutionary advantage to cytolytic strains over other, non-
cytolytic Gram-positive organisms in the intestinal tract, allowing E. faecalis to become the leading cause 
of nosocomial infections throughout the body.1,3-5  Cytolysin is a two-peptide lytic toxin with broad 
spectrum activity against eukaryotic and prokaryotic organisms;1,5 though structurally related to 
streptolysin S and lantibiotics, it is unique among both hemolysins and bacteriocins in that it has 
combined hemolytic and bactericidal activities.2,5  Lytic activity has been demonstrated against a number 
of cells, from prokaryotic to eukaryotic and even certain mammalian cell types, including retinal cells, 
macrophages, and polymorphonuclear leukocytes.1  These activities were likely selected from 
modifications to an original lantibiotic scaffold to better accommodate for habitation of niches occupied by 
other eukaryotes.1  Given the evolutionary advantage that may be afforded to E. faecalis by cytolysin in 
hospital settings, cytolysin may serve as a suitable target to decrease the level of nosocomial infections.5  
CylLS: 
MLNKENQENY YSNKLELVGP SFEELSLEEM EAIQGSGDVQ AETTPACFTA GLGVGALFSA 
KFC	  
CylLL: 
MENLSVVPSF EELSVEEMEA IQGSGDVQAE TTPVCAVAAT AAASSAACGW VGGGIFTGVT 
VVVSLKHC	  
CylM: 
MEDNLINVLS INERCFLLKQ SGKEKYDIKN LQAWKERKSV LKQDDLDYLI KYKYESLDNF 
GLGITPIENF PDKEVAIQYI KDQSWYIFFE SILDSYNDSE EKLLEVDASY PFRYFLQYAR 
LFLLDLNSEL NICTKEFIIN LLETLTQULI HLTSKTLVLD LHTFKKNEPL KGNDSSKRFI 
YYLKKRFNSK KDIIAFYTCY PELMRITVVR MRYFLDNTKQ MLIRVTEDLP SIQNCFNIQS 
SELNSISESQ GDSHSRGKTV STLTFSDGKK IVYKPKINSE NKLRDFFEFL NKELEADIYI 
VKKVTRNTYF YEEYIDNIEI NNIEEVKKYY ERYGKLIGIA FLFNVTDLHY ENIIAHGEYP 
VIIDNETFFQ QNIPIEFGNS ATVDAKYKYL DSIMVTGLVP YLAMKDKSDS KDEGVNLSAL 
NFKEQSVPFK ILKIKNTFTD EMRFEYQTHI MDTAKNTPIM NNEKISFISY EKYIVTGMKS 
ILMKAKDSKK KILAYINNNL QNLIVRNVIR PTQRYADMLE FSYHPNCFSN AIEREKVLHN 
MWAYPYKNKK VVKYEFSDLI DGDIPIFYNN ISKTSLIASD GCLVEDFYQE SALNRCLNKI 
NDLCDEDISI QTVWLEIALN IYNPYKYIND LKNQNSNKYI YTGLELNGKI IQACQKIEKK 
IFKRAIFNKK TNTVNWIDIK LDQDWNVGIL NNNMYDGLPG IFIFYVALKY ITKNHKYDYV 
IECIKNSIYT IPSEDILSAF FGKGSLIYPL LVDYRLNNDI NSLNVAVEIA DMLIEKKPIN 
NGELKNDWIH GHNSIIKVLL LLSEITEDEK YRKFSLEIFE KLSEEPYFNF RGFGHGIYSY 
VHLLSKFNRI DKANSLLHKI KESYFEEEPK NNSWCKGTVG ELLATIELYD DNISNIDINK 
TIAYKNKDCL CHGNAGTLEF LIQLAKKDPE TYQYKKNKLI SYMLNDFEKN NTLKVAGSEY 
LESLGFFVGI SGVGYELLRN LDSEIPNALL FEL	  
 
Figure 3.1.  Amino acid sequences of cytolysin peptides and synthetase. 
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3.1.2   Class II lantibiotics 
Typical class II lantibiotics are encoded with a leader sequence rich in Asp and Glu residues, end 
in a double glycine motif (Gly-Gly, Gly-Ala, or Gly-Ser/Thr), and generally contain an ELXXBX motif, 
where B can be Val, Leu, or Ile;6 the double glycine motif is present in both peptides of cytolysin, but 
neither peptide contains the ELXXBX motif – rather a ELXBXX motif.  For most two-peptide lantibiotic 
systems, two different bifunctional LanM synthetases each act on one of the precursor peptides; this is 
attributed to low homology between the peptides.7  The modified precursors are then activated and 
exported by a single bifunctional LanT protein.7 
 
3.1.3   Biosynthesis of cytolysin 
 Cytolysin is a 
class II lantibiotic that is 
transcribed as a pair of precursor 
peptides, CylLL and CylLS 
(containing 68 and 63 amino acids, 
respectively; Figure 3.1),1  that are 
modified by a set of enzymes 
(Figure 3.2).1,2 Post-translational 
modifications are installed by 
CylM, which performs dehydration 
and cyclization on both precursor 
peptides, forming CylLL* and 
CylLS*.1,8  Unique among the two-
peptide lantibiotics, both 
components are modified by the 
same enzyme, rather than each 
peptide having their own LanM, despite the presence of non-identical leader sequences (Figure 3.3).7,9  
The N-terminal domain is believed to function as a dehydratase, with the C-terminus carrying out 
cyclizations;9,10 this is corroborated by the 45.96% identity between NisC and residues 451-933 of 
CylM.5,2,8   
CylB – a secretory protein requiring ATP for activity – and CylA – a serine-type protease located 
in the extracellular milieu – proteolytically trim the peptides to the CylLL’ and CylLL’’ (or CylLS’ and CylLS’’) 
forms, respectively (Figure 3.3).1,2,5  Also present in the cluster are genes encoding the immunity protein 
CylI and the two-component regulatory system CylR1 and CylR2; unlike several other members of the 
lantibiotic class, these regulatory proteins do not share any identity with the typical histidine kinase sensor 
complex.1  Once fully processed, the lantibiotics (38 and 21 amino acids for CylLL’’ and CylLS’’, 
respectively)1,2 are slightly cationic and highly insoluble in aqueous solution.1,5 
Figure 3.2. Gene cluster and biosynthesis of cytolysin.  Genes are color-coded 
by function: red – precursor peptides; green – modification machinery; blue – 
regulatory; purple – immunity protein system. 
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This process is highly unique for several reasons.  First of all, as mentioned above, it is 
unprecendented among the two component lantibiotics for one enzyme to process both subunits.  
Second, typically in class II lantibiotics, export and proteolysis to the active form is effected by the same 
LanT enzyme.  In the case of cytolysin, the processed subunits are both exported and proteolytically 
trimmed by CylB, but are not fully activated until acted upon by a second proteolytic enzyme, CylA.  The 
method of regulation of gene transcription also differs from the typical LanR/LanK system. 
 Cytolysin production is 
controlled in a quorum-sensing 
type manner by the fully 
processed CylLS’’ peptide, 
which destabilizes the 
transcriptionally inactivating 
complex formed by CylR1 and 
CylR2.1  In the presence of 
exogenously applied phosphatidylcholine (PC), it was noted that CylLL’’ demonstrates a stronger affinity 
for the PC than does CylLS” (on the order of a 6.5-fold greater affinity),3 allowing CylLS’’ to signal for a 
derepression in production upon exposure to a target cell containing PC in the membrane.1,3 
 
3.1.4   Bacteriocin function 
 Neither CylLS nor CylLL have N-terminal tryptophan repeats characteristic of bacteriocin 
compounds.  Bacteriocin compounds also typically have GXXXG, AXXXA, or SXXXS motifs, which 
contribute to helicity of the structure.  CylLS has a single GXXXG motif, whereas CylLL has two GXXXG 
motifs and five AXXXA motifs; this may imply a strong tendency toward helicity in the CylLL peptide, 
though this may be disrupted by the typical lantibiotic modifications.  CylLS has a positive change on the 
C-terminus (K61) while CylLL has two positive charges on the C-terminus (K66, H67); a positive C-
terminus is often found in bacteriocin compounds.  These shared characteristics with bacteriocins may 
account for some of the unique activity displayed by cytolysin. 
 
3.1.5   Mode of action of other known two-component lantibiotics 
Typically, two-component lantibiotics exert their bactericidal activity synergistically, with each 
peptide serving a specific role in the activity.7,11  The first component – generally globular – serves as a 
mersacidin-type lantibiotic initiating binding to lipid II by the conserved TxS/TxEC motif and the second 
component – typically elongated and flexible – as a nisin-type lantibiotic to facilitate pore formation7,12.   
Both haloduracin and lacticin 3147 have been demonstrated to act through a 1:1 stoichiometry in 
which the α-peptide initiates binding to a target on the surface of Gram-positive cells and recruits the β-
peptide, which undergoes a conformational change to induce pore formation.7,11  Halα and Ltnα contain 
the conserved CTLTXEC thioether motif believed to be essential in lipid II binding.7,11  Other two-peptide 
	  
Figure 3.3. Proteolytic processing of CylLL and CylLS subunits.  Modifiable 
residues in the core peptide are indicated in green. 
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lantibiotic systems including staphylococcin C55 and plantaricin W have also been demonstrated to act in 
a 1:1 stoichiometry.7 However, no homology has been noted between these systems and cytolysin. 
 
3.1.6   Previous studies into residues responsible for bacteriocin and hemolysin activies 
Alanine-scanning experiments have implicated specific residues in the bactericidal and/or 
hemolytic activity of cytolysin.1  Results indicate that the N-terminus of CylLS” is important to both 
hemolytic and bactericidal activity as well as for signaling purposes.5  The central hydrophobic region and 
C63 have been demonstrated to play a role in hemolysis and self-induction in CylLS’’.5  The C-terminus of 
CylLS’’ is necessary for either hemolytic or bactericidal activities, though not both.5  A lysine at position 61, 
which serves as the only charged residue in the peptide, has been shown to be required for bacteriocin 
activity.5  As of yet, such an analysis has not been carried out on CylLL’’.5 
N-Alkyl glycine residues have been shown to increase selectivity of pore formation in bacterial 
membranes over hemolytic activity against human erythrocytes;13 therefore peptoid analogs of cytolysin 
may make the peptides more amenable to clinical use. 
Bacterial resistance to cytolysin has been attributed to D-alanyl ribitol teichoic acid, though the 
specific mechanism of protection is yet unclear.  It is believe to be due either to ablation of negative 
charge, making the surface of the cell less attractive to positive peptides, or to sterically hinder  binding of  
cytolysin to its preferred site.1  A number of mammalian erythrocytes – including rabbit, cow, horse, and 
human – are vulnerable to cytolysin-mediated lysis, while others (e.g. sheep and goat erythrocytes) are 
resistant to hemolysis, presumably due to a higher concentration of PC in the outer leaflet.1,5  
Exogenously applied PC was demonstrated to be able to inhibit lysis of horse erythrocytes.5  Cinnamycin, 
another member of the lantibiotic family, has previously been shown to bind phosphatidylethanolamine 
(PE).9,12  However, as cytolysin is also shown to be active against invertebrates, such as nematodes, a 
more ubiquitous target is implied.5  Additional evidence indicates that human intestinal epithelial (HT29) 
cells may also be targeted.1,5  It is anticipated that there is a specific membrane receptor responsible for 
the bactericidal activity of cytolysin, while the hemolytic activity is believed to occur as a result of less 
specific binding to the erythrocyte membrane.1  Both peptides are required for cytolytic activity. 
 
3.1.7   Investigations into the structure of the cytolysin peptides 
The structure of the active peptides has yet to be characterized, though the presence of lantibiotic 
rings has been explored.1  Edman degradation is halted at the first amino acid of each of the fully 
processed subunits, which may indicate of either a lanthionine ring or the presence of either a 
dehydrobutyrine or a 2-oxobutyryl residue, which forms from the hydrolysis of a N-terminal 
dehydrobutyrine.2  Following processing, mass shifts are seen in each peptide such that six dehydrations 
are expected in CylLL and four are expected in CylLS based on mass.2  The number of expected 
lanthionine rings is 1.6 and 0.7, respectively, based upon integration of paired peaks eluting from a HPLC 
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column following acidification of the peptides.2  One of the goals of this project was to determine the ring 
topology of the cytolysin subunits and to form these rings in vitro. 
 For removal of the leader peptides, CylA would be ideal, but would need to be 
cloned/overexpressed.  Both peptides are cleaved after the GDVQAE motif; GluC would be a good choice 
therefore, as there are no other glutamic acid residues in the structural region of either peptide and the 
reduced activity of GluC against aspartic acid will also not be an issue as no aspartic acid residues are 
present in the structural region of the peptides. 
 
3.1.8   Goals of this research project 
 The research project described herein was centered around the effort to characterize the 
structures of the cytolysin peptides and also to gain further understanding of how this unique system is 
able to exhibit both bactericidal and hemolytic activities.  In addition, further studies into cytolysin as a 
lantibiotic would prove useful. 
 
3.2   Results and Discussion 
3.2.1   Cloning of cylL genes into overexpression vectors 
Synthetic genes were ordered from GeneArt (Darmstadt, Germany), provided in amplifiable vectors 
with ampicillin resistance containing the genes of interest flanked by NdeI and BamHI restriction sites, 
upstream and downstream of the gene, respectively, for cloning into the pET15 and pRSFDUET-1 
(multiple cloning site 1) overexpression vectors.  The genes were generated from the known peptide 
sequences and codon optimized for expression in E. coli.  Restriction analysis of the final gene 
sequences demonstrated no incorporation of the NdeI nor the BamHI restriction sites into either gene, 
which meant aberrant digestion within the genes during molecular cloning was not expected. 
Digestions were attempted on the original vectors as well as on products from amplification of the 
genes; they were carried out both serially and simultaneously with NdeI and BamHI until successfully 
digested.  Care was taken in each subsequent round of digestion to prevent dilution of the DNA, chiefly 
by eluting the DNA into the appropriate volume of water for the next digestion reaction.  To assure 
adequate amounts of DNA for ligation post-digestion, concentrations of 600 ng/µL were sought prior to 
beginning digestions.  Pooling multiple plasmid stocks and concentrating down under nitrogen gas may 
be used to increase concentrations.  By agarose gel, digestions appeared to have worked and produced 
bands of the expected sizes (230 bp for cylLL, 215 bp for cylLS, Figure 3.4).  Clear bandshifts are evident 
between digested (2360 bp) and undigested Geneart vectors (2590 bp for cylLL, 2575 bp for cylLS).  For 
better visualization of pRSFDUET-1 digestion, vectors preloaded with halM in multiple cloning site 1 were 
used to provide a characteristic bandshift upon digestion.  A gel concentration of 2% agarose was 
determined to be optimal for resolution of the genes of interest.  The bands of interest were successfully 
extracted from the agarose gel for use in ligations. 
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To give the greatest chance of ligation succeeding, the digested bands were combined at 1:1, 1:3, 
and 1:5 ratios of empty vector to gene insert.  Ligation appears to have succeeded as indicated by the 
large number of successful transformations of DH5α.  Single colonies were produced on nearly every 
plate, giving many candidates to be checked for the correct sequences. 
Prior to submission for sequencing, the transformant plasmids were analyzed by amplification.  The 
amplification products were run on an agarose gel.  Those plasmids found to contain the substrate-
encoding gene produced a band of ~200 bp.  Vectors containing appropriately sized genes were checked 
for overexpression of gene products.  Those constructs that both contained insert and produced a 
reasonably sized peptide during test overexpression were submitted for sequencing. Constructs 
containing error-free genes were selected and used for overexpression trials. 
 Conditions could not be found for the amplification of tetra-lysine-tagged CylL peptides. 
  
3.2.2   Cloning of cylM gene into overexpression vectors 
The protein sequence for CylM was submitted to GeneArt (Darmstadt, Germany) for synthetic gene 
design; codons were chosen for optimal overexpression in E. coli.  The gene was flanked by NheI and 
	  
Figure 3.4.  Agarose gel of digested and undigested GeneArt vectors containing cylLL and cylLS genes.  The digested bands are 
indicated by blue boxes, slightly larger than the standard band corresponding to 200 bp.  100 bp = DNA ladder, with each band 
corresponding to 100 bp; cylLL = GeneArt vector containing same gene; cylLS = GeneArt vector containing same gene; ‘ = 
digestion products. 
100	  bp	  
cylLL’	  
cylLL	  
1	  kb	  
100	  bp	  
cylLS’	  
cylLs	  
100	  bp	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XhoI restriction sites to clone into pET28 and pRSFDUET-1 overexpression vectors; neither restriction 
site was present in the codon-optimized gene itself.  The original vector contained kanamycin resistance. 
 The genes and vectors were digested both serially and sequentially; digestion was also 
attempted on the vectors and on amplified gene products. After digestion, the enzymes were heat 
deactivated at 65 °C for 20 min.  Digestion success was assayed by agarose gel – the loaded GeneArt 
vector corresponded to a band at 5290 bp, whereas the digested vector led to a cylM band at 3010 bp 
and the empty vector at 2280 bp (Figure 3.5). 
Care was taken to guard against subsequent dilution during the gel analysis and purification of 
digestion products – the DNA from a previous round of digestion was diluted into the total volume for the 
next round.  An agarose gel concentration of 0.7% was determined to be optimal for resolution of the 
bands of interest.  The correct bands were successfully isolated from the agarose gel for use in ligation 
experiments. 
To increase digestion efficiency, final concentrations of restriction enzyme were raised to 10% of 
the total digestion volume and plasmid stocks were concentrated under nitrogen gas to reach 600 ng/µL 
prior to commencing digestions.  The concentrations were such that sufficient enzyme was present to 
digest all of the DNA within the time allotted for digestion – this was calculated according to the 
manufacturer’s recommendations. 
To verify digestion conditions were working, a copy of pRSFDuet-1 loaded with procM was 
digested alongside copies of cylM to be inserted into pRSFDuet-1; a bandshift of the loaded copy would 
demonstrate adequate digestion conditions. 
Amplifications to verify insertion of cylM into multiple cloning site 1 of pRSFDuet-1 often resulted in 
two bands, one at the expected size and a second at ~500 bp.  
The gene was best amplified using Phusion polymerase with the supplier-provided GC buffer and no 
DMSO.  The best results were obtained when double digested simultaneously with both NheI and XhoI.  
Despite the low GC content (36%) of the cylM synthetic gene, it was found that amplification required the 
GC buffer provided with Phusion polymerase. 
	  
Figure 3.5. Agarose gel of digested and undigested GeneArt vectors containing cylM gene.  The digested band 
is indicated by a blue box, approximately the same size as the standard band corresponding to 3000 bp.  1 kb = 
DNA ladder, with each band corresponding to 1000 bp; cylM = GeneArt vector containing same gene; ‘ = 
digestion product. 
1	  kb	  
cylM’	  
cylM	  
1	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Ligation reactions were run at 1:1, 1:3, and 1:5 plasmid to insert molar ratios.  The ligated plasmids 
were used directly to transform E. coli DH5α, and liquid cultures for plasmid isolation were inoculated with 
colonies that grew following the transformation.  All plasmids were checked for the presence of inserts 
corresponding to a size of 3 kb by PCR amplification, as well as by sequencing and test overexpressions.  
Given the large size of the cylM gene, internal primers were designed centered around every 500 bp of 
the known sequence and used to assure fidelity of the gene by sequencing. 
 Sequencing of pRSFDuet-1 vectors that had previously demonstrated an amplifiable gene of the 
correct size in MCS 2 failed to align with cylM.  Therefore a double digest was carried out on the same 
plasmids.  The digested plasmid containing substrate gene was expected at 4 kb, whereas the cylM gene 
was expected at 3 kb.  Two distinct bands could be noted for several of the constructs, one at 3 kb and 
one at slightly larger than 3 kb (Figure 3.6).  However, sequencing results of these constructs indicated 
the presence of no genes in either of the multiple cloning sites.  Digestion of the first multiple cloning site 
and subsequent agarose gel showed the presence of genes the size of the expected substrate-encoding 
genes. 
 
3.2.3   Overexpression of CylL peptides 
from pET15 vectors for in vitro cyclization 
 Test cultures (10 mL) were grown 
to OD600 0.5-0.8 and induced to a final 
concentration of 0.1 mM IPTG.  
Overexpression could be seen for His6-
CylLL (8833 Da) after 4 h of growth at 37 
°C (Figure 3.7), corresponding to 
standard protocols for overproduction of 
LanA peptides; this proved to be the 
same for production of His6-CylLS (8883 
Da). 
Several trials were undertaken 
before determining optimal overexpression, varying the amount of IPTG used to induce the cultures, the 
time after induction, the temperature of growth after induction, and the OD600 value at induction.  Notably, 
several of the cultures appeared to decrease in cell density post-induction, suggesting that the peptides 
may be toxic to the E. coli in which they are being produced.  Growth at 18 °C rather than at 37 °C 
rescued the cultures. 
 
 
 
 
	  
Figure 3.6.  Amplifications of pRSFDuet-1 putatively containing cylLX 
in MCS 1 and cylM in MCS 2.  The loaded plasmid should run at 4 
kb; cylM should appear at 3 kb. 
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3.2.4   Purification of CylL peptides from pET15 
vectors 
Well-established protocols exist within the van der 
Donk group for the purification of LanA substrate 
peptides.9  Again, the standard protocol for purification 
of unmodified LanA peptides proved effective.  Peptide 
location during elution from IMAC column was 
apparent due to color of eluent.  Peptide was further 
purified by HPLC, collecting fractions and verifying 
their contents by MALDI mass spectrometry (8882.8 
m/z for His6-CylLS, 8832.8 
m/z for His6-CylLL).  A final 
yield of 7 mg was acquired for 
each 2-L growth of His6-CylLL 
and 3.5 mg for each 2-L 
growth of His6-CylLS. 
During purification, it 
was noted that the intensity of 
peaks produced by MALDI-
MS was lower than typical for 
purification of a LanA peptide.  
This may be improved by 
introduction of a tetra-lysine 
tag or by a C-terminal His6 
tag, both of which have been 
demonstrated to improve 
ionization of LanA peptides.  
However, initial attempts at 
cloning these constructs were 
unsuccessful. 
 
3.2.5   Overexpression of 
CylM synthetase 
Several trials were 
undertaken before 
	  
Figure 3.8.  MALDI-TOF mass spectra of purified mature cytolysin peptides CylLS (A) 
and CylLL (B). 
!
!
	  
Figure 3.7.  Overexpression gel of CylLL cultures.  Lanes, 
from left to right, are ladder, and then alternate pre- and 
post-induction to the last lane.  Overexpression is seen 
post-induction. 
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determining the optimal overexpression conditions, varying 
the amount of IPTG used to induce the cultures, the time after 
induction, the temperature of growth after induction, and the 
OD600 value at induction.  Without induction, a culture of 
pET28bcylM-expressing E. coli BL21(DE3) will grow to an 
OD600 of 4.23 at 18 °C overnight, which was used to 
determine OD values at which to induce the culture.  
Eventually a set-up was found in which overexpression 
seemed to be occurring at ~110 kDa, by SDS-PAGE of pre- 
and post-induction aliquots, which is approximately where 
CylM should appear (118190 Da). 
 Test cultures (10 mL) were grown to OD600 0.5-0.8 
and induced to a final concentration of 0.1 mM IPTG.  For 
CylM overexpression, the incubation time was increased from 
4 h – as had been used for overproduction of the peptide 
substrates – to 20 h (Figure 3.9). 
 
3.2.6   Purification of CylM lantibiotic synthetase 
Lysis by cell homogenizer has proven to be a more successful technique for the isolation of soluble 
lantibiotic synthetases by other members of the group and so it was used here.  Unlike with the peptide 
purification, this was performed fully at 4 °C in the cold room and elution from the IMAC column did not 
appear evident based on SDS-PAGE of the fractions collected.  The protein appeared to have 
significantly less affinity for the resin than would typically be expected for a lantibiotic synthetase with a 
hexahistidine tag (typically elute at 100 – 200 mM imidazole). 
By PAGE, the best conditions for overexpressing and 
purifying CylM appeared to be induction at an OD600 value 
of 1.2 to a final concentration of 1 mM IPTG; post-induction, 
the culture was grown at 18 °C for 20 h prior to harvesting.  
However, a Western blot of the PAGE gel did not 
demonstrate the presence of His6-CylM. 
A sample of His6-ProcM provided by Yanxiang Shi was 
used as a control to verify the efficacy of the Western blot.  
In the end, the blot appears to have been performed 
correctly, given the presence of a properly sized band in the 
control lane.  However, no His6-CylM is evident (Figure 
3.10).  This, in combination with the premature elution from 
the IMAC column, suggests that the N-terminal His-tag may 
	  
Figure 3.9.  Overexpression gel of CylM.  From 
left, lanes are ladder, pre-induction, and post-
induction.  A band, indicated by the arrow, is 
seen between the standard bands for 100 kDa 
and 150 kDa.	  
	  
Figure 3.10.  Western blot of CylM 
overexpression and purification trials.  All lanes 
that should contain His6-CylM appear without 
bands.  Lane two contains His6-ProcM as a 
control. 	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no longer be present during the purification and Western blot steps.  As such, it was decided to create a 
C-terminally decahistidine-tagged construct to alleviate this issue.  However, this construct did not display 
increased affinity for the IMAC column. 
Without a proper overexpression protocol, the enzyme was reproducibly present in the insoluble 
pellet. Solubility of the enzyme appeared to be a major impediment to overexpression and mini-scale 
purifications. 
 
3.3   Conclusions 
CylLL and CylLS were successfully overexpressed and purified, but the CylM synthetase was not.  
Upon handing of the project over to Weixin Tang, it was discovered that though the sequencing results for 
the previously generated cylM constructs perfectly aligned with the synthetic gene, they were not in the 
intended overexpression vectors but rather still housed in the generic vector in which GeneArt had 
provided them.  This explains why no suitable overexpression conditions could be found for the 
synthetase. 
 
3.4   Future Research Direction 
Cloning of other constructs 
 Cloning of all constructs that was not successfully completed previously should be carried out.  
This includes addition of tetralysine tags to the substrate peptides, both the N-His6-tagged substrate in 
pET15b and the C-His10-tagged substrate in pET24b; a tetralysine tag may be added to the substrate 
present in pRSFDuet-1, but this should wait until after in vivo cyclization has been preliminarily probed in 
this system.  In addition, cloning efforts should be continued with the synthetase, with focus on cloning 
into multiple cloning site 2 of pRSFDuet-1 for in vivo cyclization of the substrate peptides.  If this system is 
for some reason incompatible with pRSFDuet-1, cloning into pET28b with a N-His6 tag and/or into 
pET24b with a C-His10 tag should also be attempted. 
Overexpression of CylM 
For future overexpression trials of CylM, many conditions may be varied including OD600 at 
induction (0, 0.6, 1.2, or 1.8); temperature post-induction (18 °C, 25 °C, or 37 °C); culture to flask volume 
ratio to change rate of oxygenation; co-expression with chaperones (GroESL, DnaK, HtpG, SecB, DnaJ, 
GrpE, ClpB, ClpA, and/or ClpX); use of tRNA complementation plasmids (pR.A.R.E., CodonPlus); 
changing to a richer medium (H medium, Lambda Broth, NZC Broth, Superbroth, Terrific Broth, Tryptone 
Broth, 2XYT Medium, or TYGPN Medium); changing to a poorer medium (M9 Medium, M63 Medium, A 
Medium, Studier P Medium, or osmotic stress medium with non-metabolizable sugars); and/or use of a 
different construct (C-terminal tag, pDUET vector, different promoter such as cspA, periplasmic signaling 
sequence, removal of aggregation-prone amino acid sequences, poly-Arg tag, c-Myc tag, or consensus 
biotinylation sequence).  However, hopefully overexpression will be uncomplicated once the correct 
construct has been generated. 
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In vitro cyclization of CylLL and CylLS 
Protocols for in vitro cyclization are well-established in the van der Donk group.9  Once both CylM 
and the substrate peptides have been overexpressed and purified, cyclization assays should be 
attempted to create CylLL* and CylLS* in vitro. 
Derivatizing agents for monitoring cyclization must be optimized for the given assay, but may 
include modification by IAA, PHMB, or BREA. 
Bioassays 
 Determination of the scope of antibiotic activity should be carried out to better characterize the 
bactericidal nature of the cytolysin system.  Activity assays should be performed, both for the peptides 
together and for the individual peptides to determine the nature of combined activity (synergistic, additive, 
or antagonistic).  Action should be assessed both with the CylLL peptide being added first and with the 
CylLS peptide being added first, rinsing cells before addition of the second peptide, to determine if order of 
binding has an effect on activity.  Assays may be run in the presence of potassium-reacting dyes to 
monitor for pore formation and ion efflux, which may indicate pore formation as a mechanism of action. 
 Prior to bioassay experiments, the leader tags must be removed from the peptides.  Given that 
the leader sequences of both peptides end in GDVQAE and that neither has a Glu residue within the core 
peptide, GluC is a good candidate for proteolysis.  Should the peptides prove refractory to this approach, 
aminopeptidase may be used as the first residue of each peptide is likely to be modified 
Characterization of Ring Topology of Cytolysin Subunits by Mass Spectrometry 
Use of MS/MS mass spectrometry will allow for fragmentation of the cyclized peptides to 
determine the structures.  As the sequences of both subunits are already known and both subunits are 
relatively small, it should be fairly straightforward to assign mass peaks to expected fragments, allowing 
for determination of lanthionine ring location.  From sequence alignment with lantibiotics of known 
structure, putative ring locations are predicted in Figure 3.11.  It should be noted that both CylLL and 
CylLS have alignment with typical C-terminal rings (DhbLKHC in the former, DhbAKFC in the latter), so 
this should also be considered a possible location for ring formation.  However, previous experiments 
	  	  	  	  	  	  	  	  	  	   	  
	  	  	  	  	  	  	  	  	   	  
(A)	  
(B)	  
Figure 3.11.  Sequence alignment of cytolysin subunits and predicted ring topology.  (A) Alignment of 
core peptides of nisin (NisA), epidermin (EpiA), lacticin 3147 A2 (LtnB), lacticin 3147 A1 (LtnA), and 
cytolysin.  From these alignments, placement of rings was predicted (B).  
CLUSTAL 2.0.12 MULTIPLE SEQUENCE ALIGNMENT
File: /Users/AenyssaRhone/Documents/van der Donk Lab/2010/My Lab Work/Cytolysin/Substrate Peptide Sequences - Short List CDate: Wed Apr 21 19:17:08 2010 
Page 1 of 1                           :.     .                          .                 
NisA ---------ITSISLCTPGC-KTGA-L-M-GC---------NMKTATCHCSIHVSK------------    34
EpiA ---------IASKFICTPGCAKTG--------------------SFNSYCC-----------------    22
LtnB -------------TPATPAISILSAYIST-NTC---------PTTKCTRAC-----------------    28
LtnA ---------------CSTNTFSLSDYWGNNG-AWC------TLTHECMAWCK----------------    30
CylLS ---------------TTPACFTIG--LGV-G----A--------LFSAKFC-----------------    21
CylLL --TTPVCAVAATAAASSAACGWVGGGIFT-G----------VTVVVSLKHC-----------------    38
   1.......10........20........30........40........50........60........
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have demonstrated the presence of 1.6 lanthionine rings in CylLL and 0.7 in CylLS,2 and therefore, despite 
all of the putative rings aligning with known rings of other lantibiotics, it is anticipated that at least one of 
them is not present in the fully modified peptides.  The same study also demonstrated that six residues 
are dehydrated in CylLL and four in CylLS;2 these are also putatively assigned in Figure 3.10, based on 
alignment with lantibiotics of known structure.  In addition, the N-terminal Dhb residues would 
spontaneously hydrolyze to 2-oxobutyryl residues in situ.	  
NMR characterization of cytolysin structure 
 NMR spectroscopy could be used to further probe the ring topology and three-dimensional 
structure of the individual peptides and peptide complex of cytolysin.  Initial studies should use natural 
abundance samples, which – if results indicate further experiments are warranted – could then be 
followed up by isotopically enriched overexpression and NMR studies. 
Experiments with native producer 
Use of cytolysin knockouts of the producing strain could provide interesting insight into the 
function of in vivo versus in vitro produced cytolysin species. 
 
3.5   Experimental Procedures 
3.5.1   Cloning of cylL genes into overexpression vectors 
Acquisition of codon-optimized cylL genes for overexpression in Escherichia coli (LAGJ.V.069).  Due to 
the required clearances for growing the native producer Enterococcus faecalis, which necessitates 
Biosafety Level 2 workspace, it was decided to heterologously overexpress the peptides in E. coli.  The 
amino acid sequences for CylLS, CylLL, and CylM were found by conducting a search of the E. faecalis 
genome in PubMed using each gene name.  These sequences were then submitted to GeneArt 
(Darmstadt, Germany) for E. coli codon-optimized synthesis.  The substrate-encoding genes were 
created for use in pET15b; as such, they were requested in an ampicillin resistant vector with NdeI and 
BamHI restriction sites flanking the gene. 
 Once the genes were acquired, they were rehydrated and used to transform E. coli DH5α by the 
heat shock method.  Freezer stocks of both cells and plasmid were prepared and stored at -80 °C and -20 
°C, respectively. 
 3.5.1.a   Cloning of cylL genes into pET15b for in vitro cyclization of His6-CylLX 
Digestions of cylL genes and pET vectors for generation of His6-CylLX substrate peptides for in vitro 
modification of cytolysin substrate peptides (LAGJ.VI.011).  All reactions were carried out on 50-µL scale.  
Both serial and simultaneous digests were attempted for all constructs.  The structural genes – cylLL and 
cylLS – were to be cloned into pET15 using NdeI and BamHI (New England Biolabs, Ipswich, MA).  
Reactions containing BamHI were allowed to proceed for 3 h at 37 °C; all other reactions were allowed to 
proceed for 8 h at 37 °C.  Immediately following the conclusion of the incubation, the digestion products 
were purified using 2% agarose and Quick-Load 50 bp DNA ladder (New England Biolabs, Ipswich, MA) 
for the cylLX genes and 0.7% agarose for the vector. 
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Ligations of cylL genes into pET vectors for generation of His6-CylLX substrate peptides for in vitro 
modification of cytolysin substrate peptides (LAGJ.VI.084).  DNA concentrations of inserts and vectors 
were assayed by Nanodrop.  Ligations were carried out at 1:1, 1:3, and 1:5 ratios of insert to vector in 
10.5-µL reactions with 0.5 µL T4 DNA Ligase (New England Biolabs, Ipswich, MA).  The reactions were 
incubated for 16 h at 16 °C, then diluted to 25 µL with sterile water for transformation of E. coli DH5α (Cell 
Media Facility, School of Chemical Sciences, University of Illinois at Urbana-Champaign) by the heat 
shock method.  The cells were seeded onto LB agar plates containing ampicillin. 
PCR verification of cylL genes for generation of His6-CylLX substrate peptides for in vitro modification of 
cytolysin substrate peptides (LAGJ.VII.003).  PCR amplification reactions were set up on 50-µL scale with 
0.5 µL Platinum Pfx polymerase (Life Technologies, Grand Island, NY), 1 µL MgSO4 (50 mM), and 1 µL 
DNA; the rest was composed of a master mix containing 200 µL of dNTPs (10X), 200 µL of buffer (10X), 
20 µL of each primer (100 µM), and 1500 µL of water.  Primers were acquired from IDT (Coralville, Iowa) 
for both the T7 promoter and T7 terminator regions.  For cylLX genes – which are approximately 200 bp – 
an elongation time of 0.3 min was used.  Amplification products were analyzed by agarose gels (110 V) 
using Quick-Load 50 bp DNA Ladder (New England Biolabs, Ipswich, MA) for the smaller cylLX genes; the 
gels were visualized by staining with SYBR Safe dye (Life Technologies, Grand Island, NY). 
 Overexpression of the gene product was tested by transforming BL21(DE3) E. coli cells (EMD 
Millipore, Darmstadt, Germany) with the plasmids demonstrated to contain insert by PCR.  The cells were 
thawed on ice for 10 min, then 2 µL of plasmid was added to each cell mixture.  The tubes were flicked to 
mix and then allowed to incubate on ice for 30 min.  They were heated to 42 °C for 10 s in a water bath, 
then chilled on ice for 5 min after the addition of 950 µL SOC medium.  The cells were incubated at 37 °C 
for 60 min and plated onto LB agar plates containing 100 µg/mL ampicillin; the mixture plated was 20 µL 
of SOC medium and 30 µL of cell culture.  The cells were also streaked onto plates without antibiotic to 
verify that they had survived the heat shock process. 
 From each transformation plate were taken three colonies for test overexpression, which were 
then used to inoculate 10-mL cultures in LB.  The cultures were grown to an OD600 of 0.5-0.8, then 
induced with IPTG to a final concentration of 0.1 mM.  The cells were allowed to grow overnight at 18 °C.  
Pre- and post-induction aliquots were taken from each culture and the cell density was normalized.  
Sample (10 µL) was combined with Laemmli buffer (20 µL) and boiled in a thermocycler, then run on a 4-
20% gradient acrylamide gel at 190 V. 
Sequencing of cytolysin genes for His6-CylLX substrate peptides for in vitro modification of cytolysin 
substrate peptides (LAGJ.VII.029).  Forward and reverse sequencing reactions were submitted for the 
cylLX genes in pET15b and for cylM in pET28b, using stock T7 primers. 
 3.5.1.b   Cloning of cylL genes into pRSFDuet-1 for in vivo cyclization of CylLX 
It had previously been noted by other members of the van der Donk group (Yi Yu, Yanxiang Shi) 
that overexpression within the pRSFDuet-1 vector yielded more modified, soluble peptide and more 
soluble enzyme.  Therefore, constructs were to be made. 
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Phusion amplification of cytolysin genes for generation of CylLX substrate peptides for in vivo modification 
of cytolysin substrate peptides (LAGJ.VIII.062).  A protocol was adapted from the literature provided with 
Phusion polymerase (New England Biolabs, Ipswich, MA), varying all conditions to determine those which 
were optimal for each gene and primer set.  Using Phusion polymerase, the PCR thermocycler protocol 
was changed to have 36 rounds of 10 s at 98 °C followed by 0.5 min (for cylL) at 72 °C.  Each 
amplification was carried out using both buffers provided with the Phusion polymerase kit (HF buffer, GC 
buffer) and with or without DMSO, for a total of four conditions per amplification.  All amplification 
products were visualized by agarose gel. 
For amplification of cylLL for insertion into pRSFDuet-1 multiple cloning site 1, cylLs into 
pRSFDuet-1 multiple cloning site 1 (MCS 1), and cylLS into pRSFDuet-1 multiple cloning site 2 (MCS 2), 
the best condition was found to be using the GC buffer and DMSO provided in the Phusion polymerase 
kit.  For amplification of cylLL for insertion into pRSFDuet-1 MCS 2, the best condition was found to be 
using the HF buffer provided in the Phusion polymerase kit.  Previously successful experiments with 
pRSFDuet-1 (Yanxiang Shi and prochlorosins) had inserted the lanA into MCS 1 and the lanM into MCS 
2. 
Digestion of cytolysin genes and vectors for generation of CylLX substrate peptides for in vivo modification 
of cytolysin substrate peptides (LAGJ.IX.007).  Genes were simultaneously digested but plasmids were 
serially digested.  For generation of doubly loaded pRSFDuet-1 with substrate genes in MCS 1 and 
synthetase gene in MCS 2, the substrate genes were digested with AscI and HindIII, cylM was digested 
with NdeI and XhoI, and the vector was digested with either set, one at a time.  For generation of doubly 
loaded pRSFDuet-1 with synthetase gene in multiple cloning site 1 and substrate genes in multiple 
cloning site 2, cylM was digested with BamHI and AflII, the substrate genes were digested with NdeI and 
Acc65I, and the vector was digested with either set, one at a time.  All restriction endonucleases were 
purchased from New England Biolabs (Ipswich, MA).  Gene digestion reactions occurred in 50-60 µL 
S1F: 5’ – GGC CTG GTG GCG CGC CGC AGC CAT – 3’ 
S1R: 5’ – CGG GCT TTG TTA GCA GCC GGA AGC TTA TTA GCA AAA TTT TGC GCT AAA CAG 
TGC – 3’ 
S2F: 5’ – CTG GTG CCG CGC GGC AGC CAT ATG CTG AAT AAA GAA AAT CAG GAA AAT TAT  
– 3’ 
S2R: 5’ – TTT CGG GCT TTG TTA GCA GCC GGT ACC GCA AAA TTT TGC GCT AAA CAG – 3’ 
L1F: 5’ – GGC CTG GTG GCG CGC CGC AGC ATG GAA AAT – 3’ 
L1R: 5’ – CGG GCT TTG TTA GCA GCC GGA AGC TTA TTA GCA ATG TTT CAG GCT AAC AAC 
AAC – 3’ 
L2F: 5’ – CCG CGC GGC AGC CAT ATG GAA AAT CTG AGC GTT GTT – 3’ 
L2R: 5’ – TTT CGG GCT TTG TTA GCA GCC GGT ACC GCA ATG TTT CAG GCT AAC AAC – 3’ 
Table 3.1.  Primers used for amplification of cylL genes for cloning into pRSFDuet-1.  Restriction sites are marked.  S = cylLS; L = 
cylLL; 1 = MCS 1; 2 = MCS 2; F = forward primer; R = reverse primer, 
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volume; vector digestion reactions occurred in 80 µL volume.  Following digestion, reaction products were 
analyzed by agarose gel (2%; 40 min at 110 V) and visualized by SYBR Safe dye (Life Technologies, 
Grand Island, NY) to verify the correct size using Quick-Load 50 bp DNA Ladder (New England Biolabs, 
Ipswich, MA) for cylLX genes, then cleaned using a Qiagen gel extraction kit (Valencia, CA). 
Ligation of cytolysin genes into vectors for generation of CylLX substrate peptides for in vivo modification 
of cytolysin substrate peptides (LAGJ.IX.014).  All digested genes were ligated into the vectors planned to 
house them using two methods of ligation.  The first method was 20 µL in volume, containing 2 µL vector, 
6 µL insert, and 1 µL T4 DNA Ligase (New England Biolabs, Ipswich, MA); all 20 µL of the reactions were 
used to transform E. coli DH5α (Cell Media Facility, School of Chemical Sciences, University of Illinois at 
Urbana-Champaign).  The second method was 5 µL in volume, containing 1 µL vector, 1 µL insert, and 
0.7 µL T4 DNA Ligase; the reactions were diluted to 30 µL, 10 µL of which was used to transform E. coli 
DH5α (Cell Media Facility, School of Chemical Sciences, University of Illinois at Urbana-Champaign).  
Prior to ligations, digested vectors were treated with CIP (calf intestinal alkaline phosphatase; New 
England Biolabs, Ipswich, MA) to prevent aberrant re-ligation of empty vectors.  Both ligations were 
allowed to proceed at 23 °C for 30 min, then at 24 °C for 3 h.  All ligations using the second method 
produced transformants. 
Sequencing of cytolysin ligation products for generation of CylLX substrate peptides for in vivo 
modification of cytolysin substrate (LAGJ.IX.020).  Samples were submitted, at least one from each 
construct.  Sequencing results were aligned with the expected sequences using restriction sequences as 
guidemarks.  Correctly sequenced results were obtained for both pET24bcylLL  and pET24bcylLS. 
 3.5.1.c   Cloning of cylL genes into pET24b for in vitro cyclization of CylLX-His6 
Phusion amplification of cytolysin genes for generation of CylLX-His6 substrate peptides for in vitro 
modification of cytolysin substrate peptides (LAGJ.VIII.062).  A protocol was adapted from the literature 
provided with Phusion polymerase (New England Biolabs, Ipswich, MA), varying all conditions to 
determine those which were optimal for each gene and primer set.  Using Phusion polymerase, the PCR 
thermocycler protocol was changed to have 36 rounds of 10 s at 98 °C followed by 0.5 min (for cylL) at 72 
°C.  Each amplification was carried out using both buffers provided with the Phusion polymerase kit (HF 
buffer, GC buffer) and with or without DMSO, for a total of four conditions per amplification.  All 
amplification products were visualized by agarose gel. 
SF: 5’ – CTG GTG CCG CGC GGC AGC CAT ATG CTG AAT AAA GAA AAT CAG GAA AAT TAT – 
3’ 
SR: 5’ – TTT CGG GCT TTG TTA GCA GCC CTC GAG GCA AAA TTT TGC GCT AAA CAG – 3’ 
LF: 5’ – CGC GGC AGC CAT ATG GAA AAT CTG AGC GTT GTT CCG AGC TTT – 3’ 
LR: 5’ – TTT CGG GCT TTG TTA GCA GCC CTC GAG GCA ATG TTT CAG GCT AAC AAC AAC – 3’ 
Table 3.2.  Primers for generation of C-His6-tagged cytolysin peptides.  Restriction endonuclease sites are marked. S = cylLS; L = 
cylLL; F = forward primer; R = reverse primer. 
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 For amplification of cylLL for insertion into pET24b, the best condition was found to be using the 
HF buffer provided in the Phusion polymerase kit.  For amplification of cylLS for insertion into pET24b, the 
best condition was found to be using the HF buffer and DMSO provided in the Phusion polymerase kit.   
Digestion of cytolysin genes and vectors for generation of CylLX-His6 substrate peptides for in vitro 
modification of cytolysin substrate peptides (LAGJ.IX.007).  Genes were simultaneously digested but 
plasmids were serially digested.  For generation of C-terminally His-tagged substrate-encoding genes, 
pET24b and genes were digested with NdeI and XhoI (New England Biolabs, Ipswich, MA).  Gene 
digestion reactions occurred in 50-60 µL volume; vector digestion reactions occurred in 80 µL volume.  
Following digestion, reaction products were analyzed by agarose gel (2%; 40 min at 110 V) and 
visualized by SYBR Safe dye (Life Technologies, Grand Island, NY) to verify the correct size using Quick-
Load 50 bp DNA Ladder (New England Biolabs, Ipswich, MA) for cylLX genes, then cleaned using a 
Qiagen gel extraction kit (Valencia, CA). 
Ligation of cytolysin genes into vectors for generation of CylLX-His6 substrate peptides for in vitro 
modification of cytolysin substrate peptides (LAGJ.IX.014).  All digested genes were ligated into the 
vectors planned to house them using two methods of ligation.  The first method was 20 µL in volume, 
containing 2 µL vector, 6 µL insert, and 1 µL T4 DNA Ligase (New England Biolabs, Ipswich, MA); all 20 
µL of the reactions were used to transform E. coli DH5α (Cell Media Facility, School of Chemical 
Sciences, University of Illinois at Urbana-Champaign).  The second method was 5 µL in volume, 
containing 1 µL vector, 1 µL insert, and 0.7 µL T4 DNA Ligase; the reactions were diluted to 30 µL, 10 µL 
of which was used to transform E. coli DH5α.  Prior to ligations, digested vectors were treated with CIP 
(calf intestinal alkaline phosphatase; New England Biolabs, Ipswich, MA) to prevent aberrant re-ligation of 
empty vectors.  Both ligations were allowed to proceed at 23 °C for 30 min, then at 24 °C for 3 h.  All 
ligations using the second method produced transformants. 
Sequencing of cytolysin ligation products for generation of CylLX-His6 substrate peptides for in vitro 
modification of cytolysin substrate peptides (LAGJ.IX.020).  Samples were submitted, at least one from 
each construct.  Sequencing results were aligned with the expected sequences using restriction 
sequences as guidemarks.  Correctly sequenced results were obtained for the following constructs: 
pRSFDuet-1 with cylLL in multiple cloning sites 1 and 2, and pRSFDuet-1 with cylLS in multiple cloning 
sites 1 and 2. 
 3.5.1.d   Cloning of tetralysine tag into cylL genes 
Nested PCR amplification of tetra-Lys-tagged CylLX substrate peptides for in vitro modification of cytolysin 
substrate peptides (LAGJ.IX.004).  To increase solubility of cytolysin substrate peptides, a tetralysine tag 
was to be incorporated using nested PCR.  Forward and reverse megaprimers were generated using all 
manufacturer-suggested Phusion (New England Biolabs, Ipswich, MA) amplification conditions.  
Amplification products were analyzed by agarose gel using Quick-Load 50 bp DNA Ladder (New England 
Biolabs).  No bands could be seen at any size under any of the amplification conditions. 
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3.5.2   Cloning of cylM gene into overexpression vectors 
Acquisition of codon-optimized cyl genes for overexpression in Escherichia coli (LAGJ.V.069).  Due to the 
required clearances for growing the native producer Enterococcus faecalis, which necessitates Biosafety 
Level 2 workspace, it was decided to heterologously overexpress the proteins in E. coli.  The amino acid 
sequences for CylLS, CylLL, and CylM were found by conducting a search of the E. faecalis genome in 
PubMed using each gene name.  These sequences were then submitted to GeneArt (Darmstadt, 
Germany) for E. coli codon-optimized synthesis. For the synthetase-encoding gene, which was to be 
moved into pET28b, a kanamycin resistant vector was requested to be used with NheI and XhoI 
restriction sites. 
3.5.2.a   Generation of pET28bcylM for in vitro cyclization of cytolysin peptides 
Digestions of cylM gene and pET28b vectors for generation of His6-CylM lantibiotic synthetase for 
in vitro modification of cytolysin substrate peptides (LAGJ.VI.011; LAGJ.IX.043; LAGJ.X.005). Genes 
were digested in 60-µL reactions; plasmids were digested in 80-µL reactions for the first round of 
digestion and 60-µL reactions for the second round of digestion.  To increase digestion efficiency, final 
concentrations of restriction enzyme were raised to 10% of the total volume and plasmid stocks were 
concentrated under nitrogen gas to reach 600 ng/µL prior to commencing digestions.  The concentrations 
were such that sufficient enzyme was present to digest all of it within the time window of digestion – this 
was calculated according to manufacturer’s recommendations.  Genes and plasmids were also digested 
S15F: 5’ – GTG CCG CGC GGC AGC CAT ATG AAA AAA AAA AAA CTG AAT AAA GAA AAT CAG 
GAA – 3’ 
S15R: 5’ – TTC CTG ATT TTC TTT ATT CAG TTT TTT TTT TTT CAT ATG GCT GCC GCG CGG 
CAC – 3’ 
S24F: 5’ – TAG GAG GGA GAT ATA CAT ATG AAG AAG AAG AAG CTG AAT AAG GAG AAT CAG 
GAG – 3’ 
S24R: 5’ – CTC CTG ATT CTC CTT ATT CAG CTT CTT CTT CTT CAT ATG TAT ATC TCC CTC 
CTA – 3’ 
L15F: 5’ – GTG CCG CGC GGC AGC CAT ATG AAA AAA AAA AAA GAA AAT CTG AGC GTT GTT 
CCG – 3’ 
L15R: 5’ – CGG AAC AAC GCT CAG ATT TTC TTT TTT TTT TTT CAT ATG GCT GCC GCG CGG 
CAC – 3’ 
L24F: 5’ – GAG GGA GAC ATA CAT ATG AAG AAG AAG AAG GAA AAT CTG AGC GTT GTT CCG 
ACG – 3’ 
L24R: 5’ – CGT CGG AAC AAC GCT CAG ATT TTC CTT CTT CTT CTT CAT ATG TAT GTC TCC 
CTC – 3’ 
Table 3.3.  Primers for generation of tetralysine tags.  Restriction sites are marked.  S = cylLS; L = cylLL; 15 = pET15b; 24 = 
pET24b; F = forward primer; R = reverse primer,	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in 50-µL reactions for all rounds.  Both serial and simultaneous digests were attempted for all constructs.  
The modification gene – cylM – was to be cloned into pET28 using XhoI and NheI (New England Biolabs, 
Ipswich, MA).  Reactions were allowed to proceed for 8 h at 37 °C, then the enzymes were heat 
deactivated at 65 °C for 20 min. Plasmids were treated with 1 µL of CIP (calf intestinal alkaline 
phosphatase; New England Biolabs) per reaction for 1 h at 37 °C.  Immediately following the conclusion 
of the incubation, the digestion products were assayed by agarose gel (0.7%; 35-40 min at 110 V) and 
visualized using SYBR Safe dye (Life Technologies, Grand Island, NY).  By bandshifts, the plasmids 
appeared to be cut. 
Ligations of cylM gene into pET28b vector for generation of His6-CylM lantibiotic synthetase for in vitro 
modification of cytolysin substrate peptides (LAGJ.VI.084; LAGJ.IX.014; LAGJ.IX.051; LAGJ.X.10).  DNA 
concentrations of inserts and vectors were assayed by Nanodrop. All digested genes were ligated into the 
vectors planned to house them using several methods of ligation.  First, ligations were carried out at 1:1, 
1:3, and 1:5 ratios of insert to vector in 10.5-µL reactions with 0.5 µL T4 DNA Ligase (New England 
Biolabs, Ipswich, MA).  The reactions were incubated for 16 h at 16 °C, then diluted to 25 µL with sterile 
water for transformation of E. coli DH5α (Cell Media Facility, School of Chemical Sciences, University of 
Illinois at Urbana-Champaign) using the heat shock method.  Transformed cells were cultured on LB agar 
plates containing kanamycin. 
The second method was 20 µL in volume, containing 2 µL vector, 6 µL insert, and 1 µL T4 DNA 
Ligase; all 20 µL of the reactions were used to transform E. coli DH5α.  The third method was 5 µL in 
volume, containing 1 µL vector, 1 µL insert, and 0.7 µL T4 DNA Ligase; the reactions were diluted to 30 
µL, 10 µL of which was used to transform E. coli DH5α.  Both the second and third methods of ligation 
reactions were allowed to proceed at 23 °C for 30 min, then at 24 °C for 3 h.  All ligations using the third 
method produced transformants. 
Another set of ligation reactions were set up in 5-µL volume with 1:1, 1:10, or 1:100 vector to 
insert and 0.7 µL enzyme; prior to ligation, the digested vectors were CIP treated to minimize ligation of 
empty vectors and false negatives in the transformations.  The reactions were allowed to proceed at 16 
°C for 16 h or at 23 °C for 0.5 h and 24 °C for 3 h.  After ligating, the reactions were diluted to 30 µL total 
volume, 10 µL of which was used to transform E. coli DH5α.  However, a high proportion of negative 
transformants and unexpected ratio of positive transformations uncorrelated with concentrations of 
serially diluted insert stocks indicated a problem with either the digestion and/or the CIP treatment prior to 
ligation. 
PCR verification of cylM gene for generation of His6-CylM lantibiotic synthetase for in vitro modification of 
cytolysin substrate peptides (LAGJ.VII.003).  PCR amplification reactions were set up on 50-µL scale 
using 48.5 µL of a master mix containing 200 µL of dNTPs (10X), 200 µL of 10X buffer, 20 µL of each 
forward and reverse primer (100 µM), and 1500 µL of water.  This was supplemented with 0.5 µL of 
Platinum Pfx polymerase (Life Technologies, Grand Island, NY), 1 µL of DNA, and 1 µL of 50 mM MgSO4.  
Primers used were for the T7 promoter and the T7 terminator, both acquired from IDT (Coralville, Iowa).  
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For the cylM gene – which is 3 kb – an elongation time of 3.5 min was used.  Amplification products were 
analyzed by agarose gels (110 V) and visualized using SYBR Safe dye (Life Technologies). 
 Overexpression of the gene product was tested by transforming BL21(DE3) E. coli cells (EMD 
Millipore, Darmstadt, Germany) with the plasmids demonstrated to contain insert by PCR.  The cells were 
thawed on ice for 10 min, then 2 µL of plasmid was added to each cell mixture.  The tubes were flicked to 
mix and then allowed to incubate on ice for 30 min.  They were heated to 42 °C for 10 s in a water bath, 
then chilled on ice for 5 min with 950 µL SOC medium added.  The cells were incubated at 37 °C for 60 
minutes and plated onto LB agar plates containing 50 µg/mL kanamycin; the mixture plated was 20 µL of 
SOC medium and 30 µL of cell culture.  The cells were also streaked onto plates without antibiotic to 
verify that they had survived the heat shock process. 
 From each transformation plate was taken three colonies for test overexpression, which were 
then used to inoculate 10-mL cultures in LB.  The cultures were grown to an OD600 of 0.5-0.8, then 
induced with IPTG to a final concentration of 0.1 mM.  The cells were allowed to grow overnight at 18 °C.  
Pre- and post-induction aliquots were taken from each culture and the cell density was normalized.  
Sample (10 µL) was combined with Laemmli buffer (20 µL) and boiled in a thermocycler, then run on a 4-
20% gradient acrylamide gel at 190 V.  
Sequencing of cytolysin genes for generation of His6-CylM lantibiotic synthetase for in vitro modification of 
cytolysin substrate peptides (LAGJ.VII.029; LAGJ.IX.020).  Forward and reverse sequencing reactions 
were submitted for cylM in pET28b, using stock T7 primers.  To sequence the full cylM gene, internal 
primers were ordered from IDT; if a positive sequencing result was achieved, the same sample would be 
resubmitted using the internal primers to generate a sequence for the full gene.  Each centered around 
every 500 bp within the expected sequence of the gene and were 39 bp in length; both forward and 
reverse primers were ordered (Table 3.4). Sequencing results were aligned with the expected sequences 
using restriction sequences as guidemarks. 
500 bp F: 5’ – CCC TGG TTC TGG ATC TGC ATA CCT TTA AAA AAA ATG AAC – 3’ 
1000 bp F: 5’ – ATC GAA GAA GTG AAA AAA TAT TAC GAA CGC TAT GGC AAA – 3’ 
1500 bp F: 5’ – AAA AAA AAT TCT GGC CTA TAT TAA TAA TAA TCT GCA GAA – 3’ 
2000 bp F: 5’ – AAA TTG AAA AAA AAA TCT TTA AAC GTG CCA TCT TTA ACA – 3’ 
2500 bp F: 5’ – AGC GAA GAA CCG TAT TTT AAT TTT CGT GGT TTT GGC CAT – 3’ 
2500 bp R: 5’ – ATG GCC AAA ACC ACG AAA ATT AAA ATA CGG TTC TTC GCT – 3’ 
2000 bp R: 5’ – TGT TAA AGA TGG CAC GTT TAA AGA TTT TTT TTT CAATTT – 3’ 
1500 bp R: 5’ – TTC TGC AGA TTA TTA TTA ATA TAG GCC AGA ATT TTT TTT – 3’ 
1000 bp R: 5’ – TTT GCC ATA GCG TTC GTA ATA TTT TTT CAC TTC TTC GAT – 3’ 
500 bp R: 5’ – GTT CAT TTT TTT TAA AGG TAT GCA GAT CCA GAA CCA GGG – 3’ 
Table 3.4.  Primers for sequencing full cylM gene.  Primers each center around the nucleotide at the indicated position.  F = 
forward; R = reverse. 
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3.5.2.b   Generation of pRSFDuet-1cylM for in vivo cyclization of cytolysin peptides 
Phusion amplification of cytolysin genes for generation of CylM lantibiotic synthetase for in vivo 
modification of cytolysin substrate peptides (LAGJ.VIII.062; LAGJ.IX.071).  A protocol was adapted from 
the literature provided with Phusion polymerase (New England Biolabs, Ipswich, MA), varying all 
conditions to determine those which were optimal for each gene and primer set.   
Using Phusion polymerase, the PCR thermocycler protocol was changed to include 36 rounds of 
10 s at 98 °C followed by 4 min (for cylM) at 72 °C.  Each amplification was carried out using both buffers 
provided with the Phusion polymerase kit (HF buffer, GC buffer) and with or without DMSO, for a total of 
four conditions per amplification. Freshly purified pET24bcylM was used as the template for two PCR 
amplification reactions of cylM – one for insertion into MCS1 of pRSFDuet-1 and one for insertion into 
MCS2 – in 50-µL reaction volume; all other reactions were run using the GeneArt plasmid as the 
template. A 0.7% agarose gel was poured to verify the expected ~3 kb size of the amplification products, 
which were purified using a Qiagen kit (Valencia, CA). Concentrations of DNA were assayed and the 
DNA was then further concentrated under N2 gas until the concentration was greater than 600 ng/µL; the 
stocks were stored at -20 °C. 
For amplification of cylM for insertion into pRSFDuet-1 multiple cloning site 1 or 2, the best 
condition was found to be using the GC buffer provided in the Phusion polymerase kit.  It had previously 
been noted by other members of the van der Donk group (Yi Yu, Yanxiang Shi) that overexpression 
within the pRSFDuet-1 vector yielded more modified, soluble peptide and more soluble enzyme. 
Digestion of cylM gene and pRSFDuet-1 for generation of CylM lantibiotic synthetase for in vivo 
modification of cytolysin substrate (LAGJ.IX.007; LAGJ.IX.043; LAGJ.X.005).  Genes were 
simultaneously digested but plasmids were serially digested.  Vectors previously sequenced and found to 
contain either cylLL or cylLS in either multiple cloning site 1 or site 2 of pRSFDuet-1 were isolated. To 
increase digestion efficiency, plasmid stocks were concentrated under nitrogen gas to reach 600 ng/µL 
prior to commencing digestions.  The concentrations were such that sufficient enzyme was present to 
digest all of it within the time window of digestion – this was calculated according to manufacturer’s 
recommendations.  For generation of doubly loaded pRSFDuet-1 with substrate genes in multiple cloning 
site 1 and synthetase gene in multiple cloning site 2, cylM was digested with NdeI and XhoI, with the 
1F: 
5’ – GTG CCG CGC GGC AGC CAT ATG GAT CCC ATG GAA GAT AAT CTG ATT AAT GTG – 
3’ 
1R: 
5’ – TCA GTG GTG GTG GTG GTG GTG GTG CTT AAG TTA TTA CAG TTC AAA CAG CAG 
TGC – 3’ 
2F: 
5’ – GTG CCG CGC GGC AGC CAT ATG GCT AGC ATG GAA GAT AAT CTG ATT AAT GTG – 
3’ 
2R: 5’ – GTG GTG GTG GTG GTG CTC GAG CAG TTC AAA CAG CAG – 3’ 
Table 3.5.  Primers used for generation of pRSFDuet-1 constructs for in vivo cyclization of peptides.  Restriction endonuclease 
sites are marked.  1 = MCS 1; 2 = MCS 2; F = forward; R = reverse. 
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enzymes accounting for up to 10% of the final reaction volume.  For generation of doubly loaded 
pRSFDuet-1 with synthetase gene in multiple cloning site 1 and substrate genes in multiple cloning site 2, 
cylM was digested with BamHI and AflII, with the enzymes accounting for up to 10% of the final reaction 
volume.  All restriction endonucleases were purchased from New England Biolabs (Ipswich, MA).  Gene 
digestion reactions occurred in 50-60 µL volume; plasmids were digested in 80-µL reactions for the first 
round of digestion and 60-µL reactions for the second round of digestion.  Genes and plasmids were also 
digested in 50-µL reactions for all rounds. Digestions were allowed to proceed at 37 °C for 8 h, then the 
enzymes were heat deactivated at 65 °C for 20 min; it should be noted that BamHI cannot be heat 
deactivated, but is generally not active through 8 h of digestion.  Plasmids were treated with 1 µL of CIP 
(calf intestinal alkaline phosphatase; New England Biolabs) per reaction for 1 h at 37 °C.  Following 
digestion, reaction products were analyzed by agarose gel (0.7%; 35-40 min at 110 V) and visualized 
using SYBR Safe dye (Life Technologies, Grand Island, NY), then cleaned using a Qiagen gel extraction 
kit (Valencia, CA).  By bandshifts, the plasmids appeared to be cut. 
Ligation of cylM into vector for generation of CylM lantibiotic synthetase for in vivo modification of 
cytolysin substrate (LAGJ.IX.014; LAGJ.IX.051; LAGJ.X.10).  All digested genes were ligated into the 
vectors planned to house them using three methods of ligation.  The first method was 20 µL in volume, 
containing 2 µL of vector, 6 µL of insert, and 1 µL of T4 DNA Ligase (New England Biolabs, Ipswich, MA); 
all 20 µL of the reactions were used to transform E. coli DH5α (Cell Media Facility, School of Chemical 
Sciences, University of Illinois at Urbana-Champaign).  The second method was 5 µL in volume, 
containing 1 µL of vector, 1 µL of insert, and 0.7 µL of T4 DNA Ligase; the reactions were diluted to 30 
µL, 10 µL of which was used to transform E. coli DH5α.  Both ligations were allowed to proceed at 23 °C 
for 30 min, then at 24 °C for 3 h.  All ligations using the second method produced transformants. 
A third set of ligation reactions were set up in 5-µL volume with 1:1, 1:10, or 1:100 vector to insert 
and 0.7 µL of enzyme; prior to ligation, the digested vectors were CIP (calf intestinal alkaline 
phosphatase; New England Biolabs) treated to minimize ligation of empty vectors and false negatives in 
the transformations.  The reactions were allowed to proceed at 16 °C for 16 h or at 23 °C for 0.5 h and 24 
°C for 3 h.  After ligating, the reactions were diluted to 30 µL total volume, 10 µL of which was used to 
transform E. coli DH5α.  A high proportion of negative transformants and unexpected ratio of positive 
transformants produced by serially diluted insert stocks indicated a problem with either the digestion 
and/or the CIP treatment prior to ligation. 
Colony PCR amplification of cylM-containing pRSFDuet-1 for generation of CylM lantibiotic synthetase for 
in vivo modification of cytolysin substrate peptides (LAGJ.IX.055; LAGJ.X.014).  Reactions were set up in 
20-µL volumes to amplify cylM out of pRSFDuet-1 ligation products.  Colonies were selected from each 
transformation plate.  The colonies were transferred to a fresh plate by touching with a sterile pipet tip, 
which was then used to mix the PCR reaction.  Amplification products were analyzed by agarose gel 
(0.7%).  Products containing the gene of the expected size (3 kb) were noted and their corresponding 
colonies were grown overnight to generate a glycerol stock and plasmid stock for sequencing. 
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Sequencing of cytolysin ligation products for generation of CylM lantibiotic synthetase for in vivo 
modification of cytolysin substrate peptides (LAGJ.IX.020).  Samples were submitted, at least one from 
each construct.  Sequencing of pRSFDuet-1 was carried out using the ACYCDuet UP1 and DuetDOWN1 
primers for site 1 and DuetUP2 and T7 terminator for site 2, all acquired from IDT (Coralville, Iowa).  
Sequences of cylM genes were initially requested using only external primers; if a positive sequencing 
result was achieved, the same sample would be resubmitted using internal primers to generate a 
sequence for the full gene.  Sequencing results were aligned with the expected sequences using 
restriction sequences as guidemarks.  However, all sequencing results returned negative, indicating that 
neither the synthetase-encoding nor the substrate-encoding gene were present in the final plasmid. 
3.5.2.c   Generation of pET24bcylM for in vitro cyclization of cytolysin peptides 
Phusion amplification of cytolysin genes for generation of CylM-His10 lantibiotic synthetase for in vitro 
modification of cytolysin substrate peptides (LAGJ.VIII.062).  A protocol was adapted from the literature 
provided with Phusion polymerase (New England Biolabs, Ipswich, MA), varying all conditions to 
determine those which were optimal for each gene and primer set.   
Using Phusion polymerase, the PCR thermocycler protocol was changed to include 36 rounds of 
10 s at 98 °C followed by 4 min (for cylM) at 72 °C.  Each amplification was carried out using both buffers 
provided with the Phusion polymerase kit (HF buffer, GC buffer) and with or without DMSO, for a total of 
four conditions per amplification.  All amplification products were visualized by agarose gel. 
For amplification of cylM for insertion into pET24b, the best condition was found to be using the 
GC buffer provided in the Phusion polymerase kit. 
Digestion of cylM and pET24b for generation of CylM-His10 lantibiotic synthetase for in vitro 
modification of cytolysin substrate peptides (LAGJ.VIII.073; LAGJ.IX.007).  The gene and vector were 
digested using NheI and XhoI (New England Biolabs, Ipswich, MA) in 50-µL volume. Genes were 
simultaneously digested but plasmids were serially digested, with respect to the restriction enzymes. To 
increase digestion efficiency, final concentrations of restriction enzyme were raised to 10% of the total 
volume and plasmid stocks were concentrated under nitrogen gas to reach 600 ng/µL prior to 
commencing digestions.  The concentrations were such that sufficient enzyme was present to digest all of 
it within the time window of digestion – this was calculated according to manufacturer’s 
recommendations.  Gene digestion reactions occurred in 50-60 µL volume; vector digestion reactions 
occurred in 80 µL volume.  The reactions were allowed to proceed for 8 h at 37 °C.  After digestion, the 
DNA reaction products were analyzed by agarose gel to verify the correct size, then cleaned using a 
Qiagen kit (Valencia, CA), eluting into a final volume of 35 µL, and stored at -20 °C. 
F: 5’ – CCG CGC GGC AGC CAT ATG GCT AGC ATG GAA GAT AAT CTG ATT AAT GTG CTG – 3’ 
R: 5’ – GTG GTG GTG GTG GTG GTG CTC GAG GTG GTG GTG GTG CAG TTC AAA CAG – 3’ 
Table 3.6.  Primers for generation of C-His10-tagged CylM.  Restriction sites are marked.  F = forward; R = reverse. 
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Ligation of cylM into pET24b for generation of CylM-His10 lantibiotic synthetase for in vitro modification of 
cytolysin substrate peptides (LAGJ.VIII.077; LAGJ.IX.014).  Concentrations of DNA were assayed on the 
Nanodrop. All digested genes were ligated into the vectors planned to house them using three methods of 
ligation.  First, ligation reactions were set up at 1:1, 1:3, and 1:5 ratios of plasmid to insert in 10-µL 
volumes.  The ligations were allowed to proceed for 16 h at 16 °C, then divided in half.  One 5-µL aliquot 
was diluted five-fold, to a final volume of 25 µL, and the other was left undiluted.  Each stock was used to 
transform E. coli DH5α (Cell Media Facility, School of Chemical Sciences, University of Illinois at Urbana-
Champaign). 
The second method was 20 µL in volume, containing 2 µL of vector, 6 µL of insert, and 1 µL of T4 
DNA Ligase (New England Biolabs, Ipswich, MA); all 20 µL of the reactions were used to transform E. coli 
DH5α.  The third method was 5 µL in volume, containing 1 µL of vector, 1 µL of insert, and 0.7 µL of T4 
DNA Ligase; the reactions were diluted to 30 µL, 10 µL of which was used to transform E. coli DH5α.  
Both of the latter two sets of ligations were allowed to proceed at 23 °C for 30 min, then at 24 °C for 3 h.  
All ligations using the final method produced transformants. 
Sequencing of cytolysin ligation products for generation of CylM-His10 lantibiotic synthetase for in vitro 
modification of cytolysin substrate peptides (LAGJ.IX.020).  Samples were submitted.  Sequences of cylM 
genes were initially requested using only external primers; if a positive sequencing result was achieved, 
the same sample would be resubmitted using internal primers to generate a sequence for the full gene.  
Sequencing results were aligned with the expected sequences using restriction sequences as 
guidemarks.  Correctly sequenced results were obtained for pET24bcylM. 
 
3.5.3   Overexpression of CylL peptides 
Overexpression of His6-CylLX substrate peptides for in vitro modification of cytolysin substrate peptides 
(LAGJ.VII.099).  Freshly transformed E. coli BL21(DE3) (EMD Millipore, Darmstadt, Germany) were used 
to inoculate 50-mL starter cultures containing 500 µg/mL ampicillin.  These starter cultures were grown 
overnight and each was used to inoculate a 2-L culture.  Once the cell density reached an OD600 value of 
0.6, cultures were induced to a final concentration of 1 mM IPTG.  Post-induction cultures were grown for 
4 h at 37 °C. 
 Several overexpression conditions were attempted, including varying the temperature post-
induction (18 °C, 25 °C, and 37 °C), changing the amount of IPTG used to induce the culture (0.1 mM, 
0.25 mM, 0.5 mM, and 1 mM).  Cell culture aliquots were taken at time points during the post-induction 
growth to monitor OD600 and assess whether the peptide products may be toxic to the producing cells.  
Cultures were checked for overexpression by PAGE and MALDI-MS. 
  
3.5.4   Purification of CylL peptides 
Purification of His6-CylLX substrate peptides for in vitro modification of cytolysin substrate peptides 
(LAGJ.VIII.026).  This protocol was previously reported in Li, Cooper, and van der Donk in Methods in 
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Enzymology (2009).  To summarize, thawed cell pellets were resuspended in 10 mL LanA Start Buffer 
(20 mM NaH2PO4, 500 mM NaCl, 0.5 mM imidazole, 20% [v/v] glycerol; pH 7.5) per L of culture.  The 
cells were homogenized and lysed by sonication using the microtip (35% amplitude, 4 s on, 9.9 s off; 5 
min total sonication).  Cell debris was pelleted at 23700xg at 4 °C for 30 min.  The pellet was kept and the 
supernatant set aside.  The pellet was resuspended into LanA Start Buffer and the sonication and 
pelleting was repeated.  Again, the supernatant was set aside and the pellet resuspended, this time into 
LanA Buffer 1 (6 M GnHCl, 20 mM NaH2PO4, 500 mM NaCl, 0.5 mM imidazole; pH 7.5).  The 
resuspended pellet was once more sonicated and pelleted, then the supernatant was filter clarified (0.45-
µm).  The filtered solution was added to a pre-equilibrated Ni2+-affinity column (5 mL; IMAC Sepharose 
High Performance, GE Healthcare, Piscataway, NJ), which was washed with 2 CV LanA of Buffer 1 and 2 
CV of LanA Buffer 2 (4 M GnHCl, 20 mM NaH2PO4, 300 mM NaCl, 30 mM imidazole; pH 7.5).  The 
peptide was eluted in 4 CV of LanA Elution Buffer (4 M GnHCl, 20 mM Tris, 100 mM NaCl, 1 M imidazole; 
pH 7.5), collected in 2.5-, 7.5-, 5-, and 5-mL fractions.  The second fraction was then further purified by 
HPLC using a C4 column and a gradient from 2% Buffer A (80% acetonitrile containing 0.086% TFA) with 
98% Buffer D (0.1% TFA) to 100% Buffer A over the course of 45 min at a flow rate of 8 mL/min, 
collecting peaks for MALDI analysis.  Peaks seen to contain peptide at the expected mass were 
lyophilized to powder for future use. 
 
3.5.5   Overexpression of CylM synthetase 
Overexpression of His6-CylM lantibiotic synthetase for in vitro modification of cytolysin substrate peptides 
(LAGJ.VIII.043).  Freshly transformed E. coli BL21(DE3) (New England Biolabs, Ipswich, MA) were used 
to inoculate 50-mL starter cultures containing 50 µg/mL kanamycin.  These starter cultures were each 
used to inoculate 2-L culture.  Once the cell density reached an OD600 value of 0.6, cultures were induced 
to a final concentration of 0.25 mM IPTG.  Post-induction cultures were grown overnight at 18 °C. 
 Several conditions were attempted, including post-induction growth at 18 °C, 25 °C, and 37°C; 
induction with 0.1 mM, 0.25 mM, 0.5 mM, 1 mM, and 2 mM final concentration of IPTG; and induction at 
OD600 values of 0, 0.6, 1.2, and 1.8.  Overexpression gels were run with every test condition until 
overexpression was achieved.  To verify overexpression, small scale purifications were run on pellets 
from conditions that seemed to work by PAGE gel.  This included resuspension of the pellet into 1 mL 
New Resuspension Buffer (20 mM Tris, 1 M NaCl, 10% glycerol; pH 7.6), lysis with lysozyme (1 mg per 
10 mL overexpression culture; Sigma Aldrich, St. Louis, MO) for 30 min on ice, brief sonication with the 
microtip (9.9 s on, 5 s off, 35% amplitude; 6 cycles in total), and pelleting at 10000xg for 30 min.  The 
supernatant was applied to columns from the Qiagen Ni-NTA Spin Kit (Valencia, CA) and eluted 
according to the stepwise gradient suggested in the Qiagen protocol.  The fractions were run on a 4-20% 
Tris-HCl acrylamide gel at 195 V for 50 min. 
Overexpression of CylM-His10 lantibiotic synthetase for in vitro modification of cytolysin substrate peptides 
(LAGJ.IX.039).  Freshly transformed E. coli BL21(DE3) (New England Biolabs, Ipswich, MA) were used to 
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inoculate 10-mL starter cultures.  The cultures were then used to inoculate 2-L overexpression cultures, 
one in LB and one in TB.  Once the cell density reached an OD600 value of 1.2 for LB and 0.8 for TB, the 
cultures were induced to 1 mM and 0.1 mM IPTG final concentration, respectively.  The cultures were 
grown overnight at 18 °C and then harvested, yielding 3.7 g wet cell pellet per L of LB culture and 5.1 g 
wet cell pellet per L of TB culture. 
 
3.5.6   Purification of CylM lantibiotic synthetase 
Purification of His6-CylM lantibiotic synthetase for in vitro modification of cytolysin substrate peptides 
(LAGJ.VIII.052). This protocol was previously reported by Li, Cooper, and van der Donk in Methods in 
Enzymology (2009).  To summarize, the pellet was resuspended into 35 mL of Yanxiang Shi’s LanM 
Buffer (20 mM Tris, 1 M NaCl, 10% [v/v] glycerol; pH 8) and lysed using the cell homogenizer (Avestin 
Emulsiflex-C3 Homogenizer; 15 kPsi, 6 passes) until the solution was no longer sticky.  The mixture was 
spun at 23700xg (4 °C) for 45 min to pellet the debris.  The supernatant was filter clarified (0.45-µm) and 
applied to a pre-equlibrated Ni2+-affinity column (5 mL; IMAC Sepharose High Performance, GE 
Healthcare, Piscataway, NJ) at 4 °C. The column was washed with 10 CV of Yanxiang Shi’s LanM Wash 
Buffer (20 mM Tris, 1 M NaCl, 30 mM imidazole; pH 8).  The protein was eluted with 2 CV of proportions 
of Yanxiang Shi’s LanM Start Buffer and Yanxiang Shi’s LanM Elution Buffer (20 mM Tris, 1 M NaCl, 200 
mM imidazole; pH 8) – ranging from 0-1000 mM imidazole – collecting fractions.  The fractions containing 
CylM were identified by SDS-PAGE, but the protein was found to be insoluble. 
Western blot of His6-CylM purification for in vitro modification of cytolysin substrate peptides 
(LAGJ.VIII.036).  Samples were selected and run on a 7.5% SDS-PAGE gel.  The protein bands were 
transferred to a nitrocellulose membrane (Hybond-C Extra from Amersham, Piscataway, NJ) in transfer 
buffer (25 mM Tris, 192 mM glycine, 20% [v/v] methanol; pH 8.3); this was accomplished by presoaking 
filter pads, sponges, membrane, filter paper, and gel in transfer buffer, then assembling the transfer 
apparatus according to the manufacturer’s instructions, taking care to prevent the inclusion of air bubbles.  
The transfer was run at 100 V (350 mA) for 1 h on ice.  The membrane was blocked overnight at 4 °C in 
TBST (20 mM Tris-HCl, 150 mM NaCl, 0.05% [v/v] Tween-20; pH 7.5) containing 5% milk (BioRad, 
Hercules, CA).  The membrane was tagged in TBST containing 1% milk and primary antibody 
(monoclonal anti-polyhistidine clone His-1 from Sigma, St. Louis, MO) by rocking at room temperature for 
1 h.  The membrane was rinsed three times in 20 mL aliquots of TBST, incubating with rocking for 5 min 
each wash.  The membrane was soaked in TBST containing 1% milk and secondary antibody (anti-
mouse IgG [Fc specific] alkaline phosphatase conjugate from Sigma) at room temperature for 1 h with 
gentle agitation.  The membrane was rinsed again as before, and then developed in alkaline phosphatase 
buffer (100 mM Tris-HCl, 100 mM NaCl, 5 mM MgCl2; pH 9.5) containing 66 µL of nitrobluetatrazolium (50 
mg/mL; Promega, Madison, WI) and 33 µL of 5-bromo-4-chloro-3-indolylphosphate (50 mg/mL; Promega) 
per 10 mL buffer.  The mixture was incubated in the dark for 1 h at room temperature; the control band 
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was apparent after 5 min.  The solution was decanted and the membrane was rinsed, then air dried in the 
dark.  No His6-CylM bands were visible. 
Attempted purification of CylM-His10 lantibiotic synthetase for in vitro modification of cytolysin substrate 
peptides (LAGJ.IX.046).  Cell pellet was thawed on ice and resuspended into 10 mL LanM Start Buffer 
(20 mM Tris, 500 mM NaCl, 10% [v/v] glycerol; pH 7.6) per L of culture producing the pellet.  Once 
thawed, the cells were lysed by cell homogenizer (Avestin Emulsiflex-C3 Homogenizer; 15 kPsi, 6 
passes) and the debris pelleted by spinning at 23700xg (4 °C) for 45 min.  The supernatant was filter-
clarified (0.45-µm) and applied to a previously equilibrated Ni2+-affinity column (5 mL; IMAC Sepharose 
High Performance, GE Healthcare, Piscataway, NJ).  Buffer washes were prepared by combining several 
proportions of LanM Start Buffer and LanM Elution Buffer (20 mM Tris, 500 mM NaCl, 1 M imidazole, 
10% [v/v] glycerol; pH 7.6), varying the concentration of imidazole from 0-1000 mM.  Fractions were 
analyzed for CylM content by SDS-PAGE.  Despite the increased proportion of histidine residues in and 
relocation of the tag, there did not appear to be a higher level of affinity for the column. 
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CHAPTER 4 
 
Structural Determination and Binding Characterization of NisI in the Presence of Nisin 
 
4.1   Introduction 
4.1.1.   Nisin, the prototypical lantibiotic 
As of 2007, nisin was the only lantibiotic available for commercial use.1  In fact, nisin is one of 
very few antibiotics used both as a preservative in the food industry and as an antibiotic in health care.2  
Discovered one year prior to penicillin in 1927, nisin has been widely used as a food preservative in dairy 
products, canned vegetables, and fermented beverages since 1951 without significant development of 
resistance, which is one of the principal reasons lantibiotics as a class are so appealing.1,3-6  This 
observation is often attributed to its dual mode of action.1,7,8 
Nisin is produced by the organism Lactococcus lactis and is active at nanomolar to micromolar 
concentrations against many Gram-positive bacteria, including methicillin-resistant Staphylococcus 
aureus (MRSA), vancomycin-resistant Enterococcci (VRE), and oxacillin-resistant Gram-positive 
strains.1,3,4,9  
Nisin A is a 34 amino acid peptide antibiotic with an overall positive charge – which contributes to 
its apparent affinity for anionic lipids and Gram-positive species, the membranes of which contain higher 
proportions of anionic lipids – and is synthesized by certain strains of Lactococcus lactis.6  Nisin has five 
rings, named from N- to C-terminus, separated by a flexible hinge region between rings C and D (Figure 
4.1A);10 these thioether cyclizations constrain nisin into an amphipathic, screw-like conformation with 
hydrophilic and hydrophobic residues on opposite faces.2,10  At neutral pH in aqueous solution, nisin has 
an overall charge of +4; this positive charge and the amphipathic nature is typical of pore-forming 
bacteriocins.2,10  However, at a non-acidic pH, nisin is found to be highly instable and insoluble; complete 
degradation of nisin at pH 7 has been shown to occur in ten days.11  Perturbations to the structure of nisin 
have been noted in the presence of micelles.2  A number of naturally occurring variants of nisin have 
been discovered to date;2 the research herein concerns nisin A. 
	   	  
Figure 4.1. Structures of nisin A (A) and lipid II (B). 
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Nisin is produced by a gene cluster containing genes coding for the nisin prepeptide, as well as 
the modification machinery, regulatory elements, and immunity proteins (Figure 4.2).3  NisA is a 57 amino 
acid precursor peptide containing a N-terminal leader sequence (MSTKDFNLDLVSVSKKDSGASPR) and 
a core peptide, which undergoes modification to become the mature lantibiotic;4 the leader sequence is 
believed to act as a handle for recognition by processing enzymes as well as to direct the immature 
peptide to the cytoplasmic membrane where processing occurs.3,4  Due to the presence of these N-
terminal leader sequences and the use of the ribosome in generating precursor peptides, the types of 
structures accessible for peptide-based antibiotic agents are greatly increased.12  NisB, NisT, NisC, and 
NisP serve as the modification machinery – respectively the dehydratase, transporter, cyclase, and 
protease – which all must act upon NisA to create the final active form of nisin.4  NisB catalyzes the 
dehydration of certain serines and threonines within the core region. Until recently, no LanB has ever 
been reconstituted in vitro because no LanB expressed in E. coli has ever demonstrated activity.  
However, by co-transforming E. coli cells with two vectors (pRSFDUET-1 containing nisA and nisB; 
pACYCDUET-1 containing nisC), fully modified nisin could be purified from cell culture at a yield of 24 mg 
per L.13  The cyclase, NisC, catalyzes five stereospecific ring formations between dehydrated residues 
and cysteines; these macrocycles constrain the conformation of the molecule to increase activity, 
specificity and stability.3,4,14  Nisin is exported to the extracellular space by the dedicated transporter NisT 
and then activated by cleavage of its leader sequence by NisP.3,4 
NisR and NisK serve to regulate the 
translation of the nisin gene cluster; it is 
induced in a quorum sensing manner by 
nisin and variants of nisin,15,16 with as few 
as five molecules being needed to induce 
production, and higher concentrations 
leading to higher levels of transcription of 
the genes under the nisin-inducible 
promoter (P* in Figure 2B).4  Also required 
for nisin production is acidification of the 
cell medium.17  Of particular interest are the 
immunity proteins – NisI and NisFEG – 
which in conjunction enable the producing 
organism to escape the bactericidal effects 
of its product.4  These two components 
operate with greatest efficiency 
synergistically; alone, NisI grants 1-4% of 
wild type immunity (8-20% of wild type 
immunity if expressed with other nisin-
	  
Figure 4.2. Biosynthesis of nisin A (A) and gene cluster encoding 
proteins involved in production of nisin (B).  In (B), genes are coded by 
color for function: red – precursor peptide; green – modification 
machinery; blue – regulatory; purple – immunity. 
(A)	  
(B)	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related proteins) and NisFEG grants 20%.16,18-21 
 
4.1.2   Nisin activity imparted by dual mode of action 
Nisin activity is enhanced by the presence of anionic lipids, transmembrane gradients, and lipid 
II.2  When negative charges were incorporated into the C-terminus of nisin, thereby lowering the overall 
positive charge, a sharp decrease in binding was noted, even in the presence of anionic lipids.2  N-
terminal fragments showed low affinity for the anionic membranes, suggesting localized recruitment to the 
membrane surface is mediated predominantly by the positively charged C-terminus.2  It was noted that a 
threshold potential was required across a membrane prior to measurable nisin activity; in addition, 
potentials opposing the norm were inhibitory to the activity of nisin.2  The hindrance to nisin activity 
caused by a lack of membrane potential could be overcome in the presence of sufficiently high levels of 
anionic lipids.2  It is believed that the potential serves to help mediate membrane crossing of nisin via 
lowering the energy barrier through an electrophoretic phenomenon.2  Though it is believed to act through 
a similar mechanism to magainin, the 1000-fold enhanced activity of nisin over magainin against several 
strains indicates the presence of a molecular target on the cell surface.2  Due to its ability to inhibit cell 
wall biosynthesis, nisin was thought to – and later proven by studies with the known lipid II binder 
ramoplanin – bind the ubiquitous cell wall precursor lipid II.2  Nisin also has demonstrated ability to bind 
lipid I, the immediate precursor to lipid II in peptidoglycan synthesis.2 
Nisin has high affinity for anionic lipids, due in part to its amphipathic nature and positive charges 
on one face.4,22,23  It binds specifically to lipid II, a precursor in cell wall biosynthesis common in Gram-
positive bacteria, as was seen by the abolishment of nisin and lipid II signals when the two were 
combined in NOESY experiments.9  In fact, the activity of nisin is correlated to the concentration of lipid II 
within a given membrane; while lipid II can also be found in Gram-negative bacteria, these organisms are 
protected by an outer membrane that sequesters nisin from the peptidoglycan machinery.4,24,25  For 
efficacy against Gram-negative species, nisin must be co-administered with an agent that disrupts the 
outer membrane.2  Binding of lipid II perturbs cross-linking of the cell wall, decreasing structural rigidity 
and mechanical strength of the cell.  This binding is mediated through targeting by a hydrogen bond 
interaction between the N-terminal amine of nisin (Ile1) and the pyrophosphate moiety of lipid II,26 a 
moiety also present in undecaprenyl pyrophosphate (11PP), another critical molocule in cell wall 
biogenesis.  Hydrogen bonding interactions between the amide moieties of Dhb2, Ala3, Ile4, Dha5, and 
Abu8 in nisin rings A and B then bind nisin to the pyrophosphate.27  Only 2,000 molecules of lipid II and 
2,000,000 molecules of 11PP are available per cell for cell wall biosynthesis, making these targets 
particularly effective.26,28  As mentioned before, the N-terminal portion of nisin, specifically the A and B 
rings, is responsible for binding lipid II.9  Binding to lipid II does not occur at low pH.9 
Nisin exhibits a dual mode of action by first sequestering lipid II, preventing cell wall biosynthesis, 
and then recruiting it into the formation of long-lived, 2-nm pores.  These pores have been demonstrated 
to have 8:4 nisin to lipid II stoichiometry, with a diameter of 2 nm and a lifetime of 6 seconds.10  Such 
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pores allow the dissipation of electron motive forces and vital cellular ion gradients, leading to the 
cessation of energy-requiring processes and resultant cell death.2,20,25  Upon pore formation, it was noted 
that nisin preferentially releases the anionic carboxyfluorescein over the cationic potassium ion, 
suggesting the pores formed by nisin are anion-selective which would likely result from the placement of 
positively charged residues in the interior of the pore.2,4,29-31    A Lys12Leu mutant has implicated Lys12 in 
the control of ions through the pore channel.2  Further studies suggest the nature of pore formation occurs 
through a cooperative mechanism where formation of pores is preceded by aggregation of peptide at the 
membrane surface; this was corroborated by studies with tryptophan fluorescence.2  Pore formation is 
assisted by the existence of a transmembrane potential, which facilitates the insertion of the C-terminus 
of nisin into the lipid bilayer.1,2,4,10,25,27,32  It is this activity that requires the hinge region; shortening and/or 
stiffening of this region results in abrogated efficacy.9,33  Because nisin exhibits its bactericidal activity in 
the presence of lipid II – which is present in the producing organism – it is necessary to have a method of 
self-protection.20,34  
In susceptible strains of Staphylococcus, nisin induces autolysis by causing cell wall degradation 
of septa between dividing cells, releasing cell wall hydrolyzing enzymes.24 
 Besides inhibition of cell wall biogenesis and generation of membrane-depolarizing pores, nisin 
has also been shown to prevent spore outgrowth in Gram-positive bacteria.11 
NMR structures have indicated nisin is an elongated peptide with its termini pointing inward and a 
flexible hinge region.3,4,27,35  These structures were acquired in the presence and absence of micelles to 
mimic the cell membrane; structures were also acquired with lipid II present.27  In micelles, lipid II and 
nisin were found to bind in a 1:1 ratio with the N-terminus of nisin seemingly responsible for binding;9,27,33 
in DMSO, this binding model was confirmed as the A and B rings of nisin form hydrogen bonding 
interactions with the pyrophosphate group of lipid II (Figure 4.1).27 
 
4.1.3   Resistance to nisin 
Repeated exposure to nisin can lead to physiological adaptation of an organism to develop nisin 
resistance, though this adaptation is generally lost once nisin pressure is removed.36  The primary 
mechanism for resistance to nisin involves electrostatic shielding of the organism by ablation of negative 
charges on the cell wall (i.e. by incorporation of D-Ala).36  Due to the lack of prolonged resistance as well 
as stability against proteolytic degradation, nisin and the lantibiotics should provide a fruitful avenue to 
develop more effective antibiotics. 
 To date, there are several known methods of resistance to nisin: an ABC peptide transporter that 
discharges nisin from membrane to extracellular space, sequestration of nisin to prevent binding to cell 
wall, or changes in the composition of the cell wall to prevent binding to lipid II.37  A new mechanism 
involving oxidizing critical residues of nisin has also been described.37  One form of resistance to nisin 
bioactivity is that seen in Gram-negative bacteria: an outer membrane forms a physical barrier to keep 
nisin sequestered from the cell wall, where it could exert its bactericidal effect.4 
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 Previous studies identified a 70-kb transposon encoding resistance to nisin as well as sucrose 
metabolism.38  Certain species of Bacillus contain a nisin-inactivating enzyme, dehydroalanine 
reductase.39  A 35-kDa protein known as the nisin resistance protein (NSR) has also been identified in 
some strains of nisin-resistant bacteria.39 
 Eight genes in Bacillus subtilis were seen to be upregulated during exposure to nisin.17  Using 
transcriptome and proteome analytical techniques, genes present in B. subtilis likely to contribute to 
inherent resistance were identified.17  Three of these genes were previously linked to membrane stress 
responses, during which cells have been shown to be more susceptible to nisin activity.17 
 
4.1.4   Immunity to nisin and NisI 
For those systems yet characterized, lantibiotics tend to act on a ubiquitous cell surface molecule, 
necessitating that producing organisms take precautionary measures to avert targeting their own cell;38  
this mechanism is known as immunity.40  For the lantibiotic epilancin 15X, which is proteolytically 
activated inside the producing cell, such self-protection is even more dire.41  Typically, these systems are 
comprised of an ATP binding cassette (ABC) transporter (LanFEG) and/or an immunity protein (LanI); 
potentially ancillary proteins may also be present to help assemble multimeric ABC transporters (LanH).40  
The proteins involved in immunity vary by lantibiotic and each lantibiotic producer uses its own 
combination of these systems for maximum efficacy.40 In the case of nisin, producer immunity is managed 
by the production of four proteins, NisFEG and I, all of which are required to impart full immunity.18,20  
NisFEG was found to have two subunits of the ATPase NisF, associated with NisE and NisG, 
hydrophobic intermembrane units; cells expressing NisF2EG tend to have less cellularly associated nisin, 
suggesting it functions to pump nisin out of the cell.40  NisI, on the other hand, is believed to prevent pore 
formation by binding to nisin.40,42  LanI proteins share very little sequence similarity, likely due to the 
specificity of their role in guarding against one particular lantibiotic; however, LanFE(G) proteins are more 
highly conserved, with NisF and SpaF – from nisin and subtilin producing strains, respectively – sharing 
45.5% identity.40 
NisI is a 245 residue protein evolved to prevent nisin producers from self-killing.4  It is 
predominantly hydrophilic, predicted to be between 25-27 kDa and is natively found as a dimer.16,20,38  
Sequence analyses suggest that NisI exists as a membrane-anchored lipoprotein on the extracellular side 
of the cytoplasmic membrane;38 that NisI is anchored on the extracellular side of the cytoplasmic 
membrane is corroborated by the positive N-terminus, hydrophobic regions, and signal peptidase II 
cleavage site (Figure 4.3).20,21,25  The 19 N-terminal residues are a consensus lipoprotein signaling 
sequence that codes for palmitoylation at Cys20; 4,16,20,21,25,38 this prediction was confirmed by 
experiments with 3H-palmitic acid (Immonen and Saris, unpublished work). Following palmitoylation, the 
first 19 residues are removed.4,20,25,43  However, NisI is also expressed in a soluble, lipid-free form as 
determined by SDS-PAGE;4,18,25 if lipidation does not occur prior to signal peptidase II cleavage, lipid-free 
NisI (LF-NisI) is produced.25 This form comprises 50% of the NisI produced between the early to 
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stationary phases of growth and may also be produced by replacement of the N-terminal 20 residues by a 
hexahistidine tag.18,25  Soluble NisI has no affinity for cells.25 
The putative functions of the immunity proteins are sequestration of nisin by NisI, in either its 
membrane-anchored or lipid-free form, and export of nisin by the NisFEG complex.18 It is not believed 
that either component modifies nisin.18,25  NisI has no homology with other proteins, which coincides well 
with its specificity for nisin; no interaction has been noted between NisI and the lantibiotic subtilin, the 
structure of which closely resembles that of nisin.18  Expression of NisI in nisin-susceptible bacteria, 
including strains of Bacillus subtilis, has been shown to impart immunity to nisin, though not at wild-type 
levels; full immunity requires the coexpression of NisI, NisFEG, and NisA.  NisI is believed to impart 
immunity via the sequestration of nisin, inhibiting aggregation of nisin and preventing it from aggregating 
at the cell surface or binding lipid II, which may lead to pore formation; this interaction is seen with both 
the membrane-anchored and lipid-free forms.4,18,25,38  NisI may also serve to shuttle nisin toward the 
NisFEG transporter.38  Nisin immunity relies on the co-expression of both NisI and NisFEG, as well as the 
production of nisin, due to its function as a peptide pheromone to upregulate transcription of other genes 
within the cluster.40  Experiments have demonstrated that NisFEG alone provides 20% of wildtype 
immunity to non-producing strains, NisI provides 20% of wildtype immunity, and NisI co-expressed with 
NisFEG provides 30% of wildtype immunity; to achieve wildtype levels of immunity, NisI, NisFEG, and 
NisA must all be produced.4,15,16,18-21,40,44  Impairment of NisI production results in a subsequent decrease 
in cell density and thereby nisin production.19 
The interaction between NisI and nisin has been seen to decrease by high salt or detergent 
concentrations, suggesting part of the nature of the association is due to electrostatics and not just to 
hydrophobicity.25  Under certain conditions, the interaction of NisI and nisin results in an insoluble 
complex.18 The N-terminal region of NisI allows for synergistic activity between NisI and NisFEG, while 
the C-terminal 21 residues allow binding to nisin.40,42  Nisin is produced at an acidic pH (4.0) and thus, at 
this pH, NisI is expected to bind nisin.  However, recent experiments using the NIsin Controlled 
Expression (NICE) system have indicated binding between NisI and nisin at pH 6.25. 
NisI and nisin have been shown to be produced at a constant ratio from lag phase through 
stationary phase, both on cell surfaces (1 molecule NisI to 10 molecules nisin) and in media (1 molecule 
NisI to 50 molecules nisin).25 Strangely, under certain conditions, NisI is found to enhance the efficacy of 
nisin; this is believed to be due to increasing localized concentration.25   Notably, lipid-free NisI was 
demonstrated to enhance the activity of nisin against several Gram-positive strains on solid media.25 
The biosynthesis of nisin is carried out by multiple enzymes, depicted in Figure 2.  The gene 
product of nisA is the precursor peptide, containing a N-terminal leader sequence affixed to the core 
peptide, the region that undergoes modification.12 NisB, NisT, NisC, and NisP serve as the modification 
machinery – respectively the dehydratase, transporter, cyclase, and protease – which all must act upon 
NisA to create the final active form of nisin.4   NisR and NisK serve to regulate the translation of the nisin 
gene cluster in a quorum-sensing dependent manner; a greater extracellular concentration of nisin will 
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lead to higher levels of transcription of the genes under the nisin-inducible promoter (P* in Figure 2B).4   
Of particular interest are the immunity proteins – NisI and NisFEG – which in conjunction enable the 
producing organism to escape the bactericidal effects of its product.4 
 
4.1.5   Previous studies of lantibiotic immunity proteins 
Concurrently, efforts have been made to characterize the binding of NisI to nisin via isothermal 
titration calorimetry (ITC) with Ian Gut (Blanke and van der Donk laboratories); this was previously 
attempted by the Nair lab, but abandoned when the associated complex was found to precipitate due to 
the use of the impure commercial preparation nisaplin.  No precipitate has been visible in experiments 
with purified nisin, opening up the possibility for determining the structure of the NisI:nisin complex via 
crystallographic methods should conditions for crystallization be found; no such efforts have been made 
at this point with purified nisin.   
Circular dichroism and SDS-PAGE experiments have indicated NisI and nisin associate to form 
an insoluble complex, reducing the concentration of free nisin; the complex may be separated, returning 
active NisI and nisin.4,18,19,25  High salt and detergent concentrations inhibit complex formation, indicating 
that the NisI:nisin interaction is due not only to hydrophobicity but also to electrostatic interaction.25 
Circular dichroism experiments were carried out by Ian Gut, both on NisI alone and with NisI in 
the presence of 50 µM nisin.  The data was analyzed using DichroWeb,45,46 which was recommended by 
M. Ashley Spies (School of Molecular and Cellular Biology, University of Illinois at Urbana-Champaign).  
The self-consistent method was used, along with reference database 4, corresponding to wavelengths 
from 190-240 nm.47 	  
	  
Figure 4.3.  Circular dichroism spectrum of NisI in the absence of 
nisin. 
	  
Figure 4.4.  Circular dichroism spectrum of NisI with 50 µM nisin. 
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From the data, an increase in disorder of the structure of NisI is evident in the presence of nisin. 
4.1.6   Goals of this research project 
To date, the depth of knowledge concerning NisI is somewhat lacking, especially with respect to 
its structure.  In this report, the first steps toward better characterizing the structure of NisI, both alone and 
in complex with nisin, are discussed.  Previous attempts toward this end were made in the Nair laboratory 
at the University of Illinois at Urbana-Champaign.  However, no structure could be determined due to 
unsuccessful attempts at crystallization; this may be due to a number of aberrant errors in the sequence 
of the construct of NisI that was being utilized.  As such, efforts were directed toward solving the NMR 
structure of NisI.  These efforts are described herein. 
The current aims of this project are to assess the feasibility of solving the structures of both NisI 
and the NisI:nisin complex by x-ray crystallography or NMR spectroscopy and to determine the nature of 
their interaction. 
Our research interests lie in characterizing the interaction between nisin and NisI using isothermal 
titration calorimetry and fluorescence polarization.  In addition, we would like to solve the structure of NisI 
in complex with nisin.  By determining the evolutionarily favored method of preventing nisin bactericidal 
activity, we may be able to find modifications to make nisin more efficacious. 
 
 
 
 
Result Helix1 Helix2 Strand1 Strand2 Turns Unordered Total 
Guess 0.069 0.138 0.172 0.069 0.190 0.362 1 
SVD 0.033 0.127 0.255 0.174 0.388 0.595 1.572 
Convergent 0.095 0.161 0.129 0.107 0.244 0.275 1.011 
Stage2 0.093 0.164 0.128 0.110 0.250 0.268 1.014 
Final 0.087 0.163 0.135 0.118 0.268 0.262 1.032 
Table 4.1.  Secondary structures of NisI indicated by circular dichroism experiments.  Helix1 and Strand1 correspond to regular 
forms of the named structures; Helix2 and Strand2 correspond to distorted forms.  SVD stands for singular value decomposition. 
Result Helix1 Helix2 Strand1 Strand2 Turns Unordered Total 
Guess 0.069 0.138 0.172 0.069 0.190 0.362 1 
SVD 0.032 0.115 0.311 0.182 0.369 0.518 1.527 
Convergent 0.070 0.139 0.173 0.071 0.192 0.363 1.008 
Stage2 0.070 0.139 0.173 0.071 0.192 0.363 1.007 
Final 0.070 0.139 0.173 0.071 0.192 0.363 1.007 
Table 4.2.  Secondary structures of NisI in the presence of 50 µM nisin, as indicated by circular dichroism experiments.  
Helix1 and Strand1 correspond to regular forms of the named structures; Helix2 and Strand2 correspond to distorted forms.  
SVD stands for singular value decomposition. 	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4.2   Results and Discussion 
4.2.1   Generation of NisI∆(1-20) construct 
In case Cys20 had aberrant effects on the aggregation of NisI and/or labeling with fatty 
acid/detergent-like substance, it was decided to mutate it.  In addition, purifications of NisI∆(1-19) by Ian 
Gut showed band by SDS-PAGE indicative of disulfide bond formation, which may also have occurred 
due to Cys20.  A 3-bp exclusion was effected with a new forward primer.  The primer ordered contained 
at the C-terminus, a PreScission Protease cleavage site, BamHI site for removing Cys20.  The resultant 
protein was expected to start at Tyr21, with an N-terminal Gly-Pro-Leu-Gly-Ser sequence.  Cloning was 
done in pGEX-6P-1, which contains an ampicillin resistance cassette.  Three constructs were generated 
missing Cys20; one of these also contained a single bp deletion further downstream in the sequence and 
was therefore not used.  The successful construct begins with Tyr21, with five extra N-terminal residues 
present due to the restriction sites used for gene manipulation and tag removal by PreScission Protease; 
these are Gly-Pro-Leu-Gly-Ser.  The sequence was verified in the reverse direction only. 
Though sequencing verified removal of Cys20, there were problems purifying overexpressed 
NisI∆(1-20) – it did not adhere to the GST affinity resin. Despite several changes to the overexpression 
and purification protocols, NisI could still not be purified above a threshold of 2 mg per liter of culture. 
Purification with Ian Gut, who had previously succeeded in overexpressing/purifying, demonstrated that 
the ∆(1-20) construct was significantly smaller than the ∆(1-19) construct and not consistent with the 
expected size (Figure 4.6); due to the protein’s inability to bind the GST resin, it is expected that part of 
the attenuated size results from a truncation of the N-terminal GST motif.  All subsequent experiments 
were therefore run with the ∆(1-19) construct, though primers were ordered for site-directed mutagenesis 
to remove Cys20 should this later be required. 
 
	  
Figure 4.5.  Amino acid sequence of NisI.  Shown in red are the first twenty amino acids, removed in the NisI∆(1-20) construct 
used in this work.  For NisI∆(1-19), C20 is still part of the protein sequence. 
!
Figure 4.5.  Amino acid sequence of NisI.  Shown in red are the first twenty amino acids, removed in 
the NisI!(1-20) construct used in this work.  For NisI!(1-19), C20 is still part of the the protein 
sequence. 
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4.2.2   Overexpression of NisI∆(1-19) 
Overexpression conditions for NisI∆(1-19) were modified from those used previously to better 
reflect the protocol optimized by Ian Gut for natural abundance overexpression in LB broth; this protocol 
had been demonstrated to yield larger quantities of overexpressed protein.  SDS-PAGE analysis of 
NisI∆(1-19) in overexpression cultures was performed at different time points post-induction.  Results 
indicated that overexpression was occurring, and that degradation of the protein from later time points 
post-induction was not.  Overexpression of NisI∆(1-19) typically resulted in 8.4 g cells per L of LB broth; a 
yield of 5.4 g cells was acquired per liter of Studier P minimal media for natural abundance growths.  No 
problems were apparent with the overexpression, as verified by SDS-PAGE analysis – a band appeared 
between the standard markers for 54.8 kDa and 97.3 kDa (Figure 4.6), where a dimer of NisI∆(1-19) 
would be expected.	  
 
4.2.3   Purification of NisI∆(1-19)  
Lysis of the cell pellets by sonication was occasionally problematic, due to the large volumes 
used.  In such cases, a viscous, stringy lysate was produced, which was tough to pellet and further purify.  
In addition, a translucent brown sludge layer was often present between the pellet and supernatant.  
Using smaller volumes, the blunt tip for the sonicator, and addition of lysozyme all aided in resolving this 
issue.  In addition, DNAse may help, as well as using the cell homogenizer for lysis. 
 With regard to 
the preparation of 
buffers for purification, 
it was discovered that 
addition of glutathione 
to the GST Elution 
Buffer alters the pH by 
1.5.  Therefore 
separate solutions 
should be made with 
and without glutathione 
buffers and each 
should be pH adjusted 
individually.  This 
should not have 
affected previous 
results as protein was 
not adhering to the 
column long enough to have interacted with the Elution Buffer. 
	  
Figure 4.6.  PAGE gel of overexpressions of NisI∆(1-19) (Lanes 3-6) and NisI∆(1-20) (Lanes 
10-13).  Image was provided by Ian Gut. 
!
Figure 4.X.  PAGE gel of NisI!(1-19) (Lanes 3-6) and NisI!(1-20) (Lanes 10 13
overexpression (Image provided by Ian M. Gut) 
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After problems with protein showing up in unexpected fractions, it was decided to run a gel 
filtration (GF) column following the GST column.  Therefore, the GST column buffers were modified 
slightly to serve as a buffer exchange for the sample to allow direct application to the GF column. 
A second protocol was acquired from the Satish K. Nair lab and may be used as an alternative 
method if necessary.  In brief, an on-batch cleavage of the GST-NisI was performed at a volume of 50 mL 
overnight.  The resin is spun down at 500 rpm and the beads rinsed.  NisI is purified from the solution via 
5-mL Fast Flow Q Sepharose column at pH 8.3 (Buffer A: 20 mM Tris, 100 mM KCl, 10% glycerol; Buffer 
B: 20 mM Tris, 1M KCl, 10% glycerol).  Implementation of this protocol resulted in a large peak eluting ~1 
CV into the Buffer B wash, though the peak was asymmetric.  The new protocol provided pure protein in 
high yields (Figure 4.7). 	  
 Despite significant changes to the overexpression, NisI could still not be purified above a 
threshold of 2 mg per liter of culture.  After PAGE analysis alongside Ian’s NisI∆(1-19) construct, it was 
evident that the mass of the NisI∆(1-20) construct was not consistent with the expected size of the protein 
(Figure 4.6); due to the protein’s inability to bind the GST resin, it is expected that part of the attenuated 
size results from a truncation of the N-terminal GST motif.  Using 10% Tris-HCl acrylamide gels, it was 
noted that the protein standards used from BioRad (Hercules, CA) were consistently missing an expected 
	  
Figure 4.7.  SDS-PAGE gel of purification of NisI.  Lane 1: null; lane 2: marker; lane 3: ladder; lane 4: GST column settling 
flowthrough; lane 5: GST column binding buffer wash; lane 6: GST column elution wash; lane 7: GST column post-protease 
mixture; lane 8: GST column elution; lane 9: Q column fraction E1; lane 10: Q column fraction E2; lane 11: Amicon 
flowthrough (from concentrating protein); lane 12: concentrated NisI∆(1-19); lane 13: ladder; lane 14: marker; lane 15: null. 	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band.  Upon contacting the company, it was learned that aprotinin (6700 Da) may not be sufficiently 
resolved from lysozyme (17000 Da) at this gel concentration.  It was decided to switch to New England 
Biolabs standards, which contain two stronger bands for easier identification of all standard bands.  
Curiously, sequencing of constructs demonstrated homology with both the NisI and GST encoding genes.  
But given that the NisI∆(1-20) constructs never showed any affinity for the GST column, this construct 
was abandoned and NisI∆(1-19) was used instead.  At this point, Ian’s construct was adopted for 
experiments, though primers were ordered for site-directed mutagenesis to remove Cys20 should this 
later be required. 
NisI∆(1-19) was further purified by gel filtration to assess the state of the protein during 
purification.  It was found to elute at 35 mL, corresponding to a molecular weight of 54.8 kDa, suggesting 
NisI is purified as a dimer. 
 
4.2.4   Purification of nisin A 
The best purification of nisin was seen by using food-grade nisaplin stored at -80 °C under N2 to 
prevent oxidation.  This standardized protocol produced sufficient amounts of nisin each time it was 
purified with relatively no problem.  The conditions for storing nisaplin also appear to be sufficient. 
However, it was noted that TFA has recently been omitted from the extraction mixture, which may 
account for recent aberrantly low yields.  Nisin is produced by an acidophile and is most soluble under 
acidic conditions; extraction of nisin into the aqueous layer may be hindered by this pH shift.  All future 
runs should contain 0.1% TFA in the extraction matrix.  MALDI analysis further supported this, as in the 
absence of TFA a much higher amount of contamination is noted.  
	  
Figure 4.8. MALDI-TOF mass spectrum of HPLC purified nisin (m/z 3355). 
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To assure the correct form of nisin was present in each subsequent experiment, the mass was 
verified by MALDI MS (3355 m/z) just prior to use (Figure 4.8).  The samples were graded by level of 
purity dependent on the relative abundance of other peaks to the peak of interest. 
 
4.2.5   Acquisition of preliminary NMR data 
Solution NMR of U-13C,15N-NisI∆(1-19)  was run on a 1.26 mM sample in 500 µL phosphate 
buffer provided by Ian Gut.  Solution NMR of natural abundance NisI indicated the presence of a 
contaminant which could not be removed by PD10 column treatment in the 1H 1D spectrum (Figure 4.9); 
a large peak at 3.6 ppm was seen, seemingly lipid-like in nature as identified by the Biological Magnetic 
Resonance Data Bank metabolomics website (University of Wisconsin at Madison).  A 2D 1H,15N-HSQC 
(Figure 4.10) was indicative of aggregation or oligomerization, as evidenced by the larger than normal 
linewidths and lower than expected signal-to-noise ratio; the expected concentration was ~1 mM, yet 
scarce protein signals could be seen.  A lack of dispersion among amide peaks was also evident, which 
may indicate a random coil conformation in solution.   
ESI-MS was performed to determine the mass of the contaminated NisI sample and whether it 
had become either covalently modified or strongly associated with another compound.  Initially, it was 
believed that the contamination and the aggregation may both stem from aberrant palmitoylation of 
Cys20, as is known to happen in vivo; however, given that the construct of NisI used was lacking the first 
19 amino acids – the lipoprotein consensus signal sequence, which serves as the palmitoylation signal 
sequence – it was unlikely this modification was the contaminating peak.  This was confirmed by the 
	  
Figure 4.9.  1D NMR spectrum of NisI, expanded to show region containing contaminant peaks. 
 66	  
mass spectrometry results, which showed a principal ion of 26202 Da (Figure 4.11), 406 Da greater than 
the expected mass of NisI∆(1-19) at 25796 Da – the mass of palmitic acid is 256 Da and thus 
palmitoylation was ruled out as the contaminating species.  To preclude the possibility of unexpected 
palmitoylation, it was decided to remove Cys20 by mutagenesis.  Therefore, a construct was prepared 
with Cys20 removed.  While its absence was verified by sequencing, the protein could not be purified as 
discussed above. 
The contaminant was later determined to be Tween 20, present from its use during proteolytic 
cleavage of the GST tag by PreScission Protease.  This was determined by searching for the 
contaminant resonances in the BMRB Metabolomics database. After consultation with the Nair lab, it was 
	  
Figure 4.10.  1H,15N-HSQC spectrum of U-13C,15N-NisI∆(1-19) showing unexpectedly low signal-to-noise ratio.  Approximately 
200 peaks should be visible in this region. 
!
Figure 4.10.  1H,15N-HSQC spectrum of U-13C,15N-NisI!(1-19) showing unexpectedly l w signal-to-
n ise ratio.  Approximately 200 peaks should be visible in this region. 
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determined that detergent is an unnecessary addition and that proteolysis will proceed in its absence; all 
subsequent purifications and cleavages will be performed without detergent to prevent future 
contamination.	  
Gel filtration chromatography was also undertaken to determine the oligomerization state of 
NisI∆(1-19) in solution.  Gel filtration results showed NisI∆(1-19) preferentially forms a dimer of 52.5 kDa 
in solution.  For this reason, as well as the seeming lack of secondary structure, it was decided not to 
pursue further solution NMR studies at this time as the technical requirements for solution NMR of 
proteins of this size are far more rigorous than initially expected. 
 
4.2.6   Fluorescence polarization studies of the binding of NisI∆(1-19) to nisin A 
To assess the tightness of binding between NisI and nisin, fluorescence polarization (FP) studies 
were conducted using rhodamine-nisin (655.7 µM)  provided by Ian Gut  to monitor binding between nisin 
and NisI both at pH 4.0 (acetate) and at pH 6.8 (MOPS).  Two trials were conducted, with each condition 
tested in duplicate.  For the first trial, rhodamine-nisin was kept at 5 nM while NisI was varied from 50 nM 
to 100 µM, both in MOPS buffer (pH 6.8) and in acetate buffer (pH 4.0); this ultimately resulted in data 
with poor fits.  During the second trial, rhodamine-nisin was tested at 1 µM, 500 nM, 200 nM, and 50 nM 
	  
Figure 4.11.  ESI mass spectrum of contaminated NisI sample. 
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over concentrations of NisI from 98 nM to 100 µM, again in MOPS and acetate buffers.  The best fit was 
seen at 200 nM nisin in acetate (Figure 4.12).  The calculated Kd was 4.618 µM at 0 min, but 1.775 µM at 
150 min.  Binding was only noted at pH 4.0 under the parameters tested. 
A single condition was found in which a binding constant could be quantified proximate to the 
expected literature value of 0.6 – 2 µM observed with circular dichroism.25  However, given the number of 
conditions tested and the varied results, it is unlikely that this value is dependable across all conditions. 
 
4.2.7   Isothermal titration calorimetry studies of the binding of NisI∆(1-19) to nisin A 
For crystallization studies of NisI, a minimum of 20 mg of protein is required.  To co-crystallize 
with nisin, another 20 mg of NisI is needed in addition to a stoichiometric amount of nisin (2.5 mg, 
assuming a 1:1 association).  Prior to co-crystallization, the NisI:nisin complex should be purified by gel 
filtration, presuming tight binding.  Therefore, the stoichiometry of association and strength of association 
must first be determined by another method, such as isothermal titration calorimetry (ITC).  Due to the 
inherent change of energy that occurs upon any chemical interaction, ITC may be used to better 
characterize the binding between nisin A and NisI.48  Unlike fluorescence polarization, ITC can be carried 
out without the presence of an extra tag, allowing a more biorelevant set of sample conditions.48  A simple 
experiment allows for the calculation of several thermodynamic parameters, including the equilibrium 
constant of binding and the binding stoichiometry.48  
For ITC studies, the cell to be used 
contained 1.4 mL and a protein concentration 
of 20-50 µM was optimal.  The ligand was 
needed in 400 µL volume at a concentration 
10-fold higher than that of the protein (200-500 
µM).  Each run was to be commenced with a 
blank of ligand in the syringe and buffer only in 
the cell to account for heats of dilution. 
Therefore, for each set of ITC experiments, 5.5 
mg NisI and 2.6 mg of nisin were needed (three 
injections and one blank of 1.4 mL NisI at a 
concentration of 20-50 µM; three injections of 
400 µL nisin at a concentration of 200-500 µM).	  
Ian had previous run ITC at 54 µM NisI, 
378 µM nisin, pH 6.8, the results of which were 
indicative of endothermic 1:1 binding (Figure 4.13).  ITC of NisI and nisin was carried out under a variety 
of conditions (pH 6.8: 90.1 µM and 745.2 µM, 50 nM and 437 µM, 50 µM and 467 µM; pH 4.0: 160.9 µM 
and 2.62 mM, 20.1 µM and 1.27 mM, 20.1 µM and 2.05 mM).  At 50 µM NisI and 467 µM nisin, there is 
initially 70 nmol of NisI present and 4.67 nmol of nisin per 10-µL droplet.  Therefore, to achieve a 1:1 
	  
Figure 4.12. Fluorescence polarization curve of rhodamine-nisin 
and NisI at pH 4.0. The y-axis is polarization in units of mP. 
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ratio, 15 droplets of the nisin solution must be added; a 1:2 ratio would be achieved at 30 droplets.  Both 
of these are within the confines of the designed ITC experiments, so the expected stoichiometry of 
binding should be present.   
Isothermal titration calorimetry was performed at pH 6.8 and at pH 4.0, the latter of which is the 
pH at which nisin is natively produced.  Precipitation of NisI at pH 4 in acetate buffer often was seen when 
dialyzing for ITC, though not in the ITC cell.   
Based on the Kd determined by fluorescence polarization studies, the optimal concentration for 
NisI in ITC studies should be 46-462 µM, with the concentration of nisin 20-50 times higher.48 
Concentrations for both NisI and nisin are at the lower end, which may explain why a desirable binding 
curve has not been generated by this technique.  The only reproducible data suggests no binding is 
occurring at either pH value within the confines of the ITC parameters. 
A lack of binding has been noted at pH 6.8 during both ITC and FP experiments.  This is 
somewhat expected as nisin has been demonstrated to be destabilized at pH values other than 3.11  
However, recent studies including the incorporation of nisI into the NICE system resulted in a 5-fold 
increase in the amount of nisin that could be added prior to bactericidal effects being noted, suggesting 
some sequestration at the neutral pH values (6.25) at which these cells were cultured.49  Therefore, it 
seems more likely that the optimal conditions have yet to be determined for these experiments, as 
opposed to no binding occurring.   
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Figure 4.13.  ITC data provided by Ian Gut.  This trial was run at 7:1 nisin to NisI at pH 6.8. 
 70	  
4.2.8   Structure Predictions of NisI 
 All results – including those from the Simple Modular Architecture Research Tool50,51 and Phyre52 
– indicate that NisI is intrinsically unstructured with no homology to known proteins.  This correlates well 
with CD results provided by Ian Gut. 
 
4.3   Conclusions 
 Initially, the major impediment to significant progress was an error in the GST-NisI∆(1-20) 
construct, which ablated affinity for the GST resin, thereby disallowing for purification.  The functional 
NisI∆(1-19) construct was used instead. 
NMR and CD studies, as well as structure predictions, have all indicated that NisI is intrinsically 
unstructured.  In addition, in the presence of nisin during CD experiments, it was seen that NisI becomes 
even more unstructured.  While this does not preclude the possibility of solving the structure – which 
would be devoid of recognizable motifs – it does complicate it and make the best option solution NMR 
spectroscopy, as the likelihood of crystallization is diminished. 
Given the lack of binding seen by ITC and under most of the conditions tested by FP, it appears 
that nisin and NisI may not form a long-lived complex in solution.  However, given that the Kd calculated 
from the FP experiments described here coincides well with that derived from CD experiments as 
described in the literature, in addition to the putative function of NisI as also described in the literature, a 
confounding picture is presented.  Further experiments are needed to solve this discrepancy and better 
characterize the nature of the relationship between nisin and NisI. 
 
4.4  Future Research Direction 
Co-crystallization of NisI and nisin 
 Previous attempts at crystallization of NisI have been made in Professor Satish Nair’s laboratory 
(University of Illinois at Urbana-Champaign), but no suitable conditions have yet been determined.  In  
addition, the nisin used in the previous attempts was not pure, but rather nisaplin, which contains only 2% 
nisin by weight.  Therefore, it was envisioned to crystallize NisI in collaboration with the Nair lab both in 
the absence of and in the presence of nisin.  The addition of nisin may impart greater structural rigidity; 
however, given the results of the CD experiments conducted by Ian Gut, this is not expected to prove 
optimal for crystallization.  Crystallization must produce either diffraction quality crystals or microcrystals 
for structure determination by either X-ray diffraction or solid-state NMR spectroscopy, respectively. 
To begin crystallization, at least 20 mg of protein will be necessary.  Co-crystallization with nisin 
will require a stoichiometric amount of nisin present at the beginning of crystallization attempts. As such, 
the stoichiometry will be further characterized by ITC, FP, or CD.   
Because NisI is produced at and binds nisin at pH 4.0, crystallization attempts will encompass 
this pH.  Previous work has shown that the C-terminal 21 amino acids of NisI are putatively responsible 
for binding of nisin.42  Therefore, crystallization may also be attempted with truncant species including this 
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crucial motif.  Crystallization with the naturally occurring nisin variants (F, Q, U, Z) will also be attempted 
to characterize the effect of single amino acid changes, as well as the efficacy of NisI in binding to the 
variants with respect to nisin A. 
Modifications to overexpression of NisI and change of constructs 
Overexpression under fermentation conditions may be explored in efforts to increase the yield of 
protein per liter of overexpression culture. NisI may be recloned as NisI-His6, which may aid in solubility 
and/or folding during overexpression. 
Alternatively, the NICE system may be used to overexpress constructs of NisI.  This may be more 
fidel to native production and therefore may produce bioactive NisI with better binding than is seen with 
heterologously produced samples. 
Fluorescence polarization assays of NisI and rhodamine-nisin 
 The experiments producing the results shown in Figure 4.12 should be replicated using the same 
conditions to confirm the calculated Kd.  As a second confirmation, a competition assay should be run 
using variable concentrations of unlabeled nisin.  A larger range of protein concentrations may be used in 
subsequent experiments to increase the number of data points along the x-axis and better characterize 
the binding affinity of nisin for NisI. 
 Fluorescence polarization may also be attempted in the presence of the GST tag to see if NisI is 
well-folded while tagged – this may make NisI a better binding partner for nisin.  Previous studies have 
indicated that the C-terminal 21 amino acids are the minimal residues required for recognition of and 
binding to nisin, so binding experiments may be attempted with this fragment. 
Isothermal titration calorimetry of NisI and nisin 
To determine the stoichiometry and more information regarding the peptide-protein interactions, 
including ∆H, and ∆G, of the NisI:nisin complex, ITC experiments should be repeated at the same pH 
values.  Concentrations of the ligand and macromolecule should be varied to provide more reliable and 
reproducible data.  Previous trials of ITC have indicated that the optimal conditions have not yet been 
determined for the binding of nisin and NisI.  Given that the Kd has been determined by FP, a more 
optimal range of concentrations has been calculated – NisI should be present between 46-462 µM, with 
nisin in 20- to 50-fold excess, between 920-23100 µM.   
 In addition to fine-tuning the concentrations of protein and ligand, trials may also be run with 
protein in the syringe and ligand in the cell, as well as with a 10-fold lower concentration of protein with 
respect to ligand.  This would allow for deconvolution of preferential binding to a single site.48  Trials may 
be repeated with GST-NisI to see if NisI appears better folded in the presence of the GST tag.  If so, it 
may bind more readily to nisin.  ITC may also be repeated using C-terminal truncants of NisI, putatively 
responsible for binding nisin. 
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Circular dichroism studies of NisI and nisin 
Circular dichroism studies may be repeated in the presence of a variable concentration of 
denaturant, both in the presence and absence of nisin.  In addition, attempts will be made to replicate the 
determination of the Kd value as previously done in the literature by this technique.25 
Structural Determination of NisI in Complex with Nisin 
 Depending on the quality of crystals produced, if any, the structure of NisI will be determined by 
either x-ray crystallography or by NMR spectroscopy.  It is important to keep in mind that diffraction 
quality crystals are not necessary to perform solid-state nuclear magnetic resonance (NMR) spectroscopy 
experiments, and so the quality of crystal required may be less than that for which previous attempts have 
aimed.  If no crystallization conditions are found suitable, solution NMR spectroscopy may be employed. 
In the event that structural characterization experiments will be conducted by NMR, isotopically 
labeled nisin will be needed to monitor the changes in chemical shift in both NisI and nisin upon binding of 
the other component.  However, shifts in NisI can be monitored upon binding to unlabeled nisin.  This 
would allow for determination of NisI residues important in recognition of and binding to nisin. 
Lactococcus lactis can be cultured in minimal media if supplemented with certain amino acids for 
which the organism is auxotrophic (Arg, Met, Glu, and Val will allow for 54% of growth achieved in rich 
media;53,54 addition of Asp, His, Ile, and Leu – with Arg, Met, Glu, and Val – will increase growth to 87% of 
that encountered in rich media).53,54  Other components that may be necessary for the growth of L. lactis 
are biotin, pyridoxal, folic acid, riboflavin, nicotinamide, thiamine, and pantothenic acid.55,56  Published 
protocols for both the transformation of Lactococcus species by electroporation57 and the isolation of 
plasmid DNA from Lactococcus species58 would allow for putative expression of isotopically labeled nisin 
variants to more effectively probe the structure of the complex. 
 The proposed order of experiments for a labeled sample would be as follows: 1H-15N HSQC, 
HNCO, HNCA, HNCOCA, HNCACB, HNCACO.  This order would allow for a logical expansion of 
assignments along the peptide backbone and would make for the most rapid assignment of residues. 
 If solution NMR spectroscopy is to be used, experiments may be carried out at low temperature, 
with deuteration, or in conjunction with the National Magnetic Resonance Facility at Madison (University 
of Wisconsin at Madison). 
Studies of other lantibiotic immunity systems – SpaI 
Subtilin and nisin share 63% sequence identity with 
identical organization of the five lanthionine rings, but the only 
similarity between the corresponding immunity proteins SpaI and 
NisI is a consensus lipoprotein signal sequence.40  SpaI is 165 
amino acids (19.3 kDa) and predominantly hydrophilic.40  Both 
GST- and His-tagged constructs have been prepared by Ian Gut, 
both of which have been demonstrated to overexpress well in rich 
media.  Once optimal minimal media overexpression conditions 
72 µL H2O 
10 µL 10X buffer 
10 µL 10X dNTPs 
3 µL 50 mM MgCl2 
1 µL forward primer 
1 µL reverse primer 
1 µL Taq polymerase 
2 µL DNA template 
100 µL total volume 
Table 4.3.  Components of NisI∆(1-20) 
amplification reaction. 
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have been determined, the protein will be expressed in isotopically enriched media for solution NMR 
spectroscopy studies to assign the structure. 
 
4.5   Experimental procedures 
4.5.1   Generation of NisI∆(1-20) Construct 
Cloning of nisI∆(1-20) into pGEX-6P-1 (LAGJ.II.033).  NisIΔ(1-20) was cloned using the pGEX-6P-1 
construct (empty plasmid 4900 bp, with ampicillin resistance), which contained the gene encoding 
NisIΔ(1-19) and a preceding glutathione S-transferase tag, and reverse primer provided by Ian Gut, as 
well as a new forward primer to induce the Cys20 3-bp deletion (forward primer: 5’-GTT CTG TTC CAG 
GGG CCC CTG GGA TCC TAT CAA ACA AGT CAT AAA AAG GTG AGG-3’; reverse primer: 5’-CGG 
CCG CTC GAG CTA GTT TCC TAC CTT CGT TGC AAG CTT AAA ATC ATC ATT TAT-3’).    The 
forward primer contained the C-terminus of the 
PreScission protease cleavage site and a 
BamHI restriction site; after removal of the GST 
tag by PreScission protease, the NisI was 
expected to have five non-native amino acids 
appended to the N-terminus (Gly-Pro-Leu-Gly-
Ser) with NisI beginning at Tyr21. 
Amplification reaction conditions are shown (Table 4.3).  The elongation was carried out for 2 min 
per cycle to assure that the ~2 kbp gene was fully amplified.  Once amplified, the products were digested 
using BamHI and XhoI (Invitrogen, Carlsbad, CA), both sequentially and simultaneously; a vector 
containing the gene for NisIΔ(1-19) was also digested (Table 4.4).  The gel-purified products were ligated 
together (Table 4.5).  
The ligation products were used to transform E. coli DH5α 
(Cell Media Facility, School of Chemical Sciences, University of 
Illinois at Urbana-Champaign) using the heat shock method.  One 
µL of DNA was combined with 50 µL cells and incubated on ice for 
30 min.  The cells were then heated for 1 min in a 42 °C water bath.  
LB (500 µL; Thermo Fisher Scientific, Waltham, MA; BD, Franklin 
Lakes, NJ) was added to the tube, which was cooled on ice for 15 
minutes.  The cells were grown at 37 °C for 30 min and then 50 µL of the cultures were spread onto LB 
plates containing ampicillin.  The plates were left overnight at 37 °C.  Colonies were used to inoculate 5-
mL LB cultures, also grown at 37 °C overnight.  The plasmids were isolated from the cultures and 
submitted for sequencing.  Plasmids bearing the proper sequence of NisI without Cys20 were used to 
transform E. coli BL21(DE3) cells (New England Biolabs, Ipswich, MA) via heat shock for overexpression.  
Freezerstocks were also prepared by combining 750 µL of 40% (v/v) glycerol with 750 µL of cell culture.  
 
3 µL 10X buffer 
3 µL 10X BSA (if necessary) 
1 µL restriction enzyme 1 
1 µL restriction enzyme 2 (if double digest) 
2 µL DNA 
to 30 µL total volume 
Table 4.4.  Components of digestion reactions for NisI∆(1-20) and 
pGEX-6P-1.  Restriction enzymes used were BamHI and XhoI, 
both of which required inclusion of BSA. 
2 µL plasmid 
2 µL insert 
2 µL 10X buffer 
0.5 µL T4 DNA ligase 
13.5 µL H2O 
20 µL total volume 
Table 4.5.  Components of the ligation 
reaction for NisI∆(1-20) and pGEX-6P-1. 
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4.5.2   Overexpression of NisI∆(1-19) 
Overexpression of NisI∆(1-19) (LAGJ.VI.050).  A fresh transformation of E. coli BL21(DE3) (New England 
Biolabs, Ipswich, MA) was carried out using heat shock and plating on LB plates containing 100 mg/mL 
ampicillin. This protocol was adapted from the Rienstra lab (Heather Frericks Schmidt and Gautam Shah).  
1 µL of DNA was stirred into 40 µL of competent cells and the mixture was incubated on ice for 30 min.  
The cells were heat-shocked by immersion into a 42 °C water bath for 30 s and then immediately placed 
back on ice for 2 min with the addition of 250 µL SOC media.  The cells were then incubated at 37 °C for 
30 min, at which point they were plated onto a LB plate containing ampicillin; 20 µL of cells were plated 
with 20 µL fresh SOC and the plate was incubated overnight at 37 °C. 
From the transformants, one 50-mL culture was inoculated per liter of overexpression to be 
cultivated.  Following the protocol of Ian Gut, once the OD600 had reached 0.8, the cells were pelleted at 
6000 rpm (4650xg) at 4 °C for 20 min, then resuspended into the overexpression cultures, to which 
ampicillin had been added (final concentration 500 µg/mL).  The cultures were induced with 0.6 mM final 
concentration IPTG and incubated in baffled flasks at 37 °C; they were harvested 20 h after induction.  
OD600 values were measured throughout the growth to determine whether the product appeared to be 
toxic to cells.  Cells were harvested at 4650xg at 4 °C, for 30 min.  The cells were flash frozen and stored 
at -80 °C. 
 For isotopic overexpression, cells were grown in rich media to an OD600 value of 0.8 at 37 °C, at 
which point they were harvested at 8000 rpm (6200xg) for 10 min at 23 °C and resuspended into a half-
volume of Studier P minimal media.  The cultures were induced with 0.5 mM IPTG (final concentration) 
and allowed to grow at 25 °C for 20 h.  The cultures were then pelleted at 4000 rpm (3100xg) for 30 min 
at 4 °C, resuspended into New Resuspension Buffer (20 mM Tris, 1 M NaCl, 10% [w/v] glycerol; pH 7.6) 
and stored at -80 °C to await purification. 
NisIΔ(1-19) was overexpressed in LB and Studier P media, both with natural abundance NH4Cl 
and 15NH4Cl (Cambridge Isotope Laboratories, Andover, MA).59   
PAGE analysis of overexpressions (LAGJ.V.096).  Cell culture (1 mL aliquot) was pelleted and the OD600 
values were used to normalize the pre- and post-induction samples into fresh New Resuspension Buffer.  
A 20-µL aliquot of sample was combined with 10 µL of Laemmli dye and the samples were boiled in a 
thermocycler and pelleted for 10 min at 15870xg.  For a 10-well gel, 15 µL of each sample was loaded 
into the wells; for a 15-well gel, 8 µL was loaded.  Gels (10% acrylamide) were run at 190 V, 250 mA, for 
35 min or until the dye front reached the desired location on the cassette.	  
 
4.5.3   Purification of NisI∆(1-19) 
 Two protocols were optimized for purification of NisI.  They are both presented here, with the key 
difference being method of cleavage of the GST tag and conclusion of purification subsequent to this 
step. 
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Purification of NisI∆(1-19) – protocol one (LAGJ.V.071).  The cell pellet was thawed on ice and diluted 
two-fold with New Resuspension Buffer (20 mM Tris, 1 M NaCl, 10% glycerol [w/v]; pH 7.6).  The cells 
were lysed, first with lysozyme (final concentration of 0.3 mg/mL; Sigma-Aldrich, St. Louis, MO) and then 
with sonication (microtip, 35% amplitude, 2.2 s on, 9 s off).  For volumes greater than 50 mL, the blunt 
sonication tip was used at 50% amplitude.  The cell debris was pelleted (23700xg, 4 °C, 30 min) and the 
supernatant was filtered (0.45-µm). 
To prepare the GST column (10 mL; Glutathione Sepharose 4 Fast Flow, GE Healthcare, 
Piscataway, NJ), 30 mL of Regeneration Buffer 1 (6 M guanidine hydrochloride), 100 mL of Millipore 
water, and 30 mL of Regeneration Buffer 2 (1 mM dithiothreitol) were run over the column to regenerate 
the resin.  The column was then equilibrated with 200 mL of Binding Buffer (500 mM KCl, 140 mM NaCl, 
10 mM Na2HPO4, 1.8 mM KH2PO4).  At this point, the filtered protein solution was applied to the GST 
column and slurried for 1 h at 4 °C.  When the volume of lysates were too great to slurry on column, a 
peristaltic pump was used to recycle the solution over the column.  The flowthrough was collected and the 
column was washed with 200 mL of Binding Buffer and 30 mL of Elution Buffer containing no glutathione 
(50 mM Tris, 100 mM NaCl).  The protein was eluted with 40 mL of Elution Buffer containing glutathione 
(50 mM Tris, 100 mM NaCl, 20 mM glutathione).  The protein sample was concentrated into PreScission 
Protease Buffer (50 mM Tris, 150 mM NaCl, 1 mM DTT, 1 mM EDTA; pH 7.0) for removal of the GST tag 
using a 10000 MWCO centrifugal concentrator (EMD Millipore, Darnstadt, Germany) at 5000 rpm. 
The sample (~500 µL) was combined with 50 µL PreScission protease (GE Life Sciences) and 
rocked at 4 °C for 16 h, then the mixture was reapplied to a pre-equilibrated GST column and slurried for 
1 h.  The column was allowed to settle and the eluent was collected, then concentrated.  The protein 
concentration was approximated using the known A280 for NisI∆(1-19), 28880 M-1 cm-1.  The concentrated 
sample was further purified by gel filtration column on the FPLC.  The protein-containing fractions were 
concentrated down and glycerol was added to a final concentration of 10% [w/v].  The samples were flash 
frozen and stored at -80 °C. 
Purification of NisI∆(1-19) – protocol two (LAGJ.VI.087).  This protocol was suggested by and adapted 
from the Nair lab.  A 10-mL GST column (Glutathione Sepharose 4 Fast Flow, GE Healthcare, 
Piscataway, NJ) was equilibrated into GST Binding Buffer (500 mM KCl, 140 mM NaCl, 10 mM Na2HPO4, 
1.8 mM KH2PO4; pH 7.3).  The cell pellet was thawed on ice and diluted to 30 mL with New 
Resuspension Buffer (20 mM Tris, 1 M NaCl, 10% [w/v] glycerol; pH 7.6).  The pellet was lysed using 4.5 
mg lysozyme (Sigma-Aldrich, St. Louis, MO) per L growth for 20 min on ice and then by sonication using 
the microtip (35% amplitude, 2.2 s on, 9 s off, for 25 minutes total); if the resuspended solution was 
greater than 50 mL in volume, the blunt sonication tip was used at 50% amplitude, all other parameters 
remaining the same.  The cell debris was pelleted at 15000 rpm (23700xg) and 4 °C for 30 min.  The 
supernatant was decanted and clarified with 0.45-µm syringe filter, then applied to the GST resin and 
slurried for 1 h at 4 °C.  When the volume of lysates were too great to slurry on column, a peristaltic pump 
was used to recycle the solution over the column.  The resin was allowed to settle and the flowthrough 
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collected.  The resin was resuspended into PreScission Protease buffer (50 mM Tris, 150 mM NaCl, 1 
mM DTT, 1 mM EDTA; pH 7.0) for on-resin batch cleavage and 200 µL of PreScission Protease was 
added for each 5 mL resin.  The resin was slurried in the protease mixture overnight at 4 °C on a rotary 
drum. 
A Q Sepharose column was equilibrated on the FPLC.  A constant flow of 2 mL/min was kept for 
5 CV of Buffer A (20 mM Tris, 10% [w/v] glycerol, 100 mM KCl; pH 8.3) while collecting 7.5 mL fractions 
and then 5 CV of Buffer B (20 mM Tris, 10% [w/v] glycerol, 1 M KCl; pH 8.3) while collecting 5 mL 
fractions.  After 16 h of proteolysis with PreScission Protease, the supernatant was collected from the 
GST column and loaded onto the FPLC using a SuperLoop 150; flowthrough was collected in 9 mL 
fractions.  Protein was seen to elute in fractions D1, E1, E2, E3, and E4 and then combined and 
concentrated using an Amicon centrifugal concentrator (MWCO 10000; EMD Millipore, Billerica, MA).  
The final concentration was calculated using the A280 value for NisI∆(1-19), which is 28880 M-1 cm-1. 
PAGE analysis of purification (LAGJ.V.049).  A 20-µL aliquot of sample was combined with 10 µL of 
Laemmli dye; the samples were boiled in a thermocycler and pelleted for 10 min at 15870xg.  For a 10-
well gel, 15 µL of each sample was loaded into the wells; for a 15-well gel, 5-8 µL was loaded.  Gels (10% 
acrylamide) were run at 190 V, 250 mA, for 35 min or until the dye front reached the desired location on 
the cassette.  Standard samples were acquired from New England Biolabs (Ipswich, MA). 
 
4.5.4   Purification of nisin A 
HPLC purification of nisin (LAGJ.VI.007).  This protocol was provided by Trent J. Oman.  Briefly, 3 g 
Nisaplin (Danisco, Copenhagen, Denmark; stored at -80 °C under N2 to prevent oxidation) was dissolved 
in 30 mL 30% acetonitrile, 0.1% trifluoroacetic acid.  The mixture was vortexed until it appeared 
homogenous and then sonicated for 30 min.  The solution was divided into 1-mL aliquots, four of which 
were pelleted at 15870xg for 20 min just prior to each injection (~4 mL per injection).  Using a pre-
equilibrated C4 column, the gradient proceeded from 98% Buffer A (0.1% TFA) to 100% Buffer D 
(0.086% TFA in 80% acetonitrile) over 45 minutes at a flow of 8 mL/min.  Fractions were collected for 0.4 
min (3.2 mL) each while the A280 was greater than 1, generally resulting in four fractions per run.  A 10-µL 
aliquot of each fraction was taken for MALDI analysis and the remainder of the fractions were flash frozen 
and stored at -80 °C. 
MALDI analysis of HPLC fractions (LAGJ.V.085).  MALDI matrix (α-cyano-4-hydroxycinnamic acid; 
Sigma-Aldrich, St. Louis, MO) was spotted onto the MALDI plate (~2 µL per spot) and allowed to dry.  1.5 
µL of sample was spotted on top of the matrix and mixed by pipetting.  Laser intensity was set to 2500 to 
sufficiently ionize the samples and spectra were acquired.  Samples were graded by the relative 
proportion of the nisin peak (m/z 3355) to contaminant peaks – including variously dehydrated species – 
and pooled by these rankings. 
 
 
 77	  
4.5.5   Acquisition of preliminary NMR data 
All NMR spectra were acquired in the VOICE laboratories at the University of Illinois at Urbana-
Champaign on the Varian Unity Inova 500NB (500 MHz, 5mm Varian 1H{13C/15N} PFG Z probe) and 
Varian Unity Inova 600NB (600 MHz, 5mm Varian 1H{13C/15N} PFG X, Y, Z probe) instruments. 
The first sample examined was a natural abundance sample at a concentration of 175 µM 
(provided by Ian Gut).  A 1D spectrum was taken with presaturation on the solvent peak, as well as 
HSQC, NOESY with presaturation, and NOESY with watergate solvent suppression spectra (all 2D with 
an initial 1D taken to verify the parameters).  A large contaminant was noted; it was not removed by PD10 
column.  The sample was submitted for ESI-MS analysis to determine the identity of the contaminant in 
the NMR sample.  The chemical shifts of the contaminant were also run through the BMRB Metabolomics 
search engine.  For MS analysis, the sample was exchanged into ammonium acetate (50 mM, pH 7.0) 
using a PD10 column; fractions were assayed for protein content by A280.  The sample was analyzed by 
ESI-MS in both positive and negative ion mode. 
An uniformly-13C,15N-labeled NisIΔ(1-19) sample in phosphate buffer (pH 7.5) was provided by 
Ian Gut at a concentration of 1.25 mM (33.1 mg/mL).  Isotopic labeling was accomplished by use of 13C-
glucose, 15NH4Cl, and BioExpress-Min reagents from Cambridge Isotope Laboratories (Andover, MA).  1H 
one-dimensional and 1H,15N-HSQC two-dimensional spectra were acquired.  
 
4.5.6   Fluorescence polarization studies of the binding of NisI∆(1-19) to nisin A 
Fluorescence polarization studies of NisI and nisin (LAGJ.VII.006).  A stock of 2.2 mg/mL (0.66 
mM) rhodamine-labeled nisin was provided by Ian Gut.  In the 96-well plate to be used, each well was to 
contain 20 µL solution.  The optimal concentration of labeled peptide was determined first by diluting the 
stock of labeled nisin to varying concentrations (between 0.1-100 nM) in both acetate buffer (0.1 M, pH 
4.0) and MOPS buffer (0.1 M, pH 6.8), the optimal concentration being such that a fluorescence signal of 
~150 is acquired.  A concentration of 5 nM rhodamine-nisin was selected for polarization studies with 
NisI, which was varied from 0.05-100 µM.  Readings were taken at 0, 30, 75, 165, 390 min, incubating on 
ice between measurements.  After preliminary experiments, concentrations of rhodamine-nisin were 
varied from 0.05 to 1 µM. 
The data was plotted and fitted using GraphPad Prism.  From this, Kd values could be calculated. 
Results were not reproducible under any conditions. 
 
4.5.7   Isothermal titration calorimetry studies of the binding of NisI∆(1-19) to nisin A 
For ITC studies, the cell to be used contained 1.4 mL and a protein concentration of 20-50 µM 
was optimal.  The ligand was needed in 400 µL volume at a concentration 10-fold higher than that of the 
protein (200-500 µM).  Each run was to be commenced with a blank of ligand in the syringe and buffer 
only in the cell – this accounted for heats of dilution. 
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ITC of NisI and Nisin at pH 4.0 and 6.8 (LAGJ.V.051; LAGJ.VI.009). Acetate buffer (0.1 M, pH 4.0; 20 L) 
was prepared from sodium acetate and acetic acid; also prepared was MOPS buffer (0.1 M, pH 6.8; 20 
L).  Samples of NisI were pooled and concentrated to 5 mL, then dialyzed (Slide-A-Lyzer Dialysis 
Cassettes 10000 MWCO, Thermo Scientific, Rockford, IL), in 4 L of either acetate buffer (0.1 M, pH 4.0) 
or MOPS buffer (0.1M, pH 6.8). The buffer was exchanged four times and the protein solution was 
removed, then diluted to the desired concentration with dialyzed buffer. A solution of approximately 7X 
nisin was prepared by dissolving nisin into the final dialysate.  MALDI analysis of the nisin confirmed that 
it was not oxidized The nisin solution was added to the ITC cell as the titrant, over 30 injections (10 µL in 
volume). Two titrations were attempted to verify reproducibility of the experimental set-up. 
ITC of NisI and nisin was carried out under the following conditions: 90.12 µM and 745.16 µM at 
pH 6.8; 160.94 µM and 2.623 mM at pH 4.0; 50 nM and 437 µM at pH 6.8; 50 µM and 467 µM at pH 6.8; 
20 µM and 2.05 mM at pH 4.0. 
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 CHAPTER 5 
Progress Toward Mechanistic Elucidation of Phosphite Dehydrogenase 
 
5.1   Introduction 
5.1.1   The discovery and characterization of phosphite dehydrogenase 
Phosphite dehydrogenase (PTDH), also known as NAD+:phosphite oxidoreductase or PtxD, was 
first isolated from Pseudomonas stutzeri WM88 at the University of Illinois at Urbana-Champaign in the 
lab of William Metcalf.2  The organism was grown under phosphate starvation conditions using either 
phosphite or hypophosphite as the sole phosphorus source, demonstrating the organism’s ability to 
salvage other forms of the element, a conclusion that was further corroborated by genetic analysis.3 
Several enzymes have been discovered previously that were implicated in formation or breakage of P-C 
bonds, but none of them were demonstrated to do so by redox chemistry.3  Therefore, PTDH is the first 
enzyme discovered to catalyze the oxidation of inorganic phosphorus, concomitantly generating a 
stoichiometric amount of reduced cofactor, that has been rigorously studied in a pure form; a similar 
enzyme was previously found in Pseudomonas fluorescens strain 195 and explored in cell extracts but 
was subsequently lost prior to isolation.2,4  An ortholog of PTDH was also previously identified in a strain 
of Alcaligenes faecalis demonstrated to be able to grow on phosphite, suggesting oxidation of phosphite 
may not be constrained to Pseudomonas stutzeri.3 
PTDH is a 38.5 kDa protein that exists as a dimer in its native form as determined by gel filtration 
experiments.2  Homology to D-hydroxy acid dehydrogenases is noted for PTDH (26-35% identity to other 
enzymes in this family with characterized functions),3 though it has a much lower catalytic turnover than 
typical members of this family (4 s-1 as opposed to 150 s1 for D-lactate dehydrogenase from Lactobacillus 
bulgaricus).5-9 
The oxidation of phosphite by PTDH is mechanistically similar to many known phosphoryl transfer 
reactions.5,9  It is a unique reaction that results in the nucleophilic displacement of hydride, a notoriously 
poor leaving group, by hydroxide; the hydride transfer step has been determined to be entirely rate-
limiting at high pH, with rate-limiting effects waning with decreasing pH.5,7,10  The reaction proceeds in an 
ordered bi-bi kinetic mechanism, with NAD+ binding first.2,9  Overall, the reaction is approximately 15 
kcal/mol exergonic.5,7,9  Surprisingly – given the extremely favorable thermodynamic driving force – PTDH 
has been demonstrated to have a Vmax of only 12 µmol min-1 mg-1.3 
 PTDH was found to have optimum catalytic activity (kcat/Km,phosphite) at pH 7.5 with decreasing 
activity at both lower and higher pH values.  Also discovered were two pKa values that correspond to 
single proton transfer events, one at 6.8 +/- 0.1 and one at 7.8 +/- 0.2.5,9,11,12  Given that the pKa values 
for phosphorous acid are 1.5 and 6.8, it is likely that the more acidic single proton transfer is the 
deprotonation of monoanionic phosphite to the dianionic form; it is believed that the positively charged 
conserved residue Arg237 may be responsible for binding of the dianion, in conjunction with a second 
positively charged residue.5,9,13,14  This would leave the basic limb proton transfer to correspond to 
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His292, meaning that at pH 7.5 it would likely be in its imidazolium form.  While the kcat/Km,phosphite is 
dependent on pH, both kcat and kcat/Km,NADH are pH-independent, suggesting an absence of solvent-
exposed residues whose protonation states are critical to catalytic activity when the enzyme is in the 
ternary complex.9 
PTDH catalyzes the NAD+-dependent oxidation of phosphite to phosphate (Scheme 5.1), allowing 
for growth on phosphite as the sole phosphorus source.2,5,9,15,16 It is conceivable that this is a recently 
evolved enzyme as phosphite is toxic to many microorganisms, including the Pseudomonas strains; 
generally, phosphite is found as a by-product of industrial waste.5,9  PTDH could have evolved upon 
exposure to this hazardous compound from other dehydrogenases that utilized a 2-keto acid substrate, 
especially given that no other members of the dehydrogenase family can oxidize phosphite, 
demonstrating the phenomenon is not ubiquitous across this class.9  However, the recent demonstration 
that PTDH enzymes are widespread amongst bacteria and that their sequences are very diverse argues 
against this hypothesis and suggests the enzyme is ancient.10 
 
5.1.2.  Phosphite dehydrogenase as a cofactor regeneration system for industrial applications 
 PTDH has great potential for use as a cofactor 
regeneration system in industry (Scheme 5.2).  
Oxidoreductases are often used to catalyze synthetically 
difficult reductions with great efficacy and stereoselectivity; 
such enzymes typically require prohibitively expensive 
cofactors – NADH currently costs $25 per mmol, NADPH about 
$500 per mmol.17-19  To allow economically feasible use of such 
enzymes on an industrial scale, it is necessary to have an in 
situ method of regenerating the reduced cofactor, ideally one 
that will result in environmentally innocuous by-products.  
Mutants of PTDH have been generated with relaxed specificity 
for NAD+ and NADP+ compared to wild type PTDH that regenerate both cofactors stoichiometrically with 
the oxidation of phosphite.7,13,16  This allows a catalytic efficiency 33-fold improved over the alternative 
method of NADPH regeneration currently in place using the formate dehydrogenase (FDH) system; 
beyond the improvement in catalytic efficiency, PTDH shows significantly larger Keq and kcat values 
compared to FDH (Keq,FDH = 5 x 103; Keq,PTDH = 1011; kcat,FDH = 2.5 s-1; kcat,PTDH = 7.1 s-1).2,5,7,13,17,19-24  In 
addition, a regeneration system with a large driving force may be able to drive an otherwise unfavorable 
reaction to completion.17  Due to its larger Keq – making it essentially irreversible – and higher turnover, 
Scheme 5.1.  Reaction catalyzed by PTDH, with oxidation of phosphite and stoichiometric reduction of 
NAD+. 
Scheme 5.2.  Industrial utility of PTDH in 
regeneration of cofactors. 
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PTDH is clearly an appealing system to complement FDH for industrial cofactor regeneration.7  In 
addition, PTDH has been found to generate deuterated compounds, such as NAD2H, with ease.17 
To make PTDH a more viable enzyme in an industrial setting, in which high temperatures and 
throughput are often used, mutagenesis studies were performed.  A new “wild-type” – TS-PTDH – was 
produced by the introduction of twelve mutations, made to a parent strain containing five mutations, that 
impart increased solubility and thermostability without a concomitant loss of activity.7,19,25  These 
mutations (D13E, M25I, V71I, E130K, Q132R, Q137R, I150F, E175A, Q215L, R275Q, L276Q, I313L, 
V315A, A319E, A325V, E332N, C336D) allow for solubility to 1.6 mM, a half-life at 45 °C 7000 times 
larger than for wild-type, and a T50 20 °C higher than for wild-type.19  Yet unknown about PTDH is the 
identity of its active site base, as well as the specifics of the mechanism through which the enzyme 
proceeds, including the protonation states of the enzyme and its substrate.  These are the questions the 
research described herein seeks to address. 
 
5.1.3.  Previous studies on the mechanism of phosphite dehydrogenase 
To date, several of the conserved residues within the catalytic pocket have been determined by a 
2.5 Å X-ray crystal structure (Figure 5.1);1 this work was carried out using the TS-PTDH mutant, to be 
described in further detail later.7,19  The conserved residues identified are as follows: His292, Arg301, 
Arg237, Lys76, Asp79, and Glu266.7  Of these, three (Arg237, Glu266, and His292 using PTDH 
numbering) were known to be conserved in these D-hydroxy acid dehydrogenase family.3  Three mutants 
were prepared of His292 (H292N, H292K, and H292F), all of which were found to be catalytically inactive; 
a more than 10-6-fold 
change in catalytic 
efficiency was noted.5  
Therefore, His292 was 
determined to be essential 
to catalysis in one of three 
roles: NAD+-binding, acting 
as the general base for 
catalysis, or participating in 
the nucleophilic 
displacement of hydride to 
form an enzyme-
phosphoryl intermediate 
which would then be 
hydrolyzed to yield 
phosphate and the resting 
form of the enzyme.5  It 
 
Figure 5.1.  Structure of the active site of PTDH, shown with NAD+ and the inhibitor sulfite 
bound.1 
!
Figure 5.2. Structure of the active site of PTDH, sho n with NAD+ and the inhibitor 
sulfite bound (S. Nair lab, unpublished results) 
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should also be noted that in the presence of 
NAD+ and the inhibitor sulfite, diethyl 
pyrocarbonate (DEPC) – a common histidine-
modifying reagent – fails to modify His292.5  
The crystal structure showed Arg301 within 
hydrogen bonding distance to a water poised 
to attack the sulfite inhibitor. 
Phosphite dehydrogenase catalysis 
proceeds through a sequential binding 
mechanism in which NAD+ binds first, 
followed by phosphite, both of which have a 
Km of approximately 50 µM.3  Though no 
experimental evidence has been presented 
on the order of product release, it is believed 
that phosphate leaves the active site first and 
irreversibly.3  Upon binding of NAD+, the 
enzyme putatively undergoes a 
conformational change, allowing phosphite to 
access the active site pocket.3 
The substrate specificity of PTDH has been examined extensively.  To date, only one inhibitor 
has been found, which is sulfite (Ki = 16 µM); structural homologs of phosphite such as thiophosphite, 
phosphite esters, hydrated aldehydes, methylphosphinate, and fluorophosphinate were not accepted by 
the enzyme, precluding the possibility of using a stereochemically defined substrate to monitor the 
enzyme mechanism.2,9  Sulfite, which resembles phosphite structurally though replacing the lone proton 
of phosphite with a lone pair in sulfite, was determined to form a covalent adduct with NAD+ via a bond 
forming from the sulfur to the C4 atom of the nicotinamide ring, which may resemble the transition state 
structure during hydride transfer; this bond formation may be monitored by A310.9,26  Sulfite is a 
competitive inhibitor with respect to phosphite, and an uncompetitive inhibitor with respect to NAD+.9  It 
will only bind once NAD+ is bound, consistent with the known mechanism of sequential binding of the 
substrates.2,9 
Alternative nucleophiles were also tested, including hydroxylamine, fluoride, methanol, and 
trifluoromethanol; all were outcompeted by water, the native nucleophile.9  This removes the possibility of 
using an alternative nucleophile to probe the stereochemical and electronic nature of the reaction.  The 
specificity of PTDH suggests that phosphite is the natural substrate, despite a dearth of previous reports 
of phosphite occurring in biological systems.2,9,15,27  This is further supported by the inclusion of ptxD in an 
operon that contains a putative binding protein-dependent phosphite transfer system, as well as by the 
induction of PTDH under phosphorus starvation conditions.2,9,15 
	  
Figure 5.2.  X-ray crystallographic structure of PTDH with NAD+.1  
The resolution of this structure is 2.5 Å. 
!
Figure 5.3.  X-ray crystallographic structure of PTDH with 
NAD+.{Zou, 2012 #6762}  The resolution of this structure is 2.5 
Å. 
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This enzyme shows novel chemistry in that it catalyzes displacement of a hydride leaving group, 
which is transferred to the cofactor with Re-face stereospecificity as determined by NMR spectroscopy.9,16 
 
5.1.4   Goals of this research project 
Identification of the catalytic base 
Typically, residues that 
serve as a catalytic base are 
Glu, Asp, His, or Cys; Lys and 
Tyr may also fill this role but 
typically require a localized 
depression of the pKa.28 While 
previous studies suggested 
His292 as the general base, a 
recent X-ray crystallographic 
structure with 2.5 Å resolution 
(Figures 5.2 and 5.3)1 shows 
Arg301 within hydrogen-
bonding distance to a water 
within the catalytic site, 
unveiling the possibility that it could also function as the general 
base (Figure 5.4). 
Three criteria must be examined to determine the 
viability of a residue functioning as a base: that the residue is in 
the right place, demonstrated to be essential for catalysis, and is 
in the correct protonation state.28  To be in the right place, a 
residue must be in the correct orientation at time of catalysis as 
determined by X-ray crystallography and within 3.5 Å of the atom 
bearing the hydrogen to be abstracted.28  Essentiality for 
catalysis is determined by mutagenesis studies; a 102-103 fold 
decrease in kcat should occur upon mutation of the critical 
residue.28  Both of these conditions have been confirmed for both 
His292 and Arg301 in the PTDH system.  However, whether 
these residues exist in the correct protonation state to catalyze 
the reaction has yet to be determined.  There are many issues to 
be considered in the determination of the protonation state of the 
Figure 5.4.  Two possible bases may act 
to deprotonate the water nucleophile, 
catalyzing phosphite oxidation and 
concomitant NAD+ reduction. 
	  
Figure 5.3.  Sequence of TS-PTDH.  Amino acids that are different than those in wild-
type are underlined.  Residues to be examined by NMR are bold and triplets are color-
coded (blue for His, red for Arg). 
!
Figure 5.4. Sequence of 17X PTDH.  Amino acids that are different t  t s  i  
wild-type are underlined.  Residues to be examined by NMR are bold and triplets are 
color-cod d (blue for His, red for Arg) 
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catalytic residue.  One such issue is the protonation state of the residues that participate in the reaction, 
which may exist in so-called normal or reverse protonation states; these will be discussed in greater detail 
later. 
 
The likelihood of Arg acting as a base is much debated. 
  Arg has been implicated as a catalytic base in several systems, including IMP dehydrogenase, 
pectate/pectin lyases, fumarate reductase, and L-aspartate oxidase; in all of these active sites, several 
carboxylate groups surround the catalytic Arg, potentially contributing to its basic behavior, either by 
geometric constraint of the guanidine group via hydrogen bonding or by facilitation of proton exchange.28-
32  To determine whether carboxylate groups cause deformation of the guanidine group of the catalytic 
Arg, a higher resolution X-ray crystallographic structure is required.28 
  Perturbations in pKa values on the order of 5 units have been observed when charged residues, 
such as Lys, are buried in hydrophobic environments; this could allow for the existence of a single 
deprotonated Arg residue at pH 7.5, where PTDH has optimal activity.9,28  However, an deprotonated Arg 
must be rationalized for each system based on the structure of the catalytic pocket, including the 
proximity of positive charges and hydrophobicity.28  The geometry of the guanido group of the Arg in 
question is also of importance; neutral guanidine groups favor an amino geometry that is pyramidal in 
nature, meaning that steric 
constraints on the guanidine 
group of the Arg may affect 
its pKa value.28 
Another possible 
phenomenon to consider is 
that of the enzyme being 
tuned to the pKa of its direct 
substrate, in this instance 
raising the pKa of Arg301 to 
that of water, ~16.  Rather 
than a large depression in 
its pKa, instead there could 
be a slight elevation, which 
may assist in explaining the 
anomalous kinetics in the 
face of the highly favorable 
thermodynamics.  Many 
proton transfer reactions are 
known to occur most 
Figure 5.5.  Protonation states of PTDH.  Two single proton transfer events occurring at 
pH values of 6.8 and 7.8 could pertain to either deprotonation of the phosphite substrate or 
of the enzyme general base. 
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efficiently when the pKa values of the donor and acceptor species match; this is seen in acyl-CoA 
dehydrogenase in which a catalytic Glu acts upon a carbon acid, raising the pKa of the former ~6 units 
and depressing that of the latter ~11 units.28  If tuning is occurring rather than localized depression of the 
pKa of Arg301, it should be expected that the residue would be deprotonated only a small fraction of the 
time.28 
This research aims to discover the pKa values of His292 and Arg301 using NMR spectroscopy.  If 
Arg301 is acting as the catalytic base, it should be the only unprotonated arginine residue at pH 7.5.  The 
protonation state of arginine can be determined by examination of the Nη and Nε atoms, which upon 
protonation undergo a 15 ppm and 3 ppm, respectively, downfield shift. 
 
Determination of the protonation state of enzyme/substrate 
If a reverse protonation state is used by the enzyme (Figure 5.5) – meaning one in which the 
catalytic base residue is mostly protonated and the substrate mostly in its dianionic form at the optimum 
pH – this would explain why the kinetics of the reaction are so much slower than would be expected from 
such an exergonic process, as most of the enzyme-substrate pairing would be in an inactive form.5,33-39  In 
such a mechanism, the thermodynamic disadvantage of binding the monoprotiated form of phosphite 
could be offset by a kinetic advantage provided to catalysis.  With such a mechanism, only a small 
fraction of the enzyme would be in the correct protonation state at the given pH – by calculations using 
the Henderson-Hasselbalch equation, only 4% of the enzyme-substrate pair would be in the necessary 
protonation state at any given time. The two single proton transfer events – one occurring at pH 6.8 and 
one at pH 7.8 – have been tentatively assigned, with the lower  corresponding to the second 
deprotonation of phosphite (pK2 = 6.8) and the higher to deprotonation of the active site base.5,9,33  
However, if this is true, it corresponds with the notion of a normal protonation state.  
Differentiating between the two protonation state mechanisms is nontrivial, principally due to the 
similar pKa values of the proton transfer events.5 Normally, such transfers could be readily differentiated 
with the use of an inhibitor.9  Given that the pKa values of phosphite and sulfite are 0.1 pH units apart, 
results to determine the protonation state have been inconclusive.5,9,33,40 
 
Determining the mechanism of catalysis 
The final information to be discovered is the nature of the mechanism through which the reaction 
proceeds, including the identity of the phosphite intermediate and/or transition state.  Three possible 
mechanisms have been proposed: concerted, associative, or dissociative (Figure 5.6).9  Nucleophilic 
attack and hydride displacement may occur by either a stepwise dissociative mechanism, in which a 
metaphosphate intermediate would be present, or a stepwise associative mechanism, in which the 
intermediate would be a five-coordinate phosphorane species.9  The former mechanism has been 
observed for phosphoryl transfer reactions in phosphate monoesters and monoanhydrides.41  A final 
possibility would be a concerted process in which a water species becomes deprotonated, leaving a 
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hydroxide ion which would subsequently attack the phosphorus center simultaneously misplacing the 
hydride leaving group.3 
Much data exists against the existence of a metaphosphate intermediate in enzymes catalyzing 
phosphoryl transfer reactions; it has been excluded for all systems in which it has thus been proposed,41 
though none of these systems are directly analogous to PTDH.9,16   
A phosphorane intermediate has been proven inconsistent with data provided by studies of the 
kinetic isotope effects (KIE) and Brønsted LFER in other phosphoryl transfer mechanisms involving 
phosphate monoesters.41  In addition, if the pH-rate profile of PTDH is interpreted to mean that phosphite 
is present in its dianionic 
form, it would be less 
likely for the reaction to 
proceed through an 
associative mechanism.3  
Given the evidence 
collected to date, the most 
likely reaction pathway 
would follow a concerted 
mechanism.3  Regardless, 
spectrometric analysis of 
the protonation state 
and/or intermediate 
species would greatly 
assist in determining the 
catalytic mechanism. 
To address the 
identification of the 
catalytic base, protonation 
state, and reaction 
mechanism, PTDH was 
recombinantly expressed 
with a hexahistidine tag, 
previously shown to 
minimally affect activity of 
the enzyme.5  The samples of protein were then expressed for use in solid-state NMR spectroscopy.  
Pulse sequences are available to specifically monitor the Arg sidechain; these sequences will be used in 
conjunction with pH titrations to determine first if there is a deprotonated Arg at physiological pH and 
subsequently the microscopic pKa of said residue.  For Arg, a shift of 15 and 3 ppm downfield are 
Figure 5.6.  Representations of the three proposed mechanisms by which PTDH catalyzes 
its reaction. 
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expected for the Nη and Nε chemical shifts upon protonation, respectively; the Cζ of Arg should also be 
fairly diagnostic as it appears in a region devoid of other protein chemical shifts except one carbon in the 
Tyr sidechain.  Using 31P NMR, the phosphite may also be monitored; in proton-coupled spectra, 
phosphite gives a diagnostic peak at 3.58 ppm, with JP-H = 581 Hz.17	  
Arg237 is believed to assist in binding the phosphite substrate; a positive charge at this position is 
necessary to accomplish this task.5  A R237K mutant showed a 102 decrease in kcat with a 104 loss of 
activity and significantly increased binding constants (120-fold for phosphite, 20-fold for NAD+).5 
Both Asp79 and Glu266 form hydrogen bonds to other essential residues to help position them 
optimally for binding and/or catalysis, the former positioning Arg237 and the latter His292.5,7  A D79N 
mutant showed enhanced affinity for phosphite and no notable decrease in activity.7  Similarly, a E266Q 
mutant was found to have an increased kcat with respect to wild-type PTDH, though due to an increase in 
the Michaelis constants (85-fold for phosphite, 20-fold for NAD+), an overall loss of catalytic activity was 
noted.5  Also, the Glu266 residue was determined to be unimportant for catalysis once the substrates 
were bound.5  It should be noted that none of the mutants tested produced substantially different circular 
dichroism spectra.5 
 
5.2   Results and Discussion 
5.2.1   Overexpression of natural abundance phosphite dehydrogenase 
Overexpression of PTDH was attempted in rich media (LB broth).  Natural abundance PTDH was 
produced at a yield of 3.3 - 29 mg per L of growth culture, with 5.7 – 5.9 g cells per L of growth culture. 
Mimicking the isotopic overexpression protocol, a yield of 5.7 g cells per L of overexpression culture was 
achieved. 
Initial overexpressions yielded 6.5 mg TS-PTDH for 1 L of overexpression culture, which would 
provide a 400-µL NMR sample at a concentration of 0.42 mM, a concentration lower than desired; this is 
compared to 7.8 mg TS-PTDH per L recovered by Emily Fogle. 
 
5.2.2   Overexpression of isotopically enriched phosphite dehydrogenase 
Doubly labeled TS-PTDH (U-13C,15N) could be grown to a cell mass of 2.5 – 2.9 g per L of growth 
culture in minimal media (Studier P media), with an average yield of 10 mg per liter of culture. 
 
5.2.3   Purification of phosphite dehydrogenase 
A lower yield of purified protein was correlated with a larger pellet volume and resultant poorer 
lysis.  To rectify this, lysozyme was introduced to the purification protocol, which was noted to make a 
clear difference in the lysis of cells, including making the solution less viscous and the cell debris easier to 
pellet.  Pellet volumes were also decreased so that no more than 2 L of culture (cells resuspended into 20 
mL Resuspension Buffer) were purified at any one time.  Lysis was further enhanced by the addition of 
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salt to the Resuspension Buffer; pelleting of the cell debris by centrifugation was also improved by the 
addition of salt, so that no intermediary sludgy layer was formed after the centrifugation step. 
A new Ni-NTA column was poured with a larger column volume to accommodate higher 
throughput via loading multiple cell pellets simultaneously.  During the packing process, it was noted that 
the maximum pressure rated for the IMAC resin is 0.3 MPa.  Combined with the facts that PTDH tends to 
elute between 60-125 mM imidazole and that more than one liter of start buffer was needed to wash the 
column to achieve an acceptable background absorbance reading for each run (generally meaning an 
overnight equilibration with the protein on the column), a new protocol for FPLC purification of PTDH was 
developed (Figure 5.7).  This new protocol included a higher concentration of imidazole in the wash step 
and a shallower gradient from 30-100 mM imidazole.  Several iterations were tried until an optimal 
protocol was made.  The effect of doubling the volume prior to lysis and the addition of salt to the lysis 
buffer was a shift in the concentration of imidazole required for elution of PTDH from the Ni2+ column, 
moving from elution at 70-100 mM imidazole with the previous protocol to 150-500 mM imidazole. 
Prior to thrombin cleavage, natural abundance TS-PTDH was produced and purified at a yield of 
29 mg per L of overexpression. 
The previously provided FPLC program “Ni Column Beige” proved problematic during purification.  
Large amounts of buffer (>900 mL per purification )were wasted during an overlong wash and post-
elution, in addition to poor resolution of the eluting species.  It was decided that a shorter wash with a 
	  
Figure 5.7.  FPLC trace of “Ni Column 20 mL” program with inset of PAGE purification, protein eluting cleanly as 
shown in Lane 12. 
!
Figure 2.8. FPLC trace of “Ni Column 20mL” program (Inset shows PAGE 
purification with protein eluting cleanly in Lane 12) 
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higher concentration of imidazole, as well as a shorter gradient for elution, might better optimize the 
program for more efficient purification. 
A handheld IMAC column with step gradient elution of protein demonstrated that His6-TS-PTDH 
eluted between 80-125 mM imidazole.  This was used to modify the FPLC protocol to the new “Ni Column 
20mL” for higher yield and greater purity.  The new program demonstrated elution of pure PTDH in 
significantly reduced times.  Also of note, the protein now eluted at 500 mM imidazole, as compared to 
between 80 and 125 mM imidazole before.  This was noted to be due to a dilution of the pellet during 
purification, as well as the addition of 1 M NaCl to the Resuspension Buffer, with the larger lysis volume 
shifting elution to 125-300 mM imidazole. 
After failed attempts to 
cleave off the His-tag with thrombin, 
cleavage was affected at all 
temperatures probed.  Therefore, a 
set of conditions were found that 
agree well with those previously used 
by Heather Relyea (Figure 5.8), 
namely carrying out the reaction at 
16 °C.  Activity assays were carried 
out to assure the enzyme to be 
studied by NMR was still sufficiently 
active, with the following results 
(Figure 5.9): 
Km = 48 µM phosphite (55 
µM literature)7 
kcat = 1.98 s-1 (2.42 s-1 
literature) 
kcat/Km = 4.1 x 104 M-1s-1 (6.5 
x 104 M-1s-1 literature) 
Because of the presence of the His-tag in the literature experiments, some deviation from literature 
values was expected.  Therefore, it appeared that the purification protocol yielded active protein. 
 
 
Figure 5.8.  PAGE analysis of thrombin cleavage at 16 °C over 24 h period.  
Lanes 5-7 are aliquots from the test mixture at 3, 17, and 24 h, respectively.  
Lanes 8-10 serve as a control, containing no thrombin.  A band shift is clearly 
noted. 
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5.2.4   Acquisition and analysis of 
preliminary NMR spectra 
Preliminary 1D 1H spectra 
showed a small molecule contaminant, 
as evidenced by the presence of J-
coupling and a large amount of fine 
structure.  The peaks were entered into a 
database on the Biological Magnetic 
Resonance Bank (BMRB) Metabolomics 
site and the contaminant was identified 
as glycerol.  Also of note was a 
significantly depreciated signal-to-noise 
ratio versus what was expected from the 
given concentration (Figure 5.10).  
However, this is consistent with the 
dimerized nature of the enzyme, in addition to its large mass (~75 kDa).  Due to this finding, in addition to 
concerns about the guanido groups producing peaks too broad to see, it was decided to attempt low 
temperature SS NMR as further solution state studies would require significant technical manipulation.  
 
5.2.5   Determination of crystallization conditions for SSNMR 
Crystallization conditions were provided from the Nair lab and a microcrystallization array was 
performed around these conditions to 
determine optimal salt and polyethylene 
glycol (PEG) concentrations for producing 
crystals of the quality required for SS NMR 
(Figure 5.11).  A low salt, low PEG condition 
was found (0 mM KCl, 10% PEG 3350, 50 
mM phosphate, pH 7.5), which is beneficial 
for two reasons: first of all, the low salt 
concentration facilitates simpler tuning of the 
NMR probe, and second, the low PEG 
concentration assures a higher proportion of 
protein in the mass of sample transferred to 
the rotor, which allows for a higher signal-to-
noise ratio. 
Figure 5.10.  1H,15N-HSQC of U-13C,15N-PTDH. 
Figure 5.9.  Michaelis-Menten plot of enzyme assays (Vmax and Km 
values shown) 
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 Discrepancies were noted between the amino acid sequence previously used to analyze PTDH 
for recurrent motifs and the sequence according to the first paper published on the 12X (now 
redesignated as TS-PTDH) construct.  Further disagreements surfaced when the sequence was provided 
to the Mulholland Lab (Bristol) for QM/MM calculations; a number of residues in the crystal structure were 
inconsistent with either the WT or the TS-PTDH.  Upon sequence analysis, it was determined that the TS-
PTDH mutant in fact contains 17 mutations with respect to the WT.  Part of the confusion was resolved 
with a newer version of the .pdb file of the crystal structure, leaving only Q130 and Y258 as conflicting 
residues.  The DNA sequencing files of TS-PTDH were obtained from Ty Johannes in the Zhao group 
and found to match the construct being used in the van der Donk lab.  For all future discussions, it should 
be noted that TS-PTDH has 26 arginines and 8 histidines, not 25 and 8 as previously described. 
 
5.3   Conclusions 
Currently, this project is at a standstill due to an unavailability of SSNMR facility.  However, there 
is a possibility of conducting solution NMR experiments at Wisconsin.  Solution NMR may be able to 
probe protonation states of the histidine and arginine side chains, which are well-resolved from backbone 
resonances and demonstrate a large change in chemical shift from their protonated to their deprotonated 
forms.  Minimal labeling (15N) may be enough to begin pH titration experiments.  Currently, there are 8 L 
of natural abundance cell growths and 5 L of U-13C,15N-labeled cell growths awaiting purification. 
Crystallization was successfully carried out on natural abundance PTDH at pH 7.5; future 
endeavors will include scaling up this protocol using 15N-labeled PTDH at this pH.  Crystallization will also 
be performed with substrate and cofactor bound to see if this has any affect on rigidity of the enzyme and 
on the protonation state of active site residues; this could affect the solvent exchange rate of the catalytic 
residues.  In addition, having phosphite present would allow the use of 31P correlation spectra.  The pH 
7.5 crystals will be used to check if the Arg sidechains are visible by SS NMR using a HSQC pulse 
sequence selective for the Arg sidechains; there are 25 Arg residues in PTDH.  Crystallizations will then 
be attempted at ±1 pH unit to monitor for changes in protonation state of the sidechains.  Resonances will 
Figure 5.11.  Representation of crystallization tray and its outcomes.  Red cells did not form microcrystals, yellow had 
a biphasic occurrence, and green were conditions that allowed growth of proper microcrystals. 
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be assigned, using a combination of mutants (e.g. R301K and H292N), correlation spectra, and 
auxotrophic labeling schemes. 
 
5.4   Future Research Direction 
 Due to the rigorous technical requirements and the level of expertise necessary, solid-state NMR 
spectroscopy may not be feasible for pursuing these research aims.  A number of techniques, including 
TROSY and the more recent FROSTY, have been pioneered to enable solution state assignment of 
protein complexes up to 1 MDa in size.42  By varying the concentration, temperature, and viscosity of the 
samples, the FROSTY pulse sequence may be implemented.42 
 To assure that the guanido nitrogens will be visible in the spectra, the nitrogen spectral width will 
be increased to incorporate the region around 80 ppm at which guanido nitrogens are typically found.  
However, given that the distance between the nitrogens of Arg301 and the phosphorous moieties of NAD+ 
are 13.7 and 15.6 Å, and that the maximum distance between two residues that can be measured by 31P 
REDOR experiments is 8-11 Å, a direct correlation between the 31P of NAD+ and the 15N of Arg301 would 
not be possible. 
 Given the enzymatic turnover rate of 26000 h-1, it may be possible to trap phosphite in 
microcrystals of the enzyme at low temperatures. 
Crystallization will be attempted in the presence of substrates; given that the nicotinamide 
cofactor binds first, crystallization with phosphite or the inhibitor sulfite will always contain the cofactor as 
well.  Previous success with co-crystallization in the Nair lab was had by the inclusion of 5 mM of each 
substrate.  Importantly, it has been noted that while sulfite causes a slight shift in the pKa values of both 
branches of the pH rate profile (0.3-0.6 pH unit difference),43 this is not sufficient to disrupt the expected 
protonation states of the active site residues.  Therefore, experiments with sulfite may provide insight as 
to the mechanism of enzymatic action. 
 Auxotrophic species of E. coli may be used for the overexpression of TS-PTDH containing labels 
only at the sites of the putative catalytic bases and their degenerate residues (Figure 5.3).  Labeling of 
select neighbors would allow facile assignment of the resonances of interest. 
 Cross-resonance between deuterated substrate and active site residues could be used to probe 
the active site geometry during the reaction.  Solution state NMR studies may be carried out at the 
University of Wisconsin, which has facility specifically catered toward rapid acquisition and assignment of 
spectra for proteins larger than 40 kDa. 
 Crystallization may be attempted using other phosphomimics, including BeF3- and/or carbamoyl 
phosphate, which may allow for correlation of resonances between the active site residues and the 
substrates within the active site. 
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5.5   Experimental Procedures 
5.5.1   Overexpression of natural abundance phosphite dehydrogenase 
Transformation of BL21(DE3) Cells (LAGJ.III.032).  This protocol was adapted from the Rienstra lab 
(Heather Frericks Schmidt and Gautam Shah).  1 µL of DNA was stirred into 40 µL of BL21(DE3) 
competent E. coli cells (New England Biolabs) and the mixture was incubated on ice for 30 min.  The cells 
were heat-shocked by immersion into a 42 °C water bath for 30 s and then immediately placed back on 
ice for 2 min with the addition of 250 µL of SOC media.  The cells were then incubated at 37 °C for 30 
min, at which point they were plated onto an LB plate containing ampicillin; 20 µL of cells were plated with 
20 µL of fresh SOC and the plate was incubated overnight at 37 °C. 
A freezerstock of E. coli BL21(DE3) containing a pET15b plasmid with the PTDH gene was 
provided by Emily Fogle, formerly of the van der Donk laboratory.  This freezerstock had previously been 
cultured in M9 Minimal Media.  For overexpression in minimal media, Studier P media was used. 
For all overexpression experiments, a previously published protocol was used,7 with a few 
exceptions.  In brief, the culture was grown at 37 °C to OD600 = 0.6, at which point IPTG was added to a 
final concentration of 0.3 mM.  The culture was then grown for 24 h at 37 °C, supplementing with 
ampicillin every 8 h.  The cells were pelleted at 5000xg for 20 min and resuspended in 20 mM Tris, 500 
mM NaCl, 10% (v/v) glycerol, pH 7.6 at a proportion of 10 mL per liter of cell culture.  The pellet was then 
stored at -80 °C. 
 
5.5.2   Overexpression of isotopically enriched phosphite dehydrogenase 
Preparation of Studier Media (LAGJ.I.075).  Stocks solutions were prepared of each component for 
assembly just prior to inoculation.  Studier Medium P (1 M Na2HPO4, 1 M KH2PO4, 100 mM Na2SO4, 40 
mM MgSO4) and Studier Metals (50 mM FeCl3, 20 mM CaCl2, 10 mM MnCl2, 10 mM ZnSO4, 2 mM CoCl2, 
2 mM CuCl2, 2 mM NiCl2, 2 mM Na2MoO4, Na2SeO3, 2 mM H3BO3, 60 mM HCl) were both made and 
autoclaved.  Stocks of thiamin (10 mg/mL), biotin (10 mg/mL), ampicillin (50 mg/mL), ammonium chloride 
(2 g per 100 mL), and glucose (2 g per 100 mL) were prepared and filter-sterilized.  To assemble 1 L of 
media, the following amounts of each solution were combined in a sterile flask: 50 mL Studier Medium P, 
200 µL Studier Metals, 1 mL thiamin, 1 mL biotin, 10 mL ampicillin, 100 mL ammonium chloride, and 100 
ml of glucose.  If isotopic enrichment was desired, 10 mL of BioExpress-Min Cell Growth Media 
(Cambridge Isotope Laboratories, Andover, MA) was added to the media. 
Overexpression of U-13C,15N-PTDH (LAGJ.V.059).  BL21(DE3) cells (Novagen Singles) were transformed 
and used to inoculate a 50-mL starter culture in natural abundance Studier P medium.  The culture was 
incubated overnight at 37 °C and harvested at 6000 rpm (4650xg) for 30 min.  The cells were 
resuspended into 2 L isotopically enriched Studier P medium containing 15NH4Cl, 13C-Glucose, and 
BioExpress-Min Cell Growth Media (Cambridge Isotope Laboratories, Andover, MA; 13C-glucose was 
purchased from Sigma-Aldrich, St. Louis, MO).  The culture was induced to a final concentration of 0.3 
mM IPTG once the OD600 reached 0.6.  The culture was incubated overnight at 37 °C and harvested 
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(4000 rpm, 3100xg, 4 °C, 30 min).  Cells were resuspended in 10 mL of New Resuspension Buffer (20 
mM Tris, 1 M NaCl, 10% glycerol; pH 7.6) per liter of culture and flash frozen for storage at -80 °C.  
Natural abundance overexpression experiments were performed identically, with the exception of being 
carried out in LB broth for all steps. 
A freezerstock of E. coli BL21(DE3) containing a pET15b plasmid with the PTDH gene was 
provided by Emily Fogle, formerly of the van der Donk laboratory.  This freezerstock had previously been 
cultured in M9 Minimal Media.  For minimal media overexpressions, Studier P media was used.  For 
isotopic overexpression, this media was supplemented with 15NH4Cl, 13C-glucose, and BioExpress growth 
cocktail (Cambridge Isotope Laboratories, Andover, MA). 
 
5.5.3   Purification of phosphite dehydrogenase 
FPLC Purification of PTDH – Ni2+ Affinity (LAGJ.V.055).  Cell pellet was diluted two-fold in New 
Resuspension Buffer (20 mM Tris, 1 M NaCl, 10% glycerol, pH 7.6).  Lysozyme (Sigma-Aldrich, St. Louis, 
MO) was added to a final concentration of 0.3 mg/mL and the solution was incubated for 30 min on ice, 
vortexing for 10 s to mix every 10 min.  The sample was lysed via sonication for 25 min (microtip, 35% 
amplitude, 2.2 s on, 9 s off).  For volumes greater than 50 mL, the blunt sonication tip was used at 50% 
amplitude.  The cell debris was pelleted at 15000 rpm (23700xg) for 30 min at 4 °C.  The supernatant was 
filtered via 0.45-µm and 0.22-µm syringe filters and loaded into the SuperLoop 150.  The 20-mL column 
(IMAC Sepharose High Performance affinity resin, GE Healthcare, Piscataway, NJ) had previously been 
charged with 0.1 M NiSO4 and equilibrated with Start Buffer (20 mM Tris, 10 mM imidazole, 500 mM 
NaCl, 10% glycerol, pH 7.6). The program “Ni Column 20mL” was commenced.  This program has a flow 
rate of 1 mL/min for a 20-mL column volume, as well as an alarm to shut off flow if pressure exceeds 1.0 
MPa.  The sample was injected.  The program then proceeded from 6% Buffer B to 10.2% Buffer B (30 to 
60 mM imidazole) over 10 CV (200 mL), collecting 10-mL fractions.  The next step was from 10.2% Buffer 
B to 18.4% Buffer B (60 to 100 mM imidazole) over 2 CV (40 mL), collecting 5 mL fractions.  The final 
step is 100% Buffer B (500 mM imidazole) for 5 CV (100 mL), collecting fractions; it is in these fractions 
that PTDH should be found.  Fractions containing PTDH were pooled and concentrated using an Amicon 
30000 MWCO centrifugal concentrator.  The combined fractions were diluted with glycerol to a final 
concentration of 20% glycerol and flash frozen. 
Removal of His-tag via Thrombin Cleavage (LAGJ.V.012). A biotinylated thrombin cleavage kit was 
purchased from Novagen. 35 µL PTDH was combined with 5 µL of 10X buffer, 0.5 µL of thrombin, and 
9.5 µL of water and incubated at 16 °C for 16 h.  Samples (5 µL) were removed intermittantly and 
quenched with 20 µL of Laemmli dye for PAGE analysis to monitor progress. 
 Three temperatures were assayed (4 °C, 16 °C, and 37 °C) for thrombin cleavage, both in the 
presence and absence of test peptide; a negative control was also run without thrombin to assure no self-
cleavage or degradation was occurring.  At various timepoints along the way, 5 µL of assay mixture was 
combined with 20 µL Laemmli buffer for PAGE analysis. 
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PAGE Analysis of Purifications (LAGJ.V.049).  20 µL of sample was combined with 10 µL of Laemmli dye 
and the samples were boiled in a thermocycler.  For a 10-well gel, 15 µL of each sample was loaded into 
the wells; for a 15-well gel, 8 µL was loaded.  Gels (10% acrylamide) were run at 190 V, 250 mA, for 35 
min or until the dye front reached the desired location on the cassette. 
Tagless PTDH Enzyme Assays (LAGJ.IV.080).  Stocks were prepared for the assays. MOPS (500 mM; 
pH 7.25) was prepared, to be diluted 1:5 for a final assay concentration of 100 mM.  A stock of NAD+ was 
prepared at a concentration of 100 mM; this stock was made freshly each week and was diluted 1:100 for 
trials (final concentration 1 mM).  Two phosphite stocks were prepared, one at 500 mM and one at 5 mM, 
the latter prepared as a 1:100 dilution of the former; these stocks were assayed for concentration once 
per week.  The concentration of phosphite was varied throughout the trials.  PTDH was available at 
whatever concentration to which it was previously purified, but was 0.1 µM final concentration for activity 
assays.  The concentration of each stock was verified by UV-vis spectroscopy  (PTDH at A280 ε=28880 M-
1cm-1; NAD+ at A260 ε=18000 M-1cm-1; phosphite by formation of NADH at A340 ε=6200 M-1cm-1)  For the 
reactions, the concentration of phosphite was varied by adding between 1-50 µL; the water content in the 
assays was used to compensate the change in volume from phosphite to keep a constant volume from 
data point to data point.  The initial slopes were measured as a function of increase in A340 over time.   
For NMR, fractions containing PTDH, as determined by A280, were pooled, concentrated, and 
exchanged into 50 mM phosphate buffer, pH 7.5, containing 0.02% NaN3. 
 
5.5.4   Acquisition and analysis of preliminary NMR spectra 
All NMR spectra were acquired in the VOICE laboratories at the University of Illinois at Urbana-
Champaign on the Varian Unity Inova 500NB (500 MHz, 5mm Varian 1H{13C/15N} PFG Z probe) and 
Varian Unity Inova 600NB (600 MHz, 5mm Varian 1H{13C/15N} PFG X, Y, Z probe) instruments. 
The X-ray crystal structure data was acquired from the Nair lab and converted to predicted 
chemical shifts using the ShiftX program (Wishart group, University of Alberta).  The predicted shifts were 
then converted to expected HSQC spectra using a script generated by Donghua Zhou, a recent post-doc 
of the Rienstra group at University of Illinois at Urbana-Champaign. 
1H one-dimensional and 1H,15N-HSQC two-dimensional spectra were acquired; the latter were 
acquired with a sequence called BEST-HSQC, which produces better sensitivity protein spectra in a 
shorter amount of time.  A contaminant was seen and its peaks were run through the Metabolomics data 
base on the BMRB website.  To rid the sample of the contaminant, a gel filtration column was run with the 
assistance of John Boettcher (Rienstra laboratory). 
 
5.5.5   Determination of crystallization conditions for SSNMR 
A crystallization tray was set up around the conditions specified by the Nair lab (20% [w/v] PEG 
4000, 100 mM HEPES, 100 mM KCl, pH 7.5).  A few substitutions were made due to resources available, 
namely using 50 mM phosphate buffer (0.02% NaN3, pH 7.5) and PEG 3350.  Conditions were tested 
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from 10-25% PEG 3350 (5% increments), 0-100 mM KCl (20 mM increments).  One mL of solution was 
prepared in each well of the crystal tray.  Drops were made on glass cover slides of 1:1 reservoir:protein; 
three drops were made for each well, with serial dilutions of the protein concentration (fully concentrated, 
1:2 dilution, 1:4 dilution).  The coverslips were inverted onto the reservoirs and sealed.  Crystal growth 
was checked daily by microscope. 
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